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Oh,	where	have	you	been,	my	blue-eyed	son	
And	where	have	you	been,	my	darling	young	one	
I've	stumbled	on	the	side	of	twelve	misty	mountains	
I've	walked	and	I've	crawled	on	six	crooked	highways	
I've	stepped	in	the	middle	of	seven	sad	forests	
I've	been	out	in	front	of	a	dozen	dead	oceans	
I've	been	ten	thousand	miles	in	the	mouth	of	a	graveyard	
And	it's	a	hard,	and	it's	a	hard,	it's	a	hard,	and	it's	a	hard	
It's	a	hard	rain's	a-gonna	fall	
	
	
From	“A	Hard	Rain's	a-Gonna	Fall”	by	Bob	Dylan	
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ABSTRACT	
Alzheimer’s	disease	(AD)	is	a	progressive	neurodegenerative	disorder	against	which	there	is	yet	no	
disease	 modifying	 or	 curative	 treatment.	 Degeneration	 of	 cholinergic	 basal	 forebrain	 (CBF)	
neurons	plays	a	role	in	the	pathogenesis	of	AD	and	these	neurons	are	highly	dependent	on	nerve	
growth	factor	(NGF)	for	growth	and	survival.	NGF	has	been	proposed	as	a	potential	therapy	for	AD,	
but	NGF	does	not	pass	the	blood-brain	barrier	and	must	be	delivered	 locally	to	the	CBF	to	avoid	
side-effects.	We	tested	targeted	delivery	of	NGF	to	the	CBF,	using	encapsulated	cell	biodelivery	of	
NGF	(NGF-ECB)	in	a	first-in-man	trial	in	AD	patients.	The	primary	objective	was	to	examine	safety	
and	 tolerability	 and	 the	 secondary	 objective	 to	 test	 for	 possible	 effects	 on	 cognition	 and	
biomarkers.	Ten	AD	patients	were	implanted	stereotactically	with	NGF-ECB	implants	targeting	the	
CBF	during	12	months	(papers	II-IV)	or	6	months	(paper	V).	Six	patients	were	implanted	with	first-
generation	 implants,	 which	 at	 implant	 retrieval	 showed	 a	 low	 NGF	 release.	 Following	
improvements	of	implants	and	cell	survival,	implantations	of	second-generation	NGF-ECB	implants	
were	 performed	 in	 four	 AD	 patients.	 The	 patients	 were	 monitored	 with	 regard	 to	 safety,	
tolerability	and	secondary	outcome	measures.		
In	paper	II,	we	investigated	CSF	activity	of	the	cholinergic	marker	choline	acetyltransferase	(ChAT)	
and	 found	 that	 in	half	of	 the	patients,	ChAT	activity	was	 significantly	 increased	at	12	months	of	
NGF	 delivery,	 compared	 to	 an	 age	 matched	 AD	 reference	 group.	 ChAT	 activity	 also	 correlated	
significantly	with	cognition,	nicotinic	binding	and	brain	glucose	utilization	as	well	as	brain	atrophy	
and	CSF	biomarkers.	In	paper	III,	effects	of	the	NGF	delivery	on	EEG	activity	were	investigated.	A	
significant	correlative	pattern	between	alpha	power	and	a)	changes	in	cognition	and	b)	CSF	ChAT	
activity	during	the	12	month	trial	was	found,	indicating	that	the	more	stable	cognition	or	increase	
in	cholinergic	activity,	the	more	normalized	the	EEG	activity.	In	paper	IV,	we	investigated	changes	
in	brain	atrophy	on	magnetic	resonance	imaging	(MRI)	over	12	months	of	NGF	delivery	and	found	
that	half	of	the	patients	showed	less	brain	shrinkage,	compared	to	an	age	matched	AD	reference	
group,	 and	 a	better	 progression	 in	 clinical	 variables	 and	CSF	biomarkers.	 In	 paper	V,	 in	 four	AD	
patients	 implanted	with	 second	 generation	NGF-ECB	 implants	 for	 six	months,	we	 demonstrated	
safety	and	tolerability	and	at	retrieval	at	six	months,	the	implants	exhibited	high	NGF	release	and	
good	 cell	 viability.	 All	 four	 patients	 could	 complete	 the	 study	 and	 no	 adverse	 advents	 were	
deemed	related	to	the	implants	or	NGF	delivery.	Also	in	these	four	patients,	a	significant	pattern	
of	correlations	between	ChAT	activity	and	cognition	and	nicotinic	binding	was	shown.	 In	paper	I,	
we	 investigated	 levels	 of	 pro	 and	 mature	 neurotrophins	 in	 subjects	 with	 AD,	 mild	 cognitive	
impairment	(MCI)	and	subjective	cognitive	impairment	(SCI).	Our	results	showed	the	presence	of	
both	pro	and	mature	forms	of	NGF	in	human	CSF.	Increased	proNGF	levels	in	the	MCI	group	were	
found	 compared	 to	 AD,	 and	 a	 pathological	 biomarker	 profile	 in	 CSF	 from	 MCI	 subjects	 was	
associated	with	higher	proNGF	levels.		
In	conclusion,	our	studies	on	NGF	delivery	 in	ten	AD	patients	are	the	first	cell	 therapy	studies	 in	
the	world	demonstrating	that	implantation	of	encapsulated	cells	releasing	NGF	into	the	CBF	in	AD	
patients	 is	 safe	 and	 well	 tolerated.	 Stable	 cognition	 correlated	 with	 markers	 of	 increased	
cholinergic	activity,	indicative	of	a	stimulation	of	the	cholinergic	system	and	a	possible	slowing	of	
the	neurodegenerative	process.		
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1 INTRODUCTION	
1.1 ALZHEIMER’S	DISEASE	
Dementia	 is	 defined	 as	 a	 constellation	 of	 symptoms	 of	 cognitive	 decline	 impairing	 an	
individual’s	 ability	 to	 live	 a	 normal	 life.	 Alzheimer’s	 disease	 (AD)	 is	 the	most	 common	
cause	of	dementia,	representing	60-80%	of	dementia	cases	in	Europe	and	North	America	
(1,	 2).	 AD	 is	 a	 progressive	 neurodegenerative	 disorder	 causing	 a	 successive	 decline	 in	
cognitive	functions	over	years,	eventually	leading	to	death.	Dr.	Alois	Alzheimer	described	
in	1907,	the	neuropathological	and	clinical	features	of	a	female	patient	who	had	died	of	
a	mental	 illness	that	caused	her	to	suffer	from	memory	loss,	 language	impairment	and	
behavioral	changes	(3).	After	her	death,	dr.	Alzheimer	found	clumps	and	tangled	bundles	
of	 fibers	 on	 a	 brain	 autopsy,	 now	named	 amyloid	 plaques	 and	 neurofibrillary	 tangles,	
respectively	(4).	The	plaques	and	tangles	are	still	considered	among	the	cardinal	features	
of	AD	pathophysiology.		
	
	
1.1.1 Epidemiology	
AD	 is	 the	most	 common	 dementia	 disorder	 in	 older	 people	 and	 is	 a	 growing	 epidemic	
across	the	world.	 In	2015,	the	World	Alzheimer	Report	described	a	dementia	prevalence	
of	 around	 47	million	 people	 worldwide,	 and	 estimates	 this	 number	 to	 increase	 to	 131	
million	 by	 2050	 (5).	Worldwide,	 over	 9.9	million	 new	 cases	 of	 dementia	 are	 diagnosed	
each	year	and	an	increased	proportion	of	new	cases	arise	in	Asia,	the	Americas	and	Africa,	
while	 studies	 from	 Europe	 have	 reported	 decreasing	 incidence	 (6).	 The	 global	 costs	 of	
dementia	have	increased	by	over	35%,	from	2010	to	2015,	representing	around	1.09%	of	
global	 gross	 domestic	 product	 (GDP)	 including	 informal	 care,	 and	 total	 direct	 costs	 are	
estimated	 to	 be	 around	 0.65%	 of	 global	 GDP	 (5).	 In	 Sweden,	 approximately	 100	 000	
patients	are	afflicted	by	AD	(7)	and	costs	in	Sweden	are	estimated	to	be	about	63	billion	
Swedish	kronor	(8).	
	
	
1.1.2 Risk	factors		
Risk	factors	for	AD	can	be	divided	into	modifiable	risk	factors	and	non-modifiable	genetic	
risk	factors,	but	the	most	significant	risk	factor	for	AD	is	increased	age	(9).	
Genetic	risk	factors	for	AD	include	having	an	E4	allele	of	the	APOE	gene	(APOE4),	which	is	
considered	 to	 be	 the	 major	 genetic	 risk	 factor	 for	 AD,	 where	 both	 homozygosity	 and	
heterozygosity	 pose	 an	 increased	 risk	 for	 AD	 (10,	 11).	 Mutations	 in	 amyloid	 precursor	
protein	(APP),	and	the	presenilin-1	and	presenilin-2	genes	cause	an	autosomal	dominant	
early	onset	of	AD	(12)	and	the	triggering	receptor	on	myeloid	cells	2	(TREM2)	allele	causes	
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a	 rare	 genetic	 predisposition	 to	 AD	 (13).	 Genome-wide	 studies	 have	 furthermore	
identified	more	than	20	loci	associated	with	an	increased	risk	of	AD,	pointing	at	immune	
pathways	and	inflammatory	responses,	endosomal-vesicle	recycling	and	lipid	metabolism	
(14,	15).		
Cardiovascular	 risk	 factors	 such	 as	 diabetes	 mellitus	 (DM),	 hypertension,	 obesity	 and	
smoking	 and	 psychosocial	 factors	 such	 as	 low	 education	 and	 low	 mental	 activity	 are	
thought	 to	be	 the	main	modifiable	 risk	 factors	 for	AD	and	 targets	 for	 intervention	 (16).	
Based	 on	 findings	 from	 the	 Rotterdam	population	 study,	 it	 has	 been	 hypothesized	 that	
elimination	of	modifiable	risk	factors	would	lead	to	a	reduction	in	dementia	incidence	by	
as	 much	 as	 30%	 (17).	 Studies	 have	 also	 shown	 that	 having	 the	 APOE4	 genotype	 may	
augment	both	the	risk	of	environmental	risk	 factors	and	the	severity	of	chronic	diseases	
like	 DM,	 hypertension,	 hypercholesterolemia,	 depression	 as	 well	 as	 low	 physical	 and	
cognitive	 activity	 (18,	 19).	 In	 addition,	 traumatic	 brain	 injury	 is	 considered	 to	 be	 a	
significant	environmental	risk	factor	for	AD	(20,	21),	most	 likely	 induced	both	by	chronic	
inflammation	within	the	brain	as	well	as	increased	levels	of	amyloid	beta	protein	(Ab)	(22,	
23).		
	
	
1.1.3 Pathophysiology	
Even	though	studies	have	provided	evidence	for	multicausality	of	AD,	there	is	convincing	
evidence	for	the	involvement	of	plaque	accumulation,	due	to	abnormally	folded	Ab,	and	
neurofibrillary	 tangles	 comprised	 of	 phosphorylated	 tau	 protein	 (12),	 in	
neurodegenerative	 processes	 in	 the	 brain	 (24).	 Studies	 on	 patients	 suffering	 from	 a	
familial	 form	 of	 AD,	 caused	 by	 mutations	 in	 the	 APP,	 PSEN1	 or	 PSEN2	 genes,	 provide	
evidence	 further	 linking	 Ab	 to	 the	 pathophysiological	 cascade	 in	 AD	 (25).	 APP	 is	 the	
precursor	of	Ab	and	mutations	in	the	APP	gene	affect	the	cleavage	of	Ab,	while	those	in	
the	PSEN1	and	PSEN2	genes	affect	g	secretases,	which	cleaves	APP,	causing	a	generation	
of	longer	and	more	hydrophobic	Ab	peptides	(26).	Tau	gene	mutations	on	the	other	hand	
lead	 to	 a	 development	 of	 frontotemporal	 dementia	 (27).	 Previously,	 tau	 pathology	was	
thought	to	be	downstream	of	Ab	pathology,	but	 it	has	 lately	been	hypothesized	that	Ab	
and	tau	pathologies	in	the	brain	occur	in	synergy	(28)	(figure	2).	
	
	
1.1.4 Clinical	features	and	diagnosis	
Results	 from	 prospective	 studies	 point	 out	 the	 loss	 of	 episodic	 memory	 (memory	 of	
autobiographical	 events	 e.g.	 time,	 places),	 as	 the	 most	 robust	 neuropsychological	
predictor	 of	 dementia	 development	 (29,	 30),	 which	 can	 be	 detected	 years	 before	
dementia	diagnosis	(31).	Loss	of	episodic	memory	has	also	been	shown	to	be	associated	
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with	 increased	 amyloid	 burden,	 as	 demonstrated	 by	 a	 recent	meta-analysis	 (32).	 Lower	
premorbid	episodic	memory	also	seems	to	be	a	predictor	of	developing	dementia	(33,	34).	
In	addition,	the	presence	of	an	APOE4	allele	seems	to	moderate	dementia	development	in	
subjects	with	 low	episodic	memory,	although	 reports	are	not	entirely	 consistent	on	 this	
matter	(35).	Impairment	of	semantic	memory	(memory	of	facts	and	events)	can	also	be	a	
prominent	 early	 clinical	 symptom	 in	 AD.	 Both	 semantic	 and	 episodic	memory	 functions	
are	processed	in	the	medial	temporal	lobe	albeit	in	different	subregions.	Traditionally,	it	is	
suggested	 that	 early	 signs	 of	 pathology	 can	 be	 seen	 in	 the	 transentorhinal	 cortex	
(moderating	 semantic	memory),	 and	 thereafter	 the	 entorhinal	 cortex	 and	 hippocampus	
regions	(36)	(moderating	episodic	memory).	Longitudinal	studies	have	reported	semantic	
memory	 impairment	years	before	dementia	onset,	 in	parallel	with	hippocampal	atrophy	
and	 Ab	 pathology	 (37).	 Impairment	 of	 executive	 functions	 (e.g.	 attention,	 inhibitory	
control,	working	memory,	cognitive	 flexibility,	 reasoning,	problem	solving	and	planning),	
processed	 by	 the	 prefrontal	 cortex	 (38),	 occur	 in	 the	 early	 stages	 of	 AD	 but	 there	 is	
growing	evidence	supporting	that	executive	dysfunction	may	also	occur	in	the	preclinical	
stages	(39).	
AD	has	 a	 progressive	 nature	 and	 the	 progress	 is	 often	 divided	 into	mild,	moderate	 and	
severe	stages	after	the	onset	of	dementia	syndrome.	As	the	disease	progresses	with	time,	
additional	 cognitive	 functions	 become	 affected	 such	 as	 speech,	 orientation	 and	 motor	
planning,	 leading	 to	 aphasia	 and	 apraxia.	 Behavioral	 and	 psychiatric	 symptoms	 may	
develop,	 such	 as	 depression,	mood	 instability,	 restlessness	 and	 disturbance	 in	 circadian	
rhythm.	 In	 the	 severe	 stage	 of	 AD,	 the	 patients	 have	 lost	 the	 ability	 to	 carry	 on	 a	
conversation,	respond	to	their	environment	and	eventually	control	movement	and	require	
extensive	 assistance	 with	 activities	 of	 daily	 living.	 They	 become	 vulnerable	 to	
complications	of	immobility	and	may	suffer	infections,	blood	clots	and	pressure	wounds.		
		
The	gold	standard	for	establishing	an	AD	diagnosis	is	a	brain	biopsy	or	autopsy	of	the	post-
mortem	 brain,	 displaying	 the	 presence	 of	 characteristic	 histopathological	 signs	 of	 AD.	
However,	brain	biopsy	is	not	often	performed	in	clinical	praxis,	due	to	its	invasive	nature.	
Commonly	applied	clinical	criteria	 for	diagnosis	of	AD	are	the	 International	Classification	
of	Disease	10th	revision	(ICD-10)	(40),	Diagnosis	and	Statistical	Manual	of	Mental	Disorders	
4,	 text	 revision	 (DSM-IV,	 TR)	 (41)	 and	 the	 National	 Institute	 of	 Neurological	 and	
Communicative	Disorders	and	Stroke	(NINCDS),	and	the	Alzheimer’s	Disease	and	Related	
Disorders	 Association	 (ADRDA)	 workgroup	 criteria	 (42).	More	 recent	 diagnostic	 criteria,	
developed	by	the	International	Working	Group	(IWR)	and	the	National	Institute	on	Aging	
and	 Alzheimer’s	 Association	 (NIA-AA)	 support	 the	 inclusion	 of	 cerebrospinal	 fluid	 (CSF)	
and	imaging	biomarkers	(43)	to	the	criteria.	
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1.1.4.1	 Mild	cognitive	impairment	
The	 term	mild	 cognitive	 impairment	 (MCI)	 is	 used	 to	 describe	 a	 syndrome	 of	 cognitive	
impairment	 greater	 than	 can	 be	 expected	 for	 age	 and	 education	 level,	 that	 does	 not	
significantly	 interfere	with	activities	of	daily	 living	 (44).	MCI	 can	affect	memory	 function	
(amnestic	 MCI),	 memory	 plus	 another	 cognitive	 domain	 e.g.	 language	 (multi-domain	
amnestic	MCI),	single	non-memory	domain	(non-amnestic	MCI)	or	multiple	non-memory	
domains	(multidomain	non-amnestic	MCI)	(45).	MCI	is	often	a	transitional	state	between	
normal	 cognition	 and	 clinically	 probable	 AD.	 Individuals	 with	MCI	 are	 a	 heterogeneous	
group	with	an	overall	increased	risk	for	developing	dementia	(46,	47),	but	not	all	cases	of	
MCI	 have	 a	 neurodegenerative	 etiology.	 Longitudinal	 community-based	 studies	 have	
reported	an	incidence	of	5-10%	among	MCI	patients,	but	reported	incidence	of	dementia	
among	MCI	subjects	from	specialty	clinics	is	higher,	or	10-15%	(48).	
	
Recommendations	for	general	criteria	for	MCI,	Winblad	et	al,	2004	(49):	
[Cognition]	not	normal,	not	demented	
(does	not	meet	criteria	(DSM	IV,	ICD-10)	for	a	dementia	syndrome)	
Cognitive	decline:	
-Self	and/or	informant	report	and	impairment	on	objective	cognitive	tasks	
-Evidence	of	decline	over	time	on	objective	cognitive	tasks	
Preserved	basic	activities	of	daily	living	/	minimal	impairment	in	complex	instrumental	functions	
	
	
1.1.4.2	 Subjective	cognitive	impairment	
Subjective	 cognitive	 impairment	 (SCI),	 recently	 often	 referred	 to	 as	 subjective	 cognitive	
decline	(SCD),	is	common	in	an	aging	population.	SCI	is	generally	defined	as	complaints	of	
cognitive	 decline	 in	 the	 absence	 of	 objective	 evidence	 of	 cognitive	 impairment	 on	
neuropsychological	 testing	 (50).	 The	 clinical	 picture	 is	 thus	 less	 advanced	 than	 in	 MCI,	
where	 the	cognitive	 impairment	can	be	confirmed	using	cognitive	 testing	 tools.	There	 is	
increasing	 evidence	 supporting	 that	 individuals	 with	 SCI	 are	 at	 an	 increased	 risk	 for	
developing	 an	 abnormal	 CSF	 biomarker	 profile	 and	 have	 an	 increased	 risk	 for	 further	
cognitive	decline	in	the	future	and	development	of	AD	dementia	(51-53).	
	
	
1.1.5 Predictive	and	diagnostic	biomarkers	for	AD		
A	biomarker	is	defined	as	“a	characteristic	that	is	objectively	measured	and	evaluated	as	
an	 indicator	 of	 normal	 biological	 processes,	 pathogenic	 processes	 or	 pharmacological	
responses	to	a	therapeutic	intervention”	(54).	The	National	Institute	on	Aging-Alzheimer’s	
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Association	 (NIA-AA)	has	proposed	the	use	of	a	panel	of	CSF	and	 imaging	biomarkers	 to	
determine	the	probability	of	AD	(55)	and	risk	assessment	in	prodromal	stages	of	AD	(56,	
57).		
	
Research	 biomarkers	 for	 AD	 are	 divided	 into	 three	 categories,	 each	 corresponding	 to	
pathophysiological	changes	in	the	brain	(58):	
• biomarkers	of	Ab	deposition:	
o low	Ab	in	CSF	(59),	
o amyloid	 positron	 emission	 tomography	 (PET)	 scan	 shows	 high	 tracer	
retention	(60),	
• biomarkers	of	tau	pathology:	
o increased	levels	of	phosphorylated	tau	at	threonine	181	tau	(p-tau)	in	CSF,	
o increased	tracer	retention	on	the	recently	developed	tau	PET	(61),	
• biomarkers	of	neuronal	degeneration:	
o 	increased	levels	of	total	tau	protein	(t-tau)	in	CSF,	
o diminished	brain	glucose	utilization	on	18F-fluorodeoxyglucose	(FDG)-PET,	
o atrophy	 of	 brain	 structures	 characteristically	 affected	 by	 AD	 on	 magnetic	
resonance	imaging	(MRI).		
	
There	 is	 convincing	 evidence	 suggesting	 a	 sequence	of	 pathological	 events	 in	 the	brain,	
eventually	 leading	 to	 cognitive	 decline	 and	 dementia.	 Earliest	 are	 signs	 of	 amyloid	
deposition	(detected	by	low	CSF	Ab	and	pathological	amyloid	PET),	thereafter	signs	of	tau	
pathology	and	neurodegeneration	(detected	by	CSF	p	and	t-tau	 levels,	FDG-PET,	atrophy	
parameters	on	MRI),	followed	by	cognitive	impairment	(62).	There	is	however	not	a	clear	
association	 between	 magnitude	 of	 amyloid	 and	 tau	 pathology	 and	 clinical	 severity,	
illustrated	 by	 the	 disappointing	 results	 of	 phase	 III	 clinical	 trials	 with	 monoclonal	
antibodies	targeting	Ab,	which	have	shown	a	reduction	in	biomarker	pathology	but	failed	
to	demonstrate	a	clinical	effect	(63).	Recent	data	suggest	that	tau	accumulation,	assessed	
with	tau	PET,	may	correlate	more	closely	to	clinical	status	than	Ab	deposition	(64)	and	this	
observation	is	supported	by	recent	promising	results	from	a	phase	I	clinical	trial	testing	tau	
vaccination	in	AD	patients	during	22	months	(65).	
	
In	clinical	datasets,	low	CSF	Ab,	high	t-tau	and	p-tau,	provide	a	sensitivity	of	82-86%	and	a	
specificity	of	61-87%,	for	an	individual	pathological	biomarker	for	differentiating	AD	from	
controls,	and	an	even	higher	sensitivity	and	specificity	is	attained	by	calculating	a	t-tau/Ab	
ratio	 (66).	 There	 is	 however	 a	 large	 variability	 between	 laboratories	 in	 biomarker	
measurements	 that	 has	 hampered	 efforts	 to	 define	 uniform	 reference	 intervals.	 This	 is	
caused	by	differences	 in	enzyme-linked	 immunosorbent	assay	 (ELISA)	methods	between	
laboratories	 and	 variability	 in	 reagents	 and	 manufacturing	 procedures,	 resulting	 in	
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variations	from	batch	to	batch,	most	pronounced	for	Aβ	(67),	but	standardization	work	is	
ongoing.		
	
	
1.1.6 Current	treatment	for	AD	
Current	available	 treatment	 focuses	on	 targeting	 the	early	cholinergic	dysfunction	 in	AD	
(68)	by	inhibiting	acetylcholinesterase,	with	a	drug	group	named	cholinesterase	inhibitors	
(ChEI).	 ChEIs	 do	 however	 not	 reverse	 the	 progression	 of	 AD	 but	 provide	 only	 a	
symptomatic	 relief	 (69,	 70).	 Donepezil	may	 however	 increase	 the	 clearance	 of	 Ab	 (71).	
ChEIs	can	stabilize	cognitive	outcome	and	daily	function	during	the	first	year,	but	further	
cognitive	 and	 functional	 impairment	 occurs	 (72).	 Memantine,	 a	 non-competitive	 N-
Methyl-D-aspartic	 acid	 (NMDA)	 receptor	 antagonist,	 is	 the	 only	 approved	 drug	 besides	
ChEIs	 for	 AD	 and	 it	 may	 provide	 some	 benefit	 for	 patients	 with	 moderate	 to	 severe	
dementia,	as	monotherapy	or	in	combination	with	ChEIs.	Swedish	National	Guidelines	for	
Care	 in	 cases	 of	Dementia	 recommend	ChEI	 for	 treatment	of	mild	 to	moderate	AD	and	
memantine	 for	 moderate	 to	 severe	 AD	 (7).	 For	 behavioral	 symptoms,	 non-
pharmacological	 actions	 are	 recommended	 initially,	 followed	 by	 psychotropic	 drugs	 if	
necessary.	 Supportive	 care	 from	 caregivers	 and	 family	 is	 also	 important.	 Due	 to	 the	
multicausality	of	AD,	possible	therapeutic	targets	are	many	and	new	treatment	strategies	
are	needed	urgently.		
	
	
1.2 AMYLOID	HYPOTHESIS	AND	LINKS	TO	TAU	PATHOLOGY	
The	cleavage	of	APP	by	b-	and	g-secretases	 results	 in	 formation	of	39-43	amino	acid	Ab	
peptides	 (73),	 which	 are	 secreted	 into	 the	 extracellular	 space.	 A	 major	 part	 of	 Ab	 is	
secreted	 as	 the	 Ab40	 isomer,	which	 is	 thought	 to	 have	 less	 tendency	 to	 aggregate	 (74).	
Ab42	 is	more	prone	to	 form	oligomers,	protofibrils	and	 fibrils	and	 is	 the	main	Ab	 isomer	
found	 in	amyloid	plaques	 (75,	76).	Ab42	has	 toxic	effects	on	synapses,	particularly	 in	 the	
postsynaptic	 compartment	 (77),	 resulting	 in	 impairment	 in	 long-term	 potentiation	 (78).	
Ab40	and	Ab42	can	be	measured	in	CSF	and	both	Ab42	and	the	Ab42:	Ab40	ratio	have	been	
shown	to	be	decreased	in	CSF	from	AD	patients.		
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Figure	1.	Non-amyloidogenic	and	amyloidogenic	pathways	of	APP	processing.	Ab	 isomers	
Ab40	and	Ab42	are	produced	from	the	amyloidogenic	cleavage	of	APP	via	the	b-secretase	
(BACE1)	and	γ-secretase	complexes.	The	non-amyloidogenic	pathway	via	the	α-secretase	
and	γ-secretase	complexes	abolishes	Aβ	production.	Modified	from	Del	Prete	et	al,	2014	
(79).		
	
	
	
	
The	amyloid	cascade	hypothesis,	which	has	been	the	reigning	dogma	 in	AD	research	 for	
the	 last	 decades,	 is	 a	 “linear,	 and	 quantitative	 model”	 (3),	 assuming	 direct	 cause	 and	
consequence	of	Ab	deposition,	leading	to	tau	pathology	and	subsequently	AD	pathology	in	
the	 brain	 with	 inflammation,	 synaptic	 dysfunction	 and	 neuronal	 loss.	 The	 quantitative	
aspects	 of	 the	hypothesis	 assume	 that	 the	more	 amyloid	plaques	or	Ab	 deposition,	 the	
more	pathology,	but	 this	 remains	controversial	 (80).	Moreover,	 the	association	between	
magnitude	 of	 neuropathological	 changes	 and	 clinical	 severity	 is	 rather	 weak,	 as	
demonstrated	by	the	failure	of	clinical	trials,	which	have	shown	a	partial	clearance	of	Ab	
plaques	but	failed	to	demonstrate	clinical	efficacy	(81).		
	
Hyperphosphorylated	 tau	 interferes	with	neuronal	 function	even	before	 its	 aggregation,	
through	 interference	 with	 axonal	 transport	 and	 mitochondrial	 respiration	 (82-84).	 It	
remains	unclear	where	to	place	tau	in	the	Ab	cascade	hypothesis,	whether	its	pathology	is	
upstream	 or	 downstream	 of	 Ab	 pathology	 or	 a	 parallel	 process,	 and	 evidence	 suggests	
multiple	modes	of	interaction	between	Ab	and	tau	pathologies	(85).		
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Figure	2.	Possible	modes	of	interaction	between	Ab	and	tau	pathologies:	a.	Ab	upstream	
of	tau	pathology,	 inducing	hyperphosphorylation	of	tau.	b.	Ab	toxicity	dependent	on	the	
presence	of	 tau	mediation	and	c.	Ab	and	tau	pathologies	as	parallel	processes	attacking	
cell	organelles	in	synergism.	Modified	from	Ittner	et	al,	2011	(85).		
	
	
	
	
	
1.3 CHOLINERGIC	BASAL	FOREBRAIN	AND	ITS	ROLE	IN	AD	
The	cholinergic	basal	 forebrain	(CBF)	 is	comprised	of	the	septal	nuclei	 (Ch1),	 the	vertical	
(Ch2)	and	horizontal	limbs	(Ch3)	of	the	diagonal	band	of	Broca	and	the	nucleus	basalis	of	
Meynert	 complex	 (Ch4).	 The	 CBF	 provides	major	 cholinergic	 projections	 to	 the	 cerebral	
cortices,	hippocampus	and	amygdala	(86,	87).	Studies	have	shown	that	the	CBF	system	has	
a	 highly	 organized	 topographic	 structure	 of	 efferent	 projections	 providing	 the	 major	
source	of	cholinergic	innervation	to	the	cerebral	cortex	(87-90).	There	is	a	bulk	of	evidence	
from	studies	on	animals	and	humans	suggesting	the	importance	of	the	cholinergic	system	
in	cognitive	 functions	such	as	 learning	 (91,	92),	memory	 (93)	and	 	attention	 (94).	 In	AD,	
there	is	an	early	specific	degeneration	of	the	cholinergic	synapses	in	the	basal	forebrain,	
which	correlates	highly	to	the	cognitive	loss	(95,	96),	severity	of	cortical	synapse	loss	and	
density	 of	 amyloid	 plaques	 (97).	 Interestingly,	 it	 was	 recently	 demonstrated	 that	
histopathological	changes	in	the	cholinergic	basal	forebrain	(CBF)	precede	changes	in	the	
entorhinal	 cortices	 (98).	 This	 cholinergic	 hypothesis	 for	 the	 pathogenesis	 of	 AD	 laid	 the	
ground	 for	 the	 development	 of	 the	 ChEIs,	 which	 inhibit	 the	 activity	 of	
acetylcholinesterase,	 the	synaptic	acetylcholine	(ACh)	degrading	enzyme,	thus	 increasing	
synaptic	ACh	levels.	As	the	disease	progresses,	ChEIs’	effect	become	insufficient	in	halting	
cholinergic	dysfunction,	perhaps	due	to	the	progressive	loss	of	synapses	releasing	ACh	(99)	
and	severe	loss	of	CBF	neurons	in	advanced	AD	(100).		
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Cholinergic	 neurons	 are	 defined	 by	 the	 intracellular	 presence	 of	 the	 ACh	 synthesizing	
enzyme	choline	acetyltransferase	(ChAT),	and	ChAT	is	thus	regarded	as	the	most	selective	
cholinergic	 marker.	 ChAT	 synthesizes	 ACh	 from	 Acetyl-CoA	 and	 choline	 in	 the	 cell	
cytoplasm,	which	 then	 is	 transported	 via	 synaptic	 vesicles	 and	 after	 exocytosis	 released	
into	the	synaptic	cleft,	where	it	binds	to	its	muscarinic	or	nicotinic	ACh	receptors.	ACh	at	
the	synaptic	cleft	is	degraded	by	hydrolysis	via	acetylcholine	esterase	(AChE)	(101).	
	
	
Figure	3.	Schematic	representation	of	ChAT	synthesis	in	the	cytosol,	ACh	transport	and	
degradation	in	the	synaptic	cleft.		
	
	
	
	
Researchers	 have	 shown	 that	 the	 transcription	 of	 ChAT	 is	 diminished	 in	 the	 remaining	
cholinergic	 neurons,	 leading	 to	 decreased	 ChAT	 activity	 in	 AD	 (102,	 103).	 Postmortem	
tissue	 from	 AD	 brains	 show	 signs	 of	 cholinergic	 impairment,	 including	 reduced	 ChAT	
activity,	and	diminished	ACh	release	has	been	reported	in	biopsies	from	patients	with	mild	
AD	(104).	Cholinergic	loss	in	AD	correlates	furthermore	well	with	impairment	of	memory	
and	attention	(102,	105).		
	
	
Acetylcholine	receptors	
ACh	 receptors	 are	 classified	 as	 either	 muscarinic	 or	 nicotinic,	 according	 to	 agonist	
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selectivity	 and	 pharmacological	 functions	 (101).	 Nicotinic	 ACh	 receptors	 are	 ion-gated	
receptor	 channels,	 selective	 for	 cations	 (106),	 generating	 a	 rapid	 response	 following	
activation.	Nine	types	of	nicotinic	receptors	have	been	identified	so	far.	Different	types	of	
receptors	are	expressed	 in	different	organs	of	 the	body	e.g.	 the	central	nervous	system,	
peripheral	nervous	system	and	muscles	and	each	type	of	receptor	has	distinct	properties	
(107).	Neuronal	nicotinic	ACh	receptors	are	comprised	of	a	combination	of	a	or	b	subunits	
(108)	and	the	most	widely	expressed	subunit	is	a7	(109),	composed	of	seven	nicotinic	a-
subunits.	 	 Muscarinic	 ACh	 receptors	 are	 G-protein	 receptors	 leading	 to	 activation	 of	
second	messengers.	Genes	for	five	isoforms	of	muscarinic	receptors	have	been	identified,	
M1,	 M2,	 M3,	 M4	 and	 M5	 (110),	 which	 can	 modulate	 various	 ion	 channels	 and	 can	
promote	either	cell	excitability	or	voltage	inhibition	leading	to	diminished	cell	excitability	
(101).		
	
Function	 and	 survival	 of	 the	 CBF	 neurons	 is	 highly	 dependent	 upon	 the	 neurotrophin	
nerve	 growth	 factor	 (NGF),	 retrogradely	 transported	 from	 the	 hippocampus	 and	 cortex	
(111).	 It	has	moreover	been	suggested	that	loss	of	neurotrophic	support	to	the	CBF	may	
precede	 degeneration	 of	 the	 CBF	 neurons	 (112).	 A	wealth	 of	 data	 from	animal	models,	
indicate	that	NGF	effectively	decreases	cholinergic	deficit	and	cognitive	impairment	(113).		
	
	
1.4 NEUROTROPHINS	
Neurotrophins	 comprise	 a	 family	 of	 structurally	 related	 peptides	 that	 regulate	
differentiation,	 growth	 and	 survival	 of	 neurons	 in	 both	 central	 and	 peripheral	 nervous	
systems	(114,	115).	Over	50	proteins	with	neurotrophic	properties	have	been	identified	in	
the	brain	and	 they	are	grouped	 into	 families	according	 to	 similarity	 and	properties.	 The	
group	 of	 “classic	 neurotrophins”	 consists	 of:	 NGF,	 brain-derived	 neurotrophic	 factor	
(BDNF),	 neurotrophin	 3	 (NT-3)	 and	 neurotrophin	 4/5	 (NT-4/5)	 (116).	 Studies	 on	
neurotrophins	 and	 their	 relation	 to	 the	 pathogenesis	 of	 AD,	 focus	 mainly	 on	 NGF	 and	
BDNF	 and	 neurons	 in	 the	 hippocampus	 and	 CBF	 (99).	 All	 of	 the	 neurotrophins	 are	
produced	 initially	 as	 precursor	 pro-peptides,	 after	which	 they	 are	 cleaved	 to	 produce	 a	
smaller	 mature	 neurotrophin.	 The	 pro-peptides	 have	 different	 properties	 regarding	
receptor	binding	and	different	biological	functions	than	their	mature	forms	(117).	
	
	
1.4.1 Neurotrophin	receptors	in	AD	
The	function	of	neurotrophins	 is	dependent	on	their	main	receptors,	a	selective	tyrosine	
kinase	 (Trk)	 and	 a	 pan-neurotrophic	 p75	 neurotrophin	 (p75NTR)	 receptor.	 Neurotrophin	
binding	to	Trk	receptors	 leads	to	tyrosine	phosphorylation	of	proteins	and	promotion	of	
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signal	 cascades	 generally	 associated	 with	 neuronal	 survival,	 development	 and	
maintenance	 of	 function	 in	 the	 human	 central	 and	 peripheral	 nervous	 systems	 (118).	
Mature	NGF	(matNGF)	binds	TrkA	while	BDNF	binds	TrkB.	Both	mature	and	pro-forms	of	
neurotrophins	 bind	 p75NTR,	 although	 p75NTR	 is	 more	 effectively	 activated	 by	 pro-
neurotrophins	 (119).	 This	 generally	 induces	 apoptotic	 signals,	 though	 depending	 on	
several	 factors	such	as	co-expression	of	Trks	(120)	and	 ligand	binding	to	the	co-receptor	
sortilin	(121,	122).	Postmortem	studies	on	AD	brains	have	demonstrated	a	loss	of	neurons	
expressing	 TrkA	 and	 p75NTR	 (123,	 124),	 and	 this	 decline	 correlates	 well	 with	 cognitive	
impairment	(123).	MatNGF	binds	p75NTR	with	low	affinity	(125)	while	proNGF	binds	p75NTR	
with	high	affinity	(119).	Activation	of	pathways	through	p75NTR	can	trigger	either	a	pro-	or	
anti-apoptotic	 signal,	 depending	 on	 the	 cellular	 milieu,	 such	 as	 the	 cell	 type	 and	 the	
presence	or	absence	of	co-receptors	(126).	MatNGF	binds	TrkA	with	high	affinity	when	co-
expressed	 with	 p75NTR	 (127),	 and	 upon	 binding,	 TrkA	 activates	 signal	 cascades	 that	
promotes	survival	of	the	CBF	neuronal	phenotype	by	activating	transcription	factors	that	
alter	gene	expression	(128).		
	
	
Figure	 4.	 Schematic	 representation	 of	 the	 NGF	 receptor	 functions.	 ProNGF	 induces	
programmed	cell	death	(apoptosis)	via	the	p75NTR	and	co-receptor	sortilin,	while	mature	
NGF	 induces	 cell	 growth	and	 survival	 via	TrkA	and	p75NTR.	 	Modified	 from	Longo	et	 al	
2013	(129).	
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1.4.2 Nerve	Growth	Factor	
Ideas	 about	 the	 biological	 function	 of	 NGF	 were	 early	 on	 dominated	 by	 findings	 from	
studies	 on	 the	 survival	 and	differentiation	 of	 developing	 neurons,	 but	 it	 has	 since	 been	
demonstrated	that	the	role	of	NGF	extends	beyond	the	developmental	period	and	beyond	
the	 nervous	 system	 (130).	 NGF	 has	 a	 well-established	 survival-enhancing	 effect	 on	 CBF	
neurons	 in	 animals	 (131-133),	 and	 studies	 have	 shown	 that	 transgenic	 adult	 mice	
expressing	anti-NGF	antibodies,	display	an	age-dependent	loss	of	CBF	neurons	(134,	135).	
There	is	furthermore	strong	evidence	supporting	the	role	of	NGF	in	promotion	of	neurite	
outgrowth	and	neuronal	differentiation	(136,	137).		
	
	MatNGF	is	synthesized	in	the	CBF	neurons’	target	areas	in	the	hippocampus	and	cerebral	
cortex	(138).	These	neurons	express	both	p75NTR	and	TrkA	receptors.	TrkA	binds	matNGF,	
with	 the	 help	 of	 p75NTR	 and	 this	 complex	 is	 then	 transported	 retrogradely	 to	 the	 basal	
forebrain	 where	 the	matNGF/receptor	 complex	mediates	 signal	 transduction	 (97,	 139).	
Numerous	 studies	 have	 demonstrated	 the	 importance	 of	 retrograde	 transport	 of	
neurotrophin	signaling,	 in	both	nervous	system	development	and	in	preventing	neuronal	
degeneration	(140).	Degeneration	of	neuronal	axons	(axonopathy)	 is	thought	to	precede	
neuronal	 cell	 death,	 and	 retrograde	 transport	 of	 neurotrophic	 factor/receptor	 complex	
provides	 trophic	 support	 to	 the	 axons,	 which	 is	 thought	 to	 halt	 or	 prevent	 axonal	
degeneration	 (141).	 In	 cortical	projections	 in	AD	brains,	 TrkA	gene	expression	 (142)	and	
protein	 levels	 (123)	have	been	shown	to	be	reduced,	while	cortical	p75NTR	protein	 levels	
remain	unaltered	(143).	
	
	
Figure	5.	 Schematic	 figure	 representing	 findings	of	decreased	cortical	 levels	of	TrkA	and	
increased	levels	of	proNGF	during	the	course	of	AD,	correlating	with	the	Mini-mental	state	
examination	(MMSE)	score.	Modified	from	Counts	et	al,	2005	(143).	
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In	AD,	the	ratio	of	p75NTR	to	TrkA	is	suggested	to	be	altered	 in	favor	of	 increased	p75NTR	
mediated	 activity,	 which	 in	 turn	 may	 promote	 CBF	 neuron	 apoptosis.	 ProNGF	 has	
furthermore	 been	 shown	 to	 be	 increased	 twofold	 in	 severe	 AD	 postmortem	 cortices,	
compared	to	non-demented	controls	(144),	and	proNGF	is	also	increased	in	MCI	and	mild	
AD	(145),	while	NGF	mRNA	has	been	shown	to	be	unchanged	(146).	As	a	result,	it	has	been	
hypothesized	that	reduced	TrkA	and	increased	levels	of	proNGF	in	the	AD	brain	result	in	a	
shift	 towards	 a	 proNGF	mediated	 pro-apoptotic	 signaling,	 exacerbating	 a	 shift	 from	 cell	
survival	towards	neurodegeneration	(143,	147,	148).		
	
Research	findings	have	revealed	that	proNGF	is	the	main	releasable	form	of	NGF	following	
a	 cerebral	 cortex	 stimulation	 (149)	 and	 the	 conversion	 of	 proNGF	 to	 matNGF	 and	
degradation	 of	 matNGF	 occurs	 in	 the	 extracellular	 space	 involving	 a	 highly	 complex	
protease	cascade	(150).	Considering	that	studies	have	demonstrated	an	imbalance	in	this	
maturation	 pathway,	 it	 has	 been	 hypothesized	 that	 the	 CBF	 neurons’	 trophic	 status	 is	
decided	by	 the	 levels	 of	 the	maturation	 and	degradation	pathways,	 rather	 than	protein	
levels	of	proNGF	(149).		
	
	
Figure	6.	Schematic	representation	of	the	maturation	and	degradation	pathways	of	NGF.	
Modified	from	Cuello	et	al,	2010	(149).	
	
	
	
	
MatNGF	is	converted	from	proNGF	through	activation	by	plasmin,	which	is	converted	from	
plasminogen	 through	 stimulation	 of	 tissue	 plasminogen	 activator	 (tPA).	 Degradation	 of	
NGF	 is	 mediated	 by	matrix	metalloproteinase	 9	 (MMP-9),	 which	 itself	 has	 a	 precursor,	
proMMP-9,	and	is	matured	by	way	of	plasmin	and	other	agents,	and	regulated	by	tissue	
inhibitor	 of	 matrix	 metalloproteinase	 1	 (TIMP-1)	 (149).	 A	 study	 on	 postmortem	 AD	
cerebral	cortices	demonstrated	 lower	 levels	of	plasminogen	and	higher	 levels	of	MMP-9	
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compared	 to	 non-demented	 controls	 (151),	 indicating	 a	 failure	 in	 the	 maturation	 and	
degradation	pathways	causing	less	maturation	of	NGF	and	increased	degradation,	which	in	
turn	 may	 lead	 to	 a	 decreased	 matNGF	 and	 consequently	 CBF	 neuron	 atrophy.	 This	
assumption	 is	 further	 strengthened	 by	 findings	 from	 animal	 studies	 demonstrating	 that	
pharmacological	 blocking	 of	 NGF	 maturation	 reduces	 the	 levels	 of	 matNGF,	 increases	
proNGF	and	consequently	 leads	to	cholinergic	degeneration	and	cognitive	 impairment	 in	
the	 animals	 (152).	 Furthermore,	 by	 increasing	 matNGF	 levels	 by	 blocking	 the	 NGF	
degradation	 pathway,	 the	 researchers	 found	 an	 increase	 in	 the	 density	 of	 cortical	
cholinergic	boutons	(152).		
	
	
1.4.3 Link	to	Ab	pathology	
In	postmortem	AD	brains,	MMP-9	expression	is	localized	primarily	in	neurons,	amyloid	
plaques	and	neurofibrillary	tangles	(153)	and	animal	studies	have	demonstrated	that	Ab	
stimulates	the	production	of	several	MMP	isomers	(154),	suggesting	a	coupling	to	Ab	and	
tau	pathology	in	AD.		
	
	
Figure	7.	Schematic	representation	of	the	effects	on	NGF	metabolism	from	a	shift	towards	
an	 amyloidogenic	 pathway	 after	 an	 induction	 by	 injection	 of	 Ab	 in	 a	 transgenic	 animal	
model.	Modified	from	Cuello	et	al,	2010	(149).	
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TrkA	has	been	shown	to	reduce	the	b-secretase	(BACE1)	cleavage	of	APP,	in	favor	of	the	
non-amyloidogenic	pathway,	while	p75NTR	increases	BACE1	cleavage	(155),	stimulating	the	
amyloidogenic	pathway.	Results	from	animal	studies	have	furthermore	demonstrated	that	
increased	 APP	 expression	 in	 a	 mouse	 model	 of	 Down’s	 syndrome	 reduces	 retrograde	
transport	of	NGF,	resulting	in	degeneration	of	CBF	neurons,	which	on	the	other	hand	can	
be	reversed	by	NGF	administration	directly	to	the	CBF	neuronal	bodies	(156).	 It	has	also	
been	 hypothesized	 that	 hyperphosphorylated	 tau	may	 physically	 hinder	 the	 retrograde	
transport	of	NGF	(157).		
	
	
1.4.3.1 Previous	clinical	trials	investigating	direct	delivery	of	NGF	
Results	 from	 animal	 studies	 demonstrate	 that	 the	 CBF	 neurons	 are	 viable	 albeit	
dysfunctional	in	AD	and	these	cells	die	late	in	the	disease	(133,	158-160),	indicating	that	
these	 degenerating	 cells	 may	 be	 amenable	 to	 therapeutic	 interventions	 in	 early	 and	
probably	 moderate	 AD	 (161).	 It	 has	 been	 proposed	 that	 NGF	 may	 have	 a	 possible	
disease	 modifying	 therapeutic	 potential	 in	 AD	 for	 the	 last	 30	 years	 based	 on	 the	
hypothesis	that	NGF	may	slow	down	or	stop	CBF	neuronal	loss,	thereby	halting	disease	
progression.	 However,	 NGF	 is	 a	 large	 molecule	 which	 does	 not	 pass	 the	 blood-brain	
barrier,	posing	a	challenge	with	regard	to	route	of	administration.	Different	strategies	of	
direct	delivery	of	NGF	have	been	tested,	such	as	intranasal	administration	of	NGF	(162)	
and	 a	 cell-based	 delivery	 using	 stem	 cells	 (163).	 In	 a	 previous	 clinical	 trial,	 NGF	 was	
administered	via	infusion	into	the	lateral	ventricle	of	the	brain	of	three	AD	patients.	The	
patients	showed	an	up-regulation	of	ACh	receptors	and	 increased	glucose	metabolism,	
as	 demonstrated	 by	 PET	 and	 a	 normalization	 of	 brain	 electrical	 activity	 on	
electroencephalography	 (EEG)	 (164,	 165).	 Unfortunately,	 the	 patients	 experienced	
adverse	events,	the	most	prominent	being	muscle	pain,	but	also	weight	loss,	making	this	
administration	route	unfeasible.	 In	clinical	 studies	with	NGF	administration	 in	diabetes	
peripheral	 neuropathy	 and	 HIV-associated	 neuropathy,	 the	 patients	 also	 experienced	
adverse	events	in	the	form	of	muscle	pain	(166,	167).	
Studies	on	animals	have	later	shown	that	pain	induced	by	NGF	administration	is	caused	
by	 NGF	 affecting	 the	 neurons	 in	 the	 dorsal	 root	 ganglion	 and	 hypothalamus,	 eliciting	
pain	response	and	weight	 loss	(168).	When	NGF	was	 infused	directly	 into	the	rat	brain	
parenchyma	(169),	and	 into	the	basal	 forebrain	 in	cognitively	 impaired	primates	 (170),	
no	 pain-related	 side-effects	 were	 observed.	 Further	 substantiation	 for	 the	 safety	 of	
intra-parenchymal	 administration	 of	 NGF	 was	 obtained	 from	 a	 study	 on	 Parkinson’s	
patients	 who	 received	 direct	 NGF	 infusion	 into	 the	 striatum	 and	 did	 not	 experience	
increased	pain	as	side-effects	(171).	It	has	thus	been	suggested	that	in	AD	patients,	NGF	
should	be	administered	directly	 to	 the	target	neurons	 in	 the	CBF	to	avoid	side-effects.	
This	is	however	a	challenge	with	regard	to	clinical	and	technical	methodologies.		
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The	 first	 study	with	NGF	delivery	 to	 the	 CBF	 used	 gene	 therapy	with	 the	 patients’	 own	
cells,	 fibroblasts	 genetically	 engineered	 to	 express	 and	 release	 NGF,	 then	 injected	
stereotactically	into	the	CBF	(172).	The	researchers	reported	no	NGF-related	side-effects,	
and	the	patients	exhibited	a	possible	slowing	in	cognitive	decline	and	an	increased	glucose	
metabolism	on	FDG-PET.	A	subsequent	phase	1	gene	therapy	trial	in	ten	AD	patients,	using	
a	viral	vector	(AAV2-NGF)	with	a	two-year	follow-up	also	reported	safety	and	tolerability	
of	 the	NGF	 transfer	 (173).	 A	 phase	 2	multicenter	 double-blind,	 sham-surgery	 controlled	
trial	 reported	 safety	 and	 feasibility	 but	 failed	 to	 demonstrate	 cognitive	 improvement	
(174).	 A	 post-mortem	 report	 from	 brain	 autopsies	 from	 ten	 AD	 patients	 from	 the	 two	
phase	1	trials	confirmed	trophic	effects	on	CBF	neurons	from	the	NGF	delivery	(175).	Gene	
therapy	 provides	 an	 opportunity	 to	 deliver	 a	 growth	 factor	 focally	 but	 it	may	 however	
have	hypothetical	disadvantages	and	 safety	 limitations,	 such	as	genetic	modifications	of	
neuronal	 cells	 and	 the	 lack	 of	 possibility	 to	 remove	 the	 active	 substance	 in	 case	 of	
complications.		
	
	
1.4.3.2 Encapsulated	cell	biodelivery	of	NGF	
Another	 alternative	 is	 to	 utilize	 encapsulated	 cells	 that	 can	 be	 implanted	 by	 way	 of	
stereotactic	 neurosurgery	 and	 removed	 if	 required.	 In	 collaboration	 with	 the	 biotech	
company	NsGene	Inc.,	our	research	group	developed	a	biodelivery	device	containing	ex	
vivo	 genetically	 modified,	 encapsulated	 NGF	 releasing	 cells.	 The	 capsule	 provides	
immunoisolation	while	oxygen,	nutrients	and	the	therapeutic	product	flows	freely	over	
the	capsule	wall.	 In	a	phase	 I	clinical	 trial	 (presented	 in	papers	 II	–	 IV),	 the	biodelivery	
device	(NGF-ECB	implant)	was	implanted	stereotactically	into	the	CBF	of	six	AD	patients	
during	a	12-month	 follow-up.	No	NGF	attributable	 side	effects	were	 reported	and	 the	
results	 demonstrated	 safety	 and	 feasibility	 of	 NGF	 delivery	 by	 NGF-ECB	 implantation	
(176,	177).	This	approach	has	the	advantage	compared	to	gene	therapy	that	delivery	of	
the	therapeutic	agent	can	be	stopped	and	the	cells	removed	from	the	brain,	without	the	
patient’s	genes	being	altered.		
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Figure	8.	Schematic	representation	of	the	NGF-ECB	device.	Published	with	the	permission	
of	Lars	U.	Wahlberg.		
	
	
	
	
1.4.4 Brain-derived	neurotrophic	factor	
Changes	 in	 the	 levels	of	BDNF	have	been	 linked	 to	 the	pathophysiology	of	 a	number	of	
disorders	in	the	central	nervous	system	such	as	AD,	Huntington’s	disease,	depression	and	
schizophrenia	 (99).	 BDNF	 is	 expressed	 and	 distributed	 widely	 throughout	 the	 brain,	
though	especially	(178,	179)	in	neurons	in	the	cerebral	cortex	and	hippocampus	and	it	has	
been	 shown	 to	 be	 important	 for	 the	 function	 and	 survival	 of	 both	 dopaminergic	 and	
cholinergic	 neurons	 (180,	 181).	 Mature	 BDNF	 regulates	 differentiation	 and	 plasticity	 of	
these	 neurons	 by	 activation	 of	 its	 high-affinity	 receptor	 TrkB	 and	 low-affinity	 receptor		
p75NTR	(182).		
	
Long-term	 potentiation	 (LTP)	 has	 been	 described	 as	 a	 “persistent	 increase	 in	 synaptic	
strength	 induced	 by	 brief	 high-frequency	 electrical	 stimulation	 of	 afferent	 fibres	 or	
coincident	activation	of	pre-	and	postsynaptic	neurons”	(183)	and	is	widely	accepted	as	a	
primary	hypothesis	for	the	mechanism	of	learning	on	a	cellular	level.	The	role	of	BDNF	in	
LTP	 has	 been	 established	 in	 animal	 experiments,	 which	 have	 demonstrated	 that	 LTP	 in	
hippocampal	neurons	is	enhanced	by	overexpression	of	TrkB	(184),	while	reduced	BDNF-
TrkB	 signaling	 leads	 to	 memory	 impairment	 (183).	 Some	 studies	 have	 reported	 lower	
levels	 of	 TrkB	 in	 AD	 brains	 (185),	 but	 the	 literature	 is	 inconsistent	 regarding	 this	 (186).	
Declining	 cortical	 levels	 of	 BDNF	 in	 AD	 correlate	 to	 increased	 Braak	 staging,	 a	 staging	
 	18	
based	on	 the	distribution	of	 tau	pathology	 in	AD	 (186)	and	one	study	has	also	 reported	
declined	levels	of	BDNF	mRNA	in	non-AD	tauopathies	(187).	However,	truncated	TrkB.T1	
receptor,	 which	 inhibits	 both	 TrkB	 and	 p75NTR	 receptors	 (188,	 189),	 and	 inhibits	 LTP	 in	
animal	models	(189),	has	been	found	to	be	increased	in	cerebral	cortices	from	AD	patients	
(190).	Moreover,	proBDNF	signaling	through	binding	p75NTR	promotes	long-term	neuronal	
depression	(191).	Additionally,	BDNF	may	have	a	protective	effect	against	Ab	toxicity	both	
in	vivo	and	in	vitro	(192,	193)	and	prevent	Ab	induced	LTP	impairment	in	brain	slices	from	
hippocampal	 (194)	 and	 entorhinal	 cortices	 (195).	 As	 is	 the	 case	 for	 NGF,	 BDNF’s	
pharmacokinetic	properties	are	 ill-suited	 for	 systemic	administration	due	 to	poor	blood-
brain	barrier	penetration	and	short	half-life	in	plasma.		
	
	
1.4.5 Levels	of	NGF,	BDNF	and	their	respective	pro-forms	in	CSF	
The	 presence	 of	 mature	 and	 pro-forms	 of	 BDNF	 and	 NGF	 in	 CSF	 is	 not	 yet	 well	
characterized.	 Several	 studies	 have	 however	 investigated	 levels	 of	 neurotrophins	 in	
postmortem	cortical	 and	hippocampal	 slices	 and	 found	elevated	 levels	of	proNGF	 in	AD	
and	MCI	 compared	 to	 subjects	with	 no	 cognitive	 impairment	 (145,	 196)	 and	 decreased	
levels	of	proBDNF	in	postmortem	brains	of	AD	and	MCI	patients	(197,	198).	A	recent	paper	
reported	increased	levels	of	proNGF	in	ventricular	CSF	from	deceased	AD	and	MCI	patients	
compared	to	non-demented	controls,	but	the	researchers	could	only	detect	matNGF	in	a	
few	 CSF	 samples	 (199).	 Other	 reports	 have	 found	 increased	 matNGF	 in	 CSF	 from	 AD	
patients	(200,	201).	Previous	studies	have	reported	either	decreased	levels	of	BDNF	in	CSF	
from	AD	patients	compared	to	non-demented	controls	or	other	types	of	dementia	 (202,	
203),	 or	 found	 no	 significant	 difference	 (204),	 although	 none	 of	 these	 studies	
differentiated	between	mature	and	proBDNF.		
A	 few	 studies	 have	 investigated	 the	 association	 between	 levels	 of	 BDNF	 and	 risk	 of	
progression	 of	 cognitive	 decline	 and	 development	 of	 AD	 dementia.	 Weinstein	 et	 al.	
reported,	using	ELISA,	 lower	 levels	of	serum	BDNF	in	MCI	patients	who	at	follow-up	had	
progressed	 to	AD	dementia	 in	 a	 cohort	 from	 the	 Framingham	Heart	 Study	 (205).	Other	
reports	 described	 higher	 levels	 of	 serum/plasma	 BDNF	 in	 MCI	 and	 early	 AD	 patients	
compared	to	healthy	controls	(206,	207),	suggesting	a	compensatory	mechanism	in	MCI	in	
response	to	a	developing	AD	pathology.	One	study	reported	lower	levels	of	BDNF	in	CSF	in	
AD	 patients	 in	 comparison	 to	 MCI	 and	 non-demented	 controls,	 and	 furthermore	 that	
lower	 BDNF	 levels	 seemed	 to	 be	 related	 to	 higher	 risk	 for	 conversion	 from	MCI	 to	 AD	
(208).		
In	the	light	of	the	important	roles	that	NGF	and	BDNF	play	in	cognition,	it	will	be	valuable	
to	 be	 able	 to	 investigate	 the	 levels	 of	 both	 their	 mature	 and	 pro-forms	 to	 establish	 a	
better	 understanding	 of	 the	 disease	 mechanism	 in	 AD	 and	 furthermore	 to	 develop	
strategies	for	better	identification	of	individuals	at	increased	risk	of	progression	to	AD.		
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2 AIMS	
NGF	delivery	to	the	cholinergic	basal	forebrain	has	been	suggested	as	a	potential	disease-
modifying	treatment	in	AD,	and	different	delivery	methods	have	been	investigated	for	the	
last	three	decades.		
The	main	aim	of	this	thesis	is	to	explore	the	potential	of	encapsulated	cell	biodelivery	of	
NGF,	 targeted	 to	 the	 basal	 forebrain,	 with	 regard	 to	 safety,	 tolerability	 and	 a	 possible	
disease-modifying	effect,	in	a	total	of	ten	AD	patients.		
	
Specifically,	the	aims	include	investigating:		
• levels	 of	 the	 neurotrophins	 NGF	 and	 BDNF	 and	 their	 pro-peptides	 in	 CSF	 from	
subjects	with	AD	as	compared	to	 levels	 in	subjects	with	mild	cognitive	 impairment	
and	subjective	cognitive	impairment	(paper	I),	
	
• whether	changes	in	CSF	cholinergic	markers	from	AD	patients	receiving	NGF	delivery	
for	twelve	months,	have	a	potential	for	monitoring	changes	in	cholinergic	activity	of	
the	brain	induced	by	the	NGF	delivery	(paper	II),	
	
• potential	 effects	 of	 NGF	 delivery	 on	 quantitative	 EEG	 parameters,	 and	 if	 such	
changes	correlate	with	cognitive	outcome	or	CSF	cholinergic	markers	(paper	III),	
	
• possible	 changes	 in	brain	 atrophy	on	MRI	during	NGF	delivery	 in	 comparison	 to	 a	
control	group,	and	correlative	pattern	with	cognition	and	CSF	biomarkers	(paper	IV),	
	
• safety	and	tolerability	of	 implantation	with	a	second-generation	NGF-ECB	device	in	
four	 AD	 patients,	 as	 well	 as	 effects	 on	 secondary	 outcome	 measures	 such	 as	
cognition	and	biomarkers	(paper	V).	
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3 SUBJECTS	AND	METHODS	
In	 this	 thesis,	 several	 methods	 are	 used,	 spanning	 from	 cognitive	 tests,	 imaging	 and	
neurophysiological	 investigations,	 to	 analyses	 of	 levels	 of	 CSF	 biomarkers.	 Here,	 a	 brief	
account	 of	 the	methods	 is	 given.	 Please	 see	 the	 respective	 papers	 for	 a	more	 detailed	
description.		
	
	
3.1 SUBJECTS	
	
3.1.1 Participants	in	a	two	dose-step	clinical	trial	with	NGF-ECB	(papers	II-V)	
Between	 2007	 and	 2008,	 our	 research	 group	 conducted	 a	 12-month	 open-label,	 single	
center	phase	 I	 trial	of	a	first-in-man	NGF-EC	biodelivery	to	the	CBF	 in	six	AD	patients,	 in	
two	 dose	 cohorts.	 In	 2011-2012,	 a	 dose-escalation	 step	was	 performed,	 adding	 a	 third	
cohort	of	four	AD	patients	to	the	trial	cohort.		
The	 ten	participants	were	enrolled	 to	both	 steps	of	 the	 trial	 from	 the	Memory	Clinic	 at	
Karolinska	 University	 Hospital,	 Huddinge.	 We	 used	 the	 same	 inclusion	 and	 exclusion	
criteria	 for	all	 three	cohorts,	which	were:	a)	probable	diagnosis	of	mild	 to	moderate	AD	
according	 to	 the	NINCDS-ADRDA	criteria	 (42),	b)	 age	between	50	and	80	years,	 c)	Mini-
mental	state	examination	(MMSE)	(209)	score	between	15	and	24,	d)	living	at	home	with	a	
caregiver,	 e)	 stable	 ChEI	 treatment	 for	 at	 least	 three	 months	 prior	 to	 enrollment.	 The	
exclusion	criteria	were:	a)	medical	and/or	psychiatric	comorbidities	which	would	make	it	
difficult	 for	 the	patients	 to	undergo	the	surgical	procedure	 including	general	anesthesia,	
and	complete	the	trial,	b)	ongoing	treatment	with	antipsychotic	drugs	and	c)	smoking,	not	
to	 interfere	 with	 nicotinic	 receptor	 binding	 on	 PET.	 We	 screened	 approximately	 100	
patient	 charts	 to	 identify	 candidates	 who	 fulfilled	 the	 inclusion	 criteria.	 Patients	 were	
thereafter	contacted	with	a	short	letter	with	information	on	the	trial,	followed	up	with	a	
phone	call,	after	which	patient	 information	was	sent	home	to	the	patient	and	caregiver.	
Next,	 the	 patients	 came	 for	 a	 visit	 at	 the	 Memory	 Clinic	 to	 discuss	 enrollment.	 If	 the	
patient	and	caregiver	gave	an	informed	written	consent,	the	screening	visit	was	initiated.	
Brain	MRI	was	performed	on	all	patients	at	enrollment	to	exclude	significant	neurological	
conditions	 that	 would	 contradict	 surgery.	 For	 cohort	 III,	 six	 patients	 performed	 the	
screening	visit,	five	were	enrolled	and	one	patient	was	excluded	after	MRI	due	to	signs	of	
an	old	brain	hemorrhage.		
Of	 note	 is	 that	 the	 AD	 diagnosis	 was	 confirmed	 neuropathologically	 by	 small	 cortical	
biopsies	 obtained	 at	 NGF-ECB	 implantation,	 exhibiting	 plaques	 and	 tangles	 in	 biopsies	
from	nine	out	of	ten	patients	(176,	210),	whereas	one	biopsy	showed	only	fat	tissue	(176).	
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3.1.2 Participants	in	a	study	on	CSF	levels	of	neurotrophins	(paper	I)	
The	subjects	were	 individuals	that	had	been	referred	to	the	Memory	Clinic	at	Karolinska	
University	 Hospital	 Huddinge,	 Stockholm	 between	 2007	 and	 2009,	 due	 to	 memory	
complaints,	and	received	a	diagnosis	of	AD,	MCI	or	SCI.	All	subjects	underwent	a	work-up	
according	to	a	clinical	routine	at	the	Memory	Clinic	and	following	medical	history,	history	
from	a	proxy	and	clinical	examination	including	neurological	and	psychiatric	assessments,	
cognitive	screening	was	performed	using	MMSE.	Additionally,	the	subjects	were	assessed	
by	brain	 imaging	(MRI	or	computerized	tomography	(CT)),	blood	tests	and	biomarkers	 in	
CSF.	A	majority	of	the	subjects	were	assessed	with	a	neuropsychological	test	battery.	AD	
diagnosis	was	established	according	to	the	ICD-10	criteria	(40),	and	MCI	according	to	the	
Winblad	criteria	(49)	(see	section	1.1.4.1).	For	establishing	a	diagnosis	of	SCI,	the	definition	
of	 SCI	 as	 a	 presence	 of	 cognitive	 complaints	 in	 the	 absence	 of	 pathological	
neuropsychological	 testing	was	used	(211,	212).	All	subjects	signed	an	 informed	consent	
prior	to	lumbar	puncture	(LP)	and	approved	to	donate	CSF	to	a	biobank.		
The	inclusion	criteria	were:	a)	LP	performed	as	a	part	of	the	work-up,	b)	diagnosis	of	AD,	
MCI	or	SCI.	Exclusion	criteria	were:	a)	somatic	or	psychiatric	disease	significantly	affecting	
cognition,	b)	non-AD	dementia	and	c)	first	degree	relative	with	AD	among	the	subjects	in	
the	SCI	group.	CSF	from	a	total	of	96	patients	were	collected,	22	AD	patients,	35	MCI,	and	
39	SCI	subjects.		
	
	
3.2 METHODS	
	
3.2.1 Analyses	of	neurotrophins	and	their	pro-forms	in	CSF	(paper	I)	
After	LP,	the	CSF	samples	were	stored	in	-80°	C	until	analysis.	The	CSF	levels	of	Aβ42,	t-tau	
and	 p-tau	 were	 assessed	 by	 commercially	 available	 sandwich	 ELISAs	 according	 to	
standardized	protocols.	
	
We	 used	 immunoblotting	 by	 western	 blot	 and	 electrophoresis	 on	 an	 SDS-PAGE	 gel	 in	
order	to	investigate	the	presence	of	mature	and	pro-forms	of	NGF	and	BDNF	in	CSF.	The	
levels	of	different	forms	of	NGF	and	BDNF	were	expected	to	be	low,	and	for	that	reason	
we	 lyophilized	 the	 CSF	 samples	 by	 vacuum	 centrifugation	 by	 which	 the	 samples	 were	
concentrated.	Determination	of	total	protein	was	done	in	each	sample	prior	to	lyophilizing	
and	concentrating	the	samples	and	the	lowest	protein	concentration	in	each	sample	was	
set	 to	 1.5	 µg/ml,	 thus	 enabling	 us	 to	 analyze	 the	 same	 amount	 of	 protein	 from	 each	
subject	by	electrophoresis	and	immunoblotting.	Only	immunoreactive	bands	that	could	be	
proven	to	be	specific	were	analyzed.	The	intensity	of	the	signals	from	specific	bands	were	
normalized	to	the	intensity	of	an	internal	control,	present	in	all	runs.	This	normalized	data	
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was	 thereafter	multiplied	with	 the	 factor	by	which	 the	sample	was	diluted	 to	attain	 the	
concentration	1.5	µg/ml.	The	resulting	data,	expressed	in	arbitrary	units	(a.u.),	reflects	the	
neurotrophin	levels	present	in	CSF	in	the	way	that	relative	comparisons	between	subjects	
are	possible.	The	differences	between	the	diagnostic	groups	were	thus	analyzed,	as	well	as	
correlations	with	biomarkers	 and	MMSE	 score.	 To	 investigate	 if	 an	 association	between	
progression	to	dementia	and	levels	of	neurotrophins	existed,	the	subjects’	medical	charts	
were	 inspected	 to	 explore	 if	 the	 subjects	 had	 been	 followed	 up,	 and	 if	 so	 if	 they	 had	
converted	from	MCI	to	AD.	Subjects	who	had	converted	were	assigned	as	converters	and	
those	who	remained	cognitively	stable	were	assigned	as	non-converters,	according	to	the	
clinical	diagnosis	at	the	time	of	follow-up.		
A	ratio	of	t-tau/Ab42>0.52	has	been	shown	have	a	high	sensitivity	and	specificity	(66)	for	
differentiating	AD	from	healthy	individuals,	and	such	a	biomarker	profile	can	be	regarded	
as	 pathological	 (66).	 To	 investigate	 if	 an	 association	 between	 biomarker	 profile	 and	
neurotrophin	levels	existed,	we	performed	correlative	analyses	between	CSF	neurotrophin	
levels	and	the	biomarker	status	(pathological	or	non-pathological	biomarker	profile).		
	
	
3.2.2 Encapsulated	cell	biodelivery	of	NGF	
To	 the	 first	 arm	of	 this	 phase	 I	NGF-ECB	 trial,	as	 previously	 reported	 (176,	 177),	 six	 AD	
patients	were	enrolled	 in	 two	dose	cohorts.	Cohort	 I	 (three	patients)	 received	two	NGF-
ECB	implants,	stereotactically	implanted	bilaterally	in	the	nucleus	basalis	of	Meynert	(Ch4)	
while	cohort	II	(three	patients)	received	double	bilateral	NGF-ECB	implants	(four	implants),	
implanted	in	Ch4	and	in	the	vertical	limb	of	the	diagonal	band	of	Broca	(Ch2).	The	duration	
of	 NGF	 delivery	 in	 cohorts	 I	 &	 II	 was	 twelve	months.	Cohort	 III	 (four	 patients)	 received	
double	bilateral	second-generation	NGF-ECB	implants	in	Ch2	and	Ch4	during	a	trial	period	
of	six	months.	
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Figure	9.	 Schematic	 representation	of	 the	dose-escalation	 regime	of	 the	 study.	Adapted	
from	Eyjolfsdottir	et	al,	2016	(210)	and	reprinted	with	permission	from	BioMed	Central.	
	
	
	
	
	
3.2.2.1 First	generation	NGF-ECB	implant	(NsG0202),	cohorts	I	&	II	(papers	II-IV)	
The	 implant	 consisted	 of	 human	 retinal	 pigment	 epithelial	 cells	 derived	 from	 a	
commercially	available	cell	line	(ARPE-19),	transfected	and	modified	with	the	human	NGF	
gene,	 expressing	 NGF	 but	 no	 proNGF	 (213),	 housed	 in	 the	 active	 part	 of	 the	 implant,	
behind	a	semipermeable	membrane	(see	figure	8).	The	active	part	is	attached	to	a	1	mm	
wide	tether	(see	figure	8).		
	
	
3.2.2.2 Second	generation	NGF-ECB	implant	(NsG0202.1),	cohort	III	(paper	V)	
This	 implant	 also	 consisted	 of	 human	 retinal	 pigment	 epithelial	 cells	 derived	 from	 the	
ARPE-19	cell	line,	transfected	and	modified	with	the	human	NGF	gene,	as	described	above	
and	 reported	by	 Fjord-Larsen	 et	 al,	 2012	 (214).	 The	 cells	were	 now	 co-transfected	with	
separate	plasmids	 coding	 for	human	NGF	and	a	 Sleeping	Beauty	 transposase	 (215).	 The	
polyvinyl	 alcohol	 sponge	matrix	 used	 in	 the	 first-generation	 implant	 was	 replaced	 by	 a	
polyester	terephtalate	yarn	matrix	as	supportive	scaffold	for	the	cells,	allowing	improved	
cell	adherence	and	survival.		
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Both	 implants	NsG0202	and	NsG0202.1	were	tested	for	safety	and	toxicology	 in	animals	
and	produced	under	Good	Manufacturing	Practice	(GMP).		
	
	
3.2.2.3 Neurosurgical	procedures	
The	 implantation	 and	 implant	 retrieval	 (explantation)	 procedures	 were	 performed	 by	 a	
neurosurgical	 team	 under	 general	 anesthesia.	 For	 cohort	 I,	 the	 three	 patients	 were	
implanted	stereotactically	with	bilateral	single	implants	with	the	active	part	targeting	Ch4.	
The	tether	was	thereafter	cut	to	length	and	secured	at	the	burr	hole	with	a	titanium	plate	
(177).		
Three	 months	 later,	 safety	 data	 were	 assessed	 by	 an	 independent	 review	 board,	 and	
based	 on	 the	 assessment,	 three	 patients	 (cohort	 II),	were	 approved	 for	 implantation	 of	
bilateral	 double	 implants	 to	 Ch2	 and	 Ch4.	 In	 cohort	 III	 (paper	 V),	 the	 procedures	were	
performed	 in	 the	 same	manner	 as	 described	 for	 cohorts	 I	 &	 II	 to	 the	 same	 anatomical	
targets	as	described	for	the	first	two	dose	cohorts.		
Immediately	post	operatively,	cranial	CT	scans	were	performed	on	all	patients	 for	safety	
assessment	 and	 documentation	 of	 implant	 positions.	 At	 the	 end	 of	 the	 trial	 period	 for	
cohort	III	at	six	months	and	for	cohorts	I	&	II	at	twelve	months,	all	ten	patients	underwent	
surgical	 retrieval	 of	 the	 implants	 under	 general	 anesthesia	 according	 to	 a	 protocol	
described	by	Eriksdotter-Jönhagen	et	al,	2012	and	Wahlberg	et	al,	2012	(176,	177).		
	
	
3.2.2.4 Outcome	measures	
Primary	outcome	measures	 for	 all	 three	dose	 cohorts	of	 the	NGF-ECB	 clinical	 trial	were	
safety	and	tolerability,	assessed	by	clinical	follow-up	with	regard	to	adverse	events	(AEs).	
At	baseline,	all	patients	were	examined	 thoroughly	by	a	physician	and	 investigated	with	
cranial	MRI	and	laboratory	tests.	At	3	and	6	month	follow-ups,	this	was	repeated	in	cohort	
III,	and	furthermore	at	12	months	for	cohorts	I	&	II.	Clinical	assessments	were	intensified	
close	 to	 surgery	 with	 daily	 assessments	 of	 safety	 and	 tolerability	 parameters.	 Patients	
were	admitted,	first	to	a	neurosurgery	ward,	followed	by	a	geriatric	ward	for	a	mean	stay	
of	5	days.	After	discharge,	the	patients	were	monitored	closely	with	outpatients	visits	one,	
two	and	 four	weeks	after	 surgery.	A	 similar	 intensified	monitoring	was	performed	upon	
implant	retrieval,	with	a	hospital	stay	for	a	mean	duration	of	two	days.	The	study	physician	
(HE)	was	on	standby	during	the	whole	duration	of	the	trial	and	could	always	be	reached	by	
phone.		
	
Secondary	 outcome	 measures	 included:	 a)	 cognitive	 status,	 assessed	 with	 cognitive	
screening	 tests	 (MMSE	 and	 Alzheimer’s	 Disease	 Assessment	 Scale-Cognitive	 Subscale	
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(ADAS-Cog)	(216))	and	neuropsychological	test	battery,	b)	quantitative	EEG	(paper	III),	c)	
CSF	analyses	 for	AD	biomarkers	 (Ab42,	 t-tau	and	p-tau,	measured	with	xMAP	technology	
(217),	neurofilament	light	protein	(NFL)	and	glial	fibrillary	acidic	protein	(GFAP),	analysed	
with	ELISA	assays	(218,	219)	and	the	cholinergic	markers	ChAT	and	AChE	(paper	II),	d)	MRI	
for	assessment	of	atrophy	 (paper	 IV)	and	e)	PET	 investigation	 for	assessment	of	glucose	
utilization	(FDG-PET)	and	nicotinic	receptor	binding	at	baseline,	3	and	6	months	(cohort	III)	
or	 12	 months	 (cohorts	 I	 &	 II),	 as	 a	 putative	 surrogate	 of	 the	 number	 of	 nicotinic	 ACh	
receptors.	 The	 11C-nicotinic	 binding	 sites	 were	 assessed	 using	 a	 nicotine	 tracer	 (220).	
Thereafter,	 we	 calculated	 a	 flow-compensated	 parameter,	 k2*	 for	 nicotine	 divided	 by	
cerebral	 blood	 flow	 (221,	 222),	 but	 since	 k2*	 has	 an	 inverse	 relationship	 to	 number	 of	
nicotinic	binding	sites,	we	transformed	the	values	by	calculating	1-k2*.	
	
	
3.2.3 Cholinergic	markers	in	CSF	fluid	following	NGF	delivery	(paper	II)	
CSF	 levels	 of	 the	 cholinergic	 markers	 ChAT	 and	 AChE	 were	 measured	 from	 the	 six	 AD	
patients	 in	cohorts	 I	and	 II,	who	were	implanted	with	first	generation	NGF-ECB	implants.	
CSF	ChAT	activity	was	measured	by	a	newly	developed	colorimetric	assay	(223)	and	AChE	
activity	by	modified	Ellman’s	colorimetric	assay	as	described	by	Darreh-Shori	et	al,	2008	
(224).	 Annual	 cognitive	 decline	 in	 untreated	 AD	 patients	 has	 been	 reported	 to	 be	 3-5	
points/year	 and	 2.5	 points/year	 in	 ChEI	 treated	 patients,	 assessed	 one	 year	 after	 ChEI	
therapy	start	(225,	226).	In	this	study,	three	patients	showed	a	£	2	points	annual	decline	in	
MMSE	 score	 after	 12	 months	 of	 NGF	 delivery	 and	 were	 assigned	 as	 responders,	 while	
three	patients	showed	>	2	points	annual	decline	and	were	assigned	as	non-responders.	
For	 comparison	with	 an	 AD	 group	without	NGF	 delivery,	 but	with	 ChEI	 treatment	 for	 a	
similar	duration	as	the	NGF	patients,	we	included	CSF	samples	from	17	AD	patients,	from	
whom	 CSF	 had	 been	 collected	 at	 12	 and	 24	months	 of	 ChEI	 treatment	 (227).	 Inclusion	
criteria	were	availability	of	CSF	samples	and	MMSE	scores	both	after	12	and	24	months	of	
stable	ChEI	therapy.	The	same	criteria	for	assigning	to	responder	or	non-responder	groups	
according	to	annual	MMSE	decline	was	applied.	
We	analyzed	changes	from	baseline	in	the	cholinergic	markers	at	3	and	12	month	of	NGF	
delivery	 and	 performed	 correlative	 analyses	 using	 Spearman	 rank	 non-parametric	
correlation	 between	 the	 cholinergic	markers,	 cognitive	 performance,	 glucose	 utilization	
and	nicotinic	binding	on	PET.	
	
	
3.2.4 Changes	in	EEG	activity	following	NGF	delivery	(paper	III)	
In	the	six	AD	patients	in	dose	cohorts	I	&	II,	standard	EEGs	were	recorded	according	to	the	
international	10/20	system	in	a	resting	awake	state,	with	vigilance	control.	After	digitizing	
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at	a	sampling	rate	of	256	Hz,	absolute	power	for	19	standard	electrode	locations	and	
Global	Field	Power	(GFP),	corresponding	to	the	generalized	EEG	amplitude,	was	calculated	
using	the	Brain	Vision	Analyzer	software.	In	addition,	the	absolute	power	and	GFP	were	
averaged	in	six	frequency	bands:	delta	(1-3.5	Hz),	theta	(4-7.5	Hz),	alpha	(8-11.5	Hz),	beta	
1	(12-15.5	Hz),	beta	2	(16-19.5	Hz)	and	beta	3	(20-23.5	Hz).	Values	were	logarithmically	
transformed	for	normalization	of	data	distribution.		
Advanced	statistical	analyses	of	differences	of	the	amplitude	and	spatial	distribution	of	the	
EEG	 absolute	 power	 across	 the	 whole	 spectra	 (0-70	 Hz)	 (not	 averaged	 across	 the	
frequency	bands)	were	performed	by	the	statistical	software	Randomized	Graphical	User	
Interface	 (Ragu)	 (228),	 for	 topographical	analyses	of	covariance	 (TANCOVAs)	 (229).	Ragu	
tests	whether	a	significant	amount	of	 topographic	variance	can	be	accounted	 for	by	 the	
linear	contribution	of	an	external	predictor	that	may	vary	by	different	conditions.	 In	this	
paper,	 we	 used	MMSE	 and	 ChAT	 changes	 (post	 treatment	 –	 pretreatment)	 as	 external	
predictors	and	the	recording	occasions	at	baseline,	3	and	12	months	of	NGF	delivery	were	
assigned	as	conditions.		
	
	
3.2.5 Atrophy	parameters	on	MRI	following	NGF	delivery	(paper	IV)		
The	 six	 AD	 patients	 from	 cohorts	 I	 &	 II	 were	 scanned	 on	 a	 1.5T	 MR	 scanner	 (details	
presented	in	paper	IV).	Images	were	processed	according	to	a	specific	protocol	to	acquire	
reliable	volume	estimates.	Visual	quality	control	was	performed	on	the	output	data.		
An	 index	of	brain	atrophy	was	calculated	using	the	following	formula:	 (total	gray	matter	
volume	 +	 total	 white	 matter	 volume)	 /	 total	 CSF	 volume.	 The	 index	 represents	 brain	
volume	(BV)	in	relation	to	total	volume	of	CSF	at	a	given	follow-up	point.	Lower	values	of	
BV/CSF	index	represent	greater	brain	atrophy.	Brain	volume	has	a	tendency	to	decline	in	
both	 normal	 aging	 as	 well	 as	 neurodegenerative	 disease	 while	 CSF	 increases.	 We	
furthermore	 analyzed	 hippocampal	 volume	 for	 each	 patient	 and	 normalized	 to	 each	
subjects’	intracranial	volume	(230).	
To	establish	a	reference	group	for	comparisons	of	brain	atrophy	to	an	age-matched	group	
of	 AD	 patients	 without	 NGF	 delivery,	 a	 dataset	 from	 the	 Alzheimer’s	 Disease	
Neuroimaging	 Initiative	 (ADNI)	database	 (231)	was	obtained	 from	36	AD	patients	with	a	
12-month	 MRI	 follow-up	 and	 who	 also	 were	 scanned	 on	 a	 1.5T	 MRI	 system	 (232).	
Diagnostic	 criteria	 for	 the	 ADNI	 cohort	 were	 as	 follows:	 a)	 diagnosis	 of	 probable	 AD	
according	 to	 the	 NINCDS-ADRDA	 criteria,	 b)	 Clinical	 Dementia	 Rating	 scale	 (CDR)	 score	
between	 0.5-1	 (233),	 c)	 MMSE	 scores	 20-26	 and	 d)	 age	 55-90	 years.	 Exclusion	 criteria	
were:	a)	significant	neurologic	disease	other	than	AD	and	b)	concomitant	medication	with	
psychoactive	 medication	 other	 than	 ChEIs	 and/or	 stable	 doses	 of	 baseline	 medication	
listed	in	the	ADNI	procedures	manual.	
We	assigned	the	enrolled	NGF	patients	to	responders	or	non-responders	groups	according	
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to	their	annual	change	in	MMSE	score,	according	to	the	method	described	in	section	3.2.3	
and	MMSE	results	from	ADNI	reference	group	were	treated	the	same	way.		
	
	
3.3 ETHICAL	CONSIDERATIONS	
All	studies	presented	in	this	thesis	are	conducted	according	to	the	Helsinki	Declaration	and	
were	approved	by	 the	Regional	Human	Ethics	Committee	of	Stockholm	(detailed	below)	
and	 approval	was	 also	 acquired	 from	 the	 Swedish	Medical	 Products	 Agency	 for	 studies	
presented	in	papers	II-V.	
All	 patients	 involved	 in	 this	 thesis	 granted	 their	 consent,	 and	 consent	was	 furthermore	
obtained	from	caregivers	of	the	ten	AD	patients	in	cohorts	I-III	of	the	NGF-ECB	trial.			
	
	
Ethical	permissions:		
Paper	I:	2011/680-31/1,	
Papers	II,	III	and	IV:	2007/986-31/3,	
Paper	V:	2011/1048-31,	and	subsequent	amendment	2011/1874-32.	
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4 RESULTS	AND	DISCUSSION	
	
4.1 ANALYSES	OF	NEUROTROPHINS	AND	THEIR	PRO-FORMS	IN	CSF	(PAPER	I)		
CSF	samples	from	a	total	of	96	patients	were	analyzed	for	NGF,	BDNF	and	their	respective	
pro-forms.	Demographic	data	on	the	subjects	are	summarized	in	Table	1.		
	
	
Table	 1.	 Demographic	 data	 on	 included	 subjects.	 *	 indicates	 a	 statistically	 significant	
difference	 as	 compared	 to	 AD	 (p<0.05),	 #	 indicates	 significance	 as	 compared	 to	 MCI	
(p<0.05).	
	
	 All	subjects	 SCI	 MCI		 AD		
N		
(women/men)	
96		
(61/35)	
median	(range)	
39		
(24/15)	
median	(range)	
35		
(23/12)	
median	(range)	
22		
(14/8)	
median	(range)	
Age	at	LP	 64	(42-86)	 61#	(43-86)	 69	(42-86)	 66	(55-84)	
t-tau	(ng/L)	 266	(75-1470)	 207*#	(75-728)	 276*	(79-510)	 549	(209-1470)	
Ab42	(ng/L)	 635	(300-1334)	 980*#	(300-1216)	 586*	(350-1334)	 493	(332-840)	
p-tau	(ng/L)	 59	(16-182)	 49*	(16-110)	 56*	(16-95)	 83	(45-182)	
t-tau/Ab42	 0.36	(0.1-3.55)	 0.21*#	(0.1-1.87)	 0.45*	(0.12-1.2)	 1.16	(0.36-3.55)	
MMSE	score	 28	(15-30)	 29*#	(23-30)	 28*	(23-30)	 23	(15-26)	
	
	
4.1.1 Immunoblotting	experiments	and	antibody	specificity		
By	 applying	 a	 western	 blot	 method	 on	 CSF,	 we	 discovered	 protein	 bands	 of	 specific	
immunoreactivity	 for	 BDNF	 at	 12-14	 and	 24	 kDa	 and	 we	 concluded	 that	 mature	 BDNF	
(matBDNF)	at	12-14	kDa	could	be	detected	and	a	form	of	proBDNF	at	24	kDa	in	human	CSF	
samples.	The	staining	for	NGF	produced	similar	results	with	a	band	identified	as	matNGF	
at	12-14	kDa	and	a	band	identified	as	proNGF	at	24	kDa.	These	results	are	in	accordance	
with	previous	studies	showing	forms	of	BDNF	and	NGF	at	these	molecular	weights	(234-
238).	
	
We	could	not	consistently	produce	positive	stainings	for	the	mature	neurotrophins	in	CSF.	
We	 believe	 that	 this	 may	 be	 to	 technical	 limitations	 and	 that	 these	 forms	 indeed	 are	
present	 in	human	CSF,	although	 it	has	been	recognized	that	proNGF	 is	 the	predominant	
form	 of	 NGF	 in	 brain	 samples	 (144).	 Also,	 it	 was	 recently	 reported	 that	 matNGF	 was	
variably	detectable	and	could	not	be	reliably	quantified	in	CSF	(239).	As	for	BDNF,	no	study	
 29	 	
	
has	 thus	 far,	 to	 our	 knowledge,	 differentiated	between	 the	mature	 and	pro-form	when	
reporting	levels	in	CSF.		
	
	
4.1.2 Levels	of	pro-neurotrophins	between	diagnostic	groups	
Our	 results	 show	significantly	 lower	 levels	of	proNGF	 in	CSF	 samples	 from	subjects	with	
MCI	compared	with	AD	(p<0.05)	but	compared	to	SCI,	the	difference	was	not	significant	(p	
=	 0.056).	 No	 significant	 differences	 in	 the	 levels	 of	 proBDNF	 were	 found	 between	 the	
diagnostic	groups.	Previous	reports	describe	higher	levels	of	NGF	in	CSF	from	AD	patients	
(201,	 204),	 but	 most	 studies	 thus	 far	 have,	 however,	 used	 ELISA	 for	 neurotrophin	
detection.	We	argue	that	results	based	on	ELISA	should	be	interpreted	with	caution	due	to	
difficulties	in	separating	pro	and	mature	forms	of	neurotrophins,	since	proteins	containing	
the	same	epitope,	such	as	in	the	case	of	mature	and	pro-forms	of	NGF	and	BDNF,	will	be	
detected	 together	 in	 the	 same	 ELISA	 assay.	 A	 recent	 report	 did	 however	 demonstrate	
significantly	 higher	 levels	 of	 proNGF	 in	 postmortem	 CSF	 from	 AD	 and	 MCI	 subjects,	
compared	to	subjects	with	no	cognitive	 impairment	(239),	using	western	blot	and	ELISA.	
We	believe	that	future	studies	on	CSF	samples	from	larger	cohorts	of	AD	and	MCI	subjects	
may	help	clarify	 if	there	 is	a	difference	 in	the	 levels	of	proNGF	between	these	groups	as	
indicated	by	our	data.		
The	 choice	of	 an	 SCI	 group	as	non-demented	 controls	 can	be	 criticized	 considering	 that	
the	group	consists	of	individuals	who	were	referred	to	a	memory	clinic	due	to	complaints	
of	 memory	 loss.	 They	 were,	 however,	 investigated	 extensively,	 including	 a	
neuropsychological	 evaluation	 in	 most	 cases,	 CSF	 biomarkers	 and	 imaging	 and	 no	
objective	 memory	 impairment	 could	 be	 verified.	 Accordingly,	 we	 refer	 to	 them	 as	
cognitively	 healthy	 at	 the	 time	 of	 inclusion	 to	 the	 study	 (time	 of	 LP),	 although	 several	
reports	have	demonstrated	that	SCI	may	be	associated	with	a	significantly	higher	risk	of	
developing	dementia	(240).		
	
	
4.1.3 Neurotrophins	and	relation	to	a	pathological	biomarker	profile	and	a	progress	of	
cognitive	impairment	
In	the	MCI	group,	80%	had	been	followed	up	7-9	years	after	the	first	LP	and	of	those,	39%	
had	converted	to	AD	dementia	and	one	patient	to	Lewy	body	dementia.	In	the	SCI	group,	
23%	were	followed	up	and	only	one	subject	converted	to	MCI.	Due	to	a	low	follow-up	rate	
in	 the	SCI	group,	only	data	 from	the	MCI	subjects	were	analyzed.	The	MCI	subjects	who	
converted	to	AD	were	slightly	older	than	the	non-converters,	but	the	difference	was	not	
significant	 nor	 did	 the	 groups	 differ	 significantly	 with	 regard	 to	 pathological	 biomarker	
profile	 (t-tau/Ab42>0.52).	 Our	 data	 showed	 that	 MCI	 subjects	 who	 converted	 to	 AD	
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(converters)	 showed	 significantly	 lower	 levels	 of	 proBDNF	 in	 CSF	 (p<0.05)	 compared	 to	
those	subjects	who	remained	cognitively	stable	(non-converters).	There	was	no	significant	
difference	in	CSF	levels	of	proNGF	in	relation	to	conversion	to	AD.		
We	 suggest	 that	 in	 MCI,	 there	 may	 exist	 a	 deficiency	 in	 production	 or	 metabolism	 of	
BDNF,	reflecting	a	pathological	process	in	the	brain.	These	findings	are	in	accordance	with	
a	report	from	Peng	et	al	describing	lower	levels	of	both	pro-	and	matBDNF	in	the	brain	of	
pre-clinical	AD	patients	compared	to	non-demented	controls	(197),	suggesting	that	lower	
levels	of	proBDNF	in	CSF	reflect	the	situation	in	the	brain.	Further	studies	are	needed	to	
investigate	 if	 lower	 levels	 of	 proNGF	 and	 proBDNF	 are	 due	 to	 a	 decreased	 production,	
altered	metabolism	or	both.		
	
When	 analyzing	 pro-neurotrophins	 and	 the	 association	 to	 a	 pathological	 biomarker	
profile,	we	found	that	MCI	subjects	with	such	a	biomarker	profile	showed	higher	levels	of	
CSF	proNGF	(figure	10),	but	no	significant	difference	was	found	with	regard	to	proBDNF.		
	
	
Figure	10.	CSF	levels	of	proNGF	in	MCI	subjects	with	or	without	a	pathological	biomarker	
profile	(t-tau/Ab>0.52).	ProNGF	levels	were	significantly	higher	in	subjects	with	a	
pathological	biomarker	profile	than	with	a	normal	(non-pathological)	biomarker	profile.	Y-
axis	represents	percentage	of	internal	control.	Statistical	significance	is	indicated	by	*	
(p<0.05).		
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Metabolisms	 of	 pro-	 and	 mature	 forms	 of	 NGF	 and	 BDNF	 are	 mediated	 by	 complex	
enzyme	cascades,	involving	e.g.	plasmin	(241),	and	metalloproteases	(MMPs)	(242),	which	
are	controlled	by	activators	and	inhibitors	(se	Figure	6).	A	neurodegenerative	process	that	
affects	these	enzymatic	pathways	could	well	be	reflected	in	changes	in	levels	of	NGF	and	
BDNF.	 Our	 research	 group	 has	 previously	 reported	 higher	 levels	 of	 plasminogen,	
neuroserpin	and	tissue	inhibitor	of	metalloproteases-1	(TIMP-1)	in	CSF	from	subjects	with	
MCI	(243).	Changes	in	these	enzyme	cascades	in	AD	may	thus	help	explain	our	results	and	
give	further	strength	to	a	hypothesis	that	neurotrophin	dysfunction	and	imbalance	in	MCI	
may	be	associated	with	a	progression	to	AD.	
	
	
4.2 ENCAPSULATED	CELL	BIODELIVERY	OF	NGF,	COHORTS	I	AND	II	(PAPERS	II-IV)	
	
Table	2.	Demographic	data	on	enrolled	patients	in	cohorts	I	and	II	of	the	NGF-ECB	trial,	at	
baseline,	3	and	12	months.		
	
	 		 Baseline	
median	(range)	
3	months	
median	(range)	
12	months	
median	(range)	
Gender,	n	(M/F)	 4	M/2	F	 	 	 	
Age	(years)	 62	(55-73)	 	 	 	
Memory	problems	(years)	 4	(1-6)	 	 	 	
Time	from	AD	diagnosis	(years)	 1.5	(1-3)	 	 	 	
Duration	of	ChEI	treatment	(months)	 12	(8-26)	 	 	 	
MMSE	score	 	 23	(19-24)	 22	(18-28)	 18	(14-27)	
ADAS-Cog	score	 	 27	(22-34)	 25	(22-32)	 39	(20-53)	
CDR	score	(sum	of	boxes)	 	 0.75	(0.5-1)	 1	(0.5-1)	 1	(0.5-3)	
IADL	score	 	 14	(9-21)	 17	(10-20)	 20	(13-30)	
CSF	A𝛃42	(ng/L)	 	 138	(117-213)	 130	(92-198)	 145	(82-209)	
CSF	p-tau	(ng/L)	 	 39	(39-77)	 34	(22-81)	 40	(20-46)	
CSF	t-tau	(ng/L)	 	 153	(75-180)	 114	(65-199)	 114	(60-191)	
CSF	NFL	(ng/L)	 	 158	(125-360)	 845	(550-3120)	 260	(125-420)	
CSF	GFAP	(ng/L)	 	 785	(710-930)	 600	(570-1180)	 850	(800-1280)	
CSF	ChAT	activity	(nmol/min/mL)	 	 2.6	(2.0-3.7)	 2.7	(2.3-3.1)	 3.01	(2.05-4.35)	
CSF	AChE	activity	(nmol/min/mL)	 	 14.7	(8.6-18.4)	 13.8	(10.6-23.3)	 18.6	(10.1-28.6)	
	
	
	
 	32	
4.3 CHANGES	IN	CSF	CHOLINERGIC	MARKERS	FOLLOWING	NGF	DELIVERY	(PAPER	II)		
	
4.3.1 ChAT	activity	in	CSF	increased	during	NGF	delivery	in	responders	
At	12	months	of	NGF	delivery,	the	responder	group	(defined	as	annual	decline	in	MMSE	£	
2	points)	 showed	a	 significant	 increase	 in	ChAT	activity	 compared	 to	 the	non-responder	
group	(p<0.05)	(defined	as	annual	decline	in	MMSE	>2	points)	(p<0.05),	but	we	found	no	
significant	difference	in	CSF	ChAT	activity	over	12	months	in	a	reference	group	of	17	long-
term	stably	ChEI	 treated	AD	patients,	and	neither	did	we	find	changes	when	we	divided	
the	reference	group	to	responders	and	non-responders	according	to	the	same	criteria.	The	
presence	of	extracellular	ChAT	was	recently	discovered	 (223),	and	this	 is	 the	 first	 report	
publishing	data	on	ChAT	activity	in	CSF	in	response	to	a	long-term	stable	ChEI	treatment.	
We	 argue	 that	 the	 observed	 increase	 in	 ChAT	 activity	 during	 NGF	 delivery	 cannot	 be	
explained	by	the	concomitant	ChEI	treatment	alone,	as	these	changes	were	not	observed	
in	 the	 ChEI	 treated	 reference	 group.	 On	 the	 contrary,	 ChAT	 activity	 amongst	 the	 non-
responders	 in	 the	 reference	 group	 declined	 during	 the	 12-month	 period.	 Furthermore,	
ChAT	activity	has	been	 suggested	 to	 increase	both	 in	 vivo	and	 in	 vitro	 as	 a	 response	 to	
NGF	administration	 in	rats	and	 in	vitro	 (244,	245),	giving	further	support	to	our	findings.	
The	patients’	cognitive	performance	on	MMSE	was	followed	up	for	15	months	and	ADAS-
Cog	 for	 7	months	 after	 removal	 of	 the	NGF-ECB	 implants	 and	MMSE	assessments	were	
also	available	 for	an	average	of	20	months	previous	to	the	trial	baseline.	We	found	that	
the	responders	showed	no	significant	decline	in	MMSE	performance,	compared	with	own	
score	at	baseline,	and	compared	to	non-responders	for	15	months	post	NGF	delivery	and	
the	same	pattern	was	observed	for	3	months	post	NGF	delivery	 for	ADAS-Cog.	Thus,	we	
found	 indications	 for	 a	 cognitive	 stabilization	 by	NGF	 delivery	 that	was	 enduring	 in	 the	
responders	group	for	at	least	3	months	post	NGF.			
	
	
4.3.2 AChE	activity	in	CSF	increased	in	the	whole	group	at	12	months	of	NGF	delivery	
The	activity	of	AChE	in	CSF	was	increased	at	12	months	of	NGF	delivery	 in	the	total	NGF	
group,	(p<0.05),	compared	to	baseline,	but	we	found	no	statistically	significant	difference	
between	 the	 responder	 and	 non-responder	 groups.	 The	 reference	 group	 showed	 a	
decrease	in	AChE	activity	over	a	12	month	period,	most	pronounced	in	the	non-responders	
in	the	reference	group	(p<0.05).		
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Figure	11.	Changes	from	baseline	in	ChAT	and	AChE	activities	in	CSF	at	12	months	of	NGF	
delivery.	 Adapted	 from	 Karami,	 Eyjolfsdottir	 et	 al,	 2015	 and	 reprinted	 with	 permission	
from	Elsevier	(227).	*p<0.05:	difference	from	baseline.	
	
	
	
	
	
Studies	demonstrate	that	following	ChEI	treatment	in	AD	patients,	AChE	protein	levels	and	
activity	 in	 CSF	 show	 an	 increase	 (224,	 246),	 and	 that	 increased	 enzyme	 activity	 reflects	
enzyme	inhibition	(247).	The	increase	in	CSF	AChE	activity	observed	in	this	study	is	though	
unlikely	 to	 be	 explained	 by	 ChEI	 treatment,	 as	 the	NGF	 cohort	 had	 been	 treated	 for	 at	
least	 8	 months	 before	 NGF-ECB	 implantation.	 Moreover,	 the	 reference	 group	 did	 not	
exhibit	the	same	increase	which	gives	further	support	to	our	proposition	that	the	increase	
in	CSF	cholinergic	markers	 is	 likely	to	be	a	consequence	of	stimulation	of	the	cholinergic	
basal	forebrain	induced	by	NGF	delivery.	
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4.3.3 Increase	over	time	in	CSF	cholinergic	markers	correlated	with	cognition,	brain	
glucose	utilization	and	nicotine	receptor	binding	
We	found	a	significant	positive	correlation	between	ChAT	activity	in	CSF	and	performance	
on	MMSE,	both	for	absolute	values	(r=0.89,	p	=	0.014)	and	percent	change	from	baseline	
(r	=	0.92,	p<0.005),	at	12	months	of	NGF	delivery,	but	not	at	3	months.	Similar	correlative	
patterns	were	found	when	we	examined	the	association	between	change	from	baseline	in	
CSF	ChAT	at	12	months	and	performance	on	ADAS-Cog	(r	=	-0.91,	p	=	0.0093).		
CSF	ChAT	activity	also	correlated	with	in	vivo	brain	glucose	utilization	measured	with	FDG-
PET	after	12	months	of	NGF	delivery	in	the	average	cortical	regions	(r	=	0.83,	p	=	0.037).	
AChE	activity	correlated	with	glucose	brain	utilization	in	overall	brain	regions	(r	=	0.82,	p	=	
0.043).	ChAT	and	AChE	activities	in	CSF	also	correlated	with	11C	nicotine	binding,	measured	
with	PET,	though	particularly	in	the	left	hemisphere.	Furthermore,	changes	in	levels	of	11C-
nicotine	binding	correlated	with	changes	in	cognitive	performance,	measured	with	MMSE	
and	 ADAS-Cog,	 during	 a	 12	month	NGF	 delivery	 (r	 =	 0.82,	 p	 =	 0.048	 and	 r	 =	 -0.89,	 p	 =	
0.013,	respectively).		
	
The	 cholinergic	 system	 exhibits	 deficiencies	 early	 on	 in	 AD,	 substantiated	with	 reduced	
levels	of	ChAT	in	the	brain	and	a	decrease	in	nicotinic	ACh	receptors.	A	disease-modifying	
treatment	to	AD	therefore	has	to	be	able	to	stop	or	even	reverse	the	cholinergic	deficit.	It	
is	 intriguing	 to	 speculate	 that	 the	 findings	 from	 our	 NGF	 delivery	 trial	 suggest	 disease-
modifying	effects	for	the	first	time.		
	
	
4.4 EFFECTS	ON	QUANTITATIVE	EEG	PARAMETERS	FOLLOWING	NGF	DELIVERY	 (PAPER	
III)	
Since	there	is	a	slowing	of	the	background	rhythmic	activity	in	EEG	in	AD,	with	reduction	of	
the	 fast	 alpha	 power	 and	 increase	 in	 the	 slow	 theta	 power,	 we	 hypothesized	 that	
following	the	NGF	delivery,	an	increase	in	alpha	and	decrease	in	theta	power	would	occur.	
Also,	in	our	previous	paper	on	NGF	delivery	(165)	with	intracerebroventricular	infusion	of	
NGF,	 positive	 effects	 on	 EEG	 activity	 were	 found.	 Thus,	 it	 was	 important	 to	 study	 the	
effects	on	EEG	also	in	this	NGF	delivery	trial.		
	
	
4.4.1 Stable	or	increased	MMSE	following	NGF	delivery	correlated	with	an	increase	in	
alpha	power	
Using	 the	 Ragu	 software,	 we	 looked	 for	 possible	 changes	 in	 absolute	 power	 in	 the	
continuous	frequency	range	from	0	to	70	Hz,	and	whether	those	changes	correlated	with	
changes	between	 the	end	of	NGF	delivery	and	baseline,	across	 the	 three	 time	points	of	
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EEG	 observations	 (baseline,	 3	 or	 12	 months)	 during	 the	 NGF	 delivery.	 The	 results	 are	
presented	as	topographic	analysis	of	covariance	(TANCOVA)	maps	of	qEEG	spectral	power	
and	correlation	to	MMSE	changes	over	time.	We	found	a	significant	correlation	between	
alpha	power	at	around	11	Hz	 (10-11.5	Hz)	and	changes	 from	baseline	 in	MMSE,	 i.e.	 less	
change	in	MMSE	by	the	end	of	the	study	correlated	with	an	increase	in	a	narrow	band	of	
fast	 alpha	 power.	 QEEG	 at	 3	 months	 compared	 to	 baseline	 was	 marginally	 significant	
(0.059)	while	baseline	against	12	months	(p=0.033)	and	baseline	against	merged	3	and	12	
months	 (p=0.023)	 showed	 a	 clearer,	 statistically	 significant	 trend.	 Interestingly,	 no	
additional	change	was	observed	between	3	and	12	months	(p=0.56).		
	
	
Figure	12.	TANCOVA	interaction	between	change	from	baseline	in	MMSE	and	EEG	alpha	
power	in	the	alpha	frequency	range,	at	10-11.5	Hz.		
a. Probability,	p	(y-axis)	of	the	noll	hypothesis	for	a	TANCOVA	correlation	between	time	
and	change	 from	baseline	 (BL)	 in	MMSE,	as	a	 function	of	 frequency	 in	Hz	 (x-axis).	
Significant	(p<0.05)	frequency	range	is	marked	by	a	white	line.			
b. Topographic	maps	of	the	correlations	between	change	from	baseline	(BL)	in	MMSE	
for	the	EEG	observations	at	3	months	(3m)	and	12	months	(12m).	Red	maps	display	
correlations	between	 less	 than	average	change	 from	baseline	 in	MMSE	score	 (less	
decline)	and	increase	in	alpha	power	in	the	10-11.5	Hz	frequency	range.	Blue	maps	
display	 correlations	 between	 higher	 than	 average	 change	 from	 baseline	 in	MMSE	
score	 (more	 decline)	 and	 a	 decrease	 in	 alpha	 power	 in	 the	 respective	 frequency	
range.		
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4.4.2 Increased	CSF	ChAT	activity	correlated	with	decrease	in	theta	and	increase	in	
alpha	power	following	NGF	delivery	
In	 the	 theta	 frequency	 band,	 at	 a	 frequency	 between	 6-6.5	 Hz,	 we	 found	 a	 weak	
correlation	between	 theta	power	 in	EEG	and	 less	 than	average	 change	 from	baseline	 in	
CSF	ChAT	activity	(12	months	minus	baseline).	This	 indicates	that	the	more	theta	power,	
the	less	the	increase	in	ChAT	activity,	but	the	correlation	was	only	significant	when	3	and	
12-months	were	merged,	compared	to	baseline	(p	=	0.023).		
Furthermore,	we	 found	a	 correlation	between	 the	positive	 change	 from	baseline	 in	CSF	
ChAT	activity	at	12	months	and	increased	power	in	the	alpha	power	band	at	11	–	11.5	Hz.	
The	association	was	most	prominent	at	3	months	(p	=	0.042),	indicating	that	at	3	months,	
the	patients	exhibited	more	fast	alpha	power	associated	with	an	increase	in	ChAT	activity	
and	this	effect	on	EEG	was	marginally	prolonged	to	12	months	(p	=	0.056).	
	
Here,	for	the	first	time,	we	demonstrate	a	relation	between	the	cholinergic	marker	ChAT	
and	EEG	activity,	particularly	in	the	narrow	fast	alpha	band	during	NGF	delivery	to	the	CBF	
in	six	AD	patients.	Nucleus	basalis	of	Meynert	is	a	major	source	of	cholinergic	projections	
to	the	cortex	and	hippocampus,	and	a	reduction	in	the	cholinergic	markers	ChAT	and	AChE	
in	the	AD	brain,	reflects	the	loss	of	cholinergic	innervation	(248).	Particularly,	ChAT	activity	
has	 been	 used	 as	 a	marker	 of	 cholinergic	 neuronal	 loss	 in	 lesion	 studies	 (249,	 250).	 In	
animal	models	with	nucleus	basalis	of	Meynert	lesions,	EEG	changes	have	been	reported,	
with	 an	 increased	 power	 in	 the	 low	 frequency	 bands	 and	 decreased	 power	 in	 the	 high	
frequency	bands,	paralleled	by	decreased	cortical	activity	of	ChAT	 (251).	ChEI	 treatment	
has	repeatedly	been	shown	to	increase	fast	EEG	activity	in	the	alpha	band,	particularly	in	
the	posterior	regions	of	the	brain	(252,	253),	and	this	effect	correlates	well	with	improved	
cognition,	 measured	 with	 MMSE	 (253).	 Even	 cholinergic	 stimulation	 of	 non-demented	
subjects,	 with	 the	 ChEI	 galantamine	 results	 in	 increased	 alpha	 power	 and	 improved	
working	memory	performance	(254).	Our	results	indicate	an	association	between	changes	
in	ChAT,	a	marker	of	cholinergic	activity,	and	EEG	activity,	both	in	the	slow	theta	and	the	
fast	alpha	frequencies,	mainly	though	during	the	first	three	months	of	NGF	delivery.	The	
patients	had	been	treated	stably	with	ChEIs	for	at	least	eight	months	prior	to	enrollment,	
which	makes	it	less	likely	that	the	ChEI	treatment	would	explain	the	observed	association	
between	the	cognitive	stabilization	and	cholinergic	stimulation	and	increased	alpha	power	
in	 EEG	 during	 the	 study.	 While	 an	 earlier	 study	 on	 ChEI	 treated	 AD	 patients	 showed	
limited	 improvements	 of	 qEEG	parameters	 for	 up	 to	 6	months	 (252),	 the	 present	 study	
showed	 sustained	 association	 between	 a	 cognitive	 stabilization	 on	 MMSE	 and	 alpha	
power	during		NGF	delivery.	There	was	however	no	significant	association	between	theta	
power	and	MMSE	change,	as	was	demonstrated	for	alpha	power.	Theta	power	increases	
early	 on	 in	 AD	 and	 thereafter	 reaches	 a	 plateau	 during	 the	 course	 of	 the	 disease	 (255,	
256).	Theta	power	may	therefore	not	be	used	as	a	single	electrophysiological	marker	for	
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monitoring	disease	activity	and	therapeutic	effect	of	stimulation	of	the	cholinergic	system,	
but	should	rather	be	used	as	an	indicator	of	baseline	disease	severity.		
	
	
4.5 STRUCTURAL	BRAIN	CHANGES	ON	MRI	FOLLOWING	NGF	DELIVERY	(PAPER	IV)	
	
4.5.1 Changes	in	brain	atrophy	following	NGF	delivery	
At	baseline	of	the	study,	the	NGF	responders	(using	the	same	definition	of	responders	and	
non-responders	as	 in	paper	II)	exhibited	a	 lower	BV/CSF	index	(15.6	±	0.1)	than	the	non-
responders	 (22.2	±	8.2),	while	the	36	ADNI	controls	showed	a	 lower	BV/CSF	 index	 in	the	
non-responder	 group	 (19.9	 ±	 7.5)	 as	 compared	 to	 responders	 (24.1	 ±	 11.3),	 indicating	 a	
higher	degree	of	brain	atrophy	 for	 the	NGF	 responders	at	baseline	as	compared	 to	non-
responders.	The	NGF	responders	however	showed	a	slower	decline	in	brain	atrophy	during	
the	12	months	of	NGF	delivery	than	the	non-responders,	while	for	the	ADNI	controls,	there	
was	 no	 significant	 difference	 between	 the	 corresponding	 groups	 at	 the	 12	 month	
observation.	Mean	BV/CSF	index	for	the	NGF	cohort	was	18.9	(±6.30)	at	baseline	and	15.6	
(±4.67)	 at	 follow-up	 at	 12	 months	 and	 the	 difference	 was	 statistically	 significant	 (p	 =	
0.028).	 For	 the	ADNI	 controls,	mean	BV/CSF	 index	 also	 decreased	 significantly	 between	
baseline	 and	 12	months.	We	 found	 no	 difference	 in	 hippocampal	 volume	 between	 the	
NGF	responders	and	non-responders.		
	
	
	
Figure	 13.	A.	Means	 for	 the	 following	 groups	 at	 two	 time	 points,	 baseline	 (BL)	 and	 12-
months	 (Follow-up):	 NGF	 cohort	 (black)	 and	 ADNI	 cohort	 (gray),	 responders	 in	 both	
cohorts	 are	 displayed	 in	 solid	 lines,	 non-responders	 in	 dotted	 lines.	 B.	 Change	 from	
baseline	for	individual	NGF	patient,	responders	are	displayed	in	solid	lines,	non-responders	
in	dotted	lines.	The	arrows	show	normative	cut-offs	calculated	from	responders	and	non-
responders	in	the	ADNI	cohort.	C.		NGF	responders	showed	slower	decline	than	NGF	non-
responders,	 while	 the	 corresponding	 ADNI	 groups	 showed	 a	 similar	 decline	 in	 brain	
atrophy	during	the	follow-up	period.	Reprinted	from	Ferreira	et	al,	2015	with	permission	
from	IOS	press	(257).	
	
	
 	38	
	
	
	
4.5.2 Stabilization	of	brain	atrophy	following	NGF	delivery	correlated	with	clinical	
outcome	measures	
Upon	 follow-up	 at	 12	 months,	 the	 NGF	 responders	 showed	 less	 decline	 on	 outcome	
measures,	such	as	CDR	sum	of	boxes,	ADAS-Cog,	CSF	Ab	and	on	the	Instrumental	activities	
of	 daily	 living	 (IADL)	 scale	 (258).	 They	 also	 showed	a	 less	 increase	 in	NFL	 than	 the	non-
responder	group	but	they	also	exhibited	more	increase	in	CSF	t-tau.	Baseline	BV/CSF	index	
correlated	 significantly	 with	 longitudinal	 changes	 in	 CSF	 Ab42	 (r	 =	 -0.943,	 p	 =	 0.005),	
indicating	that	patients	with	greater	brain	atrophy	at	baseline	showed	an	improvement	in	
CSF	Ab42	at	follow-up.		
	
At	 baseline,	 the	 NGF	 responders	 exhibited	 a	 higher	 degree	 of	 neuronal	 degeneration,	
indicated	by	more	brain	atrophy	and	higher	t-tau.	Interestingly,	this	group	showed	a	more	
favorable	clinical	progression	and	less	progression	of	brain	atrophy	at	the	end	of	the	study	
as	well	as	stable	levels	of	CSF	Ab42	and	t-tau.	The	fact	that	the	responder	group	exhibited	a	
higher	 degree	 of	 neurodegeneration	 at	 the	 start	 of	 the	 study	 and	 at	 the	 same	 time	
showed	 a	 more	 favorable	 overall	 clinical	 status	 at	 the	 end	 of	 the	 study	 may	 seem	
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contradictory.	In	the	literature,	the	differentiation	between	clinical	and	pathophysiological	
severity	has	been	attributed	to	cognitive	reserve	(259),	or	the	ability	to	endure	brain	injury	
without	 showing	a	corresponding	degree	of	 clinical	 symptoms.	We	hypothesize	 that	 the	
responder	 patients	may	have	had	a	higher	degree	of	 cognitive	 reserve	but	 this	must	be	
studied	 further	 and	 additional	 proxies	 of	 cognitive	 reserve,	 e.g.	 social	 and	 intellectual	
engagements	and	brain	reserve	(status	of	functional	brain	networks)	may	be	of	interest	to	
further	test	this	hypothesis.	
At	the	end	of	the	study,	the	responder	group	showed	lower	progress	in	brain	atrophy,	less	
worsening	 in	 clinical	 parameters	 as	well	 as	 less	 pronounced	 changes	 in	 CSF	 biomarkers	
which	 may	 further	 support	 this	 hypothesis	 of	 cognitive	 reserve.	 The	 NGF	 responders	
showed	 a	 similar	 degree	 of	 hippocampal	 atrophy	 as	 the	 non-responders	 over	 time,	
suggesting	 a	 more	 generalized	 response	 to	 NGF	 delivery	 in	 the	 brain	 involving	 wide	
cerebral	projections,	rather	than	a	focal	response	in	hippocampal	projections.		
Results	 obtained	 from	 automatic	MRI	 segmentation	 (as	 applied	 in	 this	 study),	 have	 the	
advantage	 of	 being	 free	 from	 rater	 bias,	 placebo	 effect	 or	 chance	 and	 are	 thus	 used	
increasingly	 as	 outcome	 measures	 in	 clinical	 trials	 (260).	 We	 furthermore	 propose	 the	
usefulness	 of	 the	 BV/CSF	 index	 as	 a	 tool	 for	 monitoring	 longitudinal	 changes	 in	 brain	
atrophy	in	clinical	trials	where	a	marker	of	brain	atrophy	is	needed.	To	our	knowledge,	this	
is	 the	 first	 study	 reporting	 longitudinal	 changes	 in	 atrophy	 parameters	 in	 patients	
receiving	 NGF	 delivery	 to	 the	 basal	 forebrain.	 Due	 to	 the	 small	 cohort	 size,	 the	 results	
must	be	interpreted	with	caution	and	confirmed	in	larger	studies.		
	
	
	
4.6 ENCAPSULATED	CELL	BIODELIVERY	OF	NGF	TO	THE	BASAL	FOREBRAIN	IN	FOUR	AD	
PATIENTS,	A	DOSE	ESCALATION	STEP	(PAPER	V)	
	
4.6.1 Patient	demographics	and	diagnosis	of	AD	
Four	patients	were	enrolled	to	this	third	dose	step	of	the	NGF-ECB	trial	with	a	duration	of	
six	months	and	demographic	data	are	presented	in	table	3.	The	patients	were	treated	with	
a	 stable	 ChEI	 treatment	 for	 a	 median	 duration	 of	 17	 months	 prior	 to	 enrollment,	 and	
remained	on	ChEI	 treatment	 throughout	 the	 study.	All	 four	patients	had	well-controlled	
hypertension	and	were	normotensive	at	enrollment.	Three	of	four	patients	had	a	history	
of	mild	 to	moderate	 depression	 and	 one	 patient	was	 treated	 for	 hypothyroidism.	 Brain	
glucose	 utilization,	 assessed	 with	 FDG-PET	 at	 baseline,	 was	 consistent	 with	 AD	 and	
histology	by	cortical	biopsies	taken	from	the	implant	site	confirmed	the	diagnosis	of	AD	in	
all	four	patients.		
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Table	3.	Demographic	and	CSF	data	on	enrolled	patients,	at	baseline,	3	and	6	months.	
	
	
		 	 Baseline	
median	(range)	
3	months	
median	(range)	
6	months	
median	(range)	
Gender,	n	(M/F)	 3M	/1F	 	 	 	
Age	(years)	 63.5	(57-68)	 	 	 	
Memory	problems	(years)	 4	(0.5-8)	 	 	 	
Time	from	AD	diagnosis	(years)	 1.5	(0.5-5)	 	 	 	
Duration	of	ChEI	(months)	 1.4	(0.5-5)	 	 	 	
MMSE	score	 	 21	(16-23)	 18	(15-24)	 19	(14-21)	
ADAS-Cog	score	 	 29	(23-35)	 37	(21-46)	 33	(26-41)	
CDR	score	(sum	of	boxes)	 	 0.75	(0.5-1)	 1	(0.5-1)	 1	(1-2)	
IADL	score	 	 19	(17-21)	 17	(15-23)	 23	(14-24)	
CSF	A𝛃42	(ng/L)	 	 188	(134-208)	 202	(113-207)	 183	(123-206)	
CSF	t-tau	(ng/L)	 	 128	(70-235)	 120	(64-256)	 113	(76-187)	
CSF	p-tau	(ng/L)	 	 36	(18-76)	 42	(35-48)	 46	(33-53)	
CSF	NFL	(ng/L)	 	 301	(57-557)	 1959	(846-2632)	 718	(236-758)	
CSF	GFAP	(ng/L)	 	 586	(395-891)	 612	(387-943)	 589	(535-833)	
CSF	ChAT	activity	(nmol/min/mL)	 	 374	(317-447)	 367	(279-414)	 358	(337-410)	
CSF	AChE	activity	(nmol/min/mL)			 	 12	(9-22)	 10	(8.6-20.9)	 10	(9-23)	
	
	
4.6.2 Safety	and	tolerability	
All	four	patients	underwent	stereotactic	implantations	of	the	second-generation	NGF-ECB	
implants,	 without	 immediate	 surgical	 complications.	 Cranial	 CT	 scans	 were	 performed	
post-operatively	 to	 confirm	 implant	 positions,	 showing	 no	 adverse	 events.	 The	 scalp	
incisions	healed	well	in	all	patients,	and	the	postoperative	course	was	mainly	uneventful.	
16	adverse	events	(AEs)	were	reported	during	the	study	but	no	serious	adverse	event.	One	
AE	 was	 of	 medical	 importance	 though,	 a	 left-side	 parieto-occipital	 subacute	 subdural	
hematoma	(SDH),	discovered	incidentally	at	the	3-month	MRI	follow-up,	without	a	midline	
shift,	 and	 in	 no	 connection	 to	 the	 NGF-ECB	 implants.	 It’s	 important	 to	 note,	 that	 one	
patient	in	the	first	cohort	of	the	NGF-ECB	trial	suffered	a	SDH,	also	incidentally	discovered	
at	the	3-month	MRI	follow-up,	and	had	resolved	within	3	months	(176).	Both	these	SDHs	
gave	no	or	very	mild	symptoms	of	fatigue.	They	were	treated	conservatively	and	resolved		
completely.	 They	 may	 be	 related	 to	 the	 previous	 surgery	 in	 combination	 with	 brain	
atrophy.	 None	 of	 the	 patients	 showed	 any	 sign	 of	 weight	 loss	 or	 back	 pain.	 The	most	
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common	AEs	were	a	mild	post-operative	headache	and	transient	post-operative	delirium.	
All	AEs	were	resolved	at	the	end	of	the	trial	and	all	four	patients	could	complete	the	study.		
	
	
4.6.3 Implant	performance	
Pre-operative	release	of	NGF	for	the	sixteen	NsG0202.1	 implants	selected	for	 implanting	
was	 on	 average	 8.6	 ±	 2.2	 ng	 NGF/24	 hours,	 and	 was	 thus	 five	 times	 higher	 than	 NGF	
release	of	the	first-generation	NGF	implant,	NsG002	(177).	Upon	retrieval	of	the	implants	
at	the	end	of	this	dose	step,	all	implants	were	proven	to	be	intact,	and	no	inflammation	or	
connective	 tissue	 was	 found.	 13	 out	 of	 16	 implants	 released	 NGF	 and	 48	 hours	 after	
retrieval,	 the	average	NGF	released	per	 implant/24	hours	was	6.1	ng,	5.9	ng,	6.8	ng	and	
37.2	ng.		
	
As	a	result	of	dissatisfactory	gene	expression	and	low	cell	survival	at	retrieval	for	the	first-
generation	 implant,	 we	 developed	 this	 second-generation	 NGF-ECB	 implant,	 NsG0202.1	
for	 a	 dose-escalation	 step.	 The	 implant	 and	 cell	 line	 were	 subjected	 to	 modifications,	
including	optimization	of	the	plastic	material	in	the	implant,	providing	better	cell	support	
and	 improved	 manufacturability	 and	 application	 the	 Sleeping	 Beauty	 (SB)	 transposon	
expression	system	(261)	to	achieve	a	higher	secretion	of	NGF.	The	SB	gene	vector	system	
is	a	non-viral	system,	able	to	provide	an	efficient	and	stable	gene	transfer	with	long-term	
gene	 expression	 (262)	 and	 this	 study	 is	 the	 first	 to	 report	 a	 clinical	 application	 of	 SB	
transposon-mediated	gene	delivery	to	the	central	nervous	system	in	man.		
	
	
4.6.4 Secondary	outcome	measures	
All	four	patients	showed	a	decline	in	cognitive	performance	on	MMSE	by	2-3	points	and	an	
increase	 in	 ADAS-Cog	 score	 (inverse	 scale,	 the	 higher	 the	 score,	 the	 worse	 cognitive	
performance)	during	the	6-month	trial	period,	paralleled	by	a	decrease	in	BV/CSF	index	on	
MRI	from	baseline.		
Further	 analyses	 revealed	 no	 significant	 differences	 in	 the	 CSF	 AD	 biomarkers,	 as	
compared	to	baseline.	Levels	CSF	NFL	increased	at	the	3-month	observation	point,	but	had	
decreased	at	6	months,	albeit	not	to	baseline	levels.	Activities	of	CSF	ChAT	and	AChE	were	
increased	 in	 two	 patients	 at	 6	months	 and	 this	 increase	 correlated	with	 a	more	 stable	
cognitive	performance	(less	decline	in	MMSE)	at	the	end	of	the	trial	step.		
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Figure	 14.	 Correlations	 between	 changes	 from	 baseline	 in	 MMSE	 and	 CSF	 cholinergic	
markers	(a	&	b),	and	nicotine	receptor	binding	in	the	whole	brain	(c).	The	baseline	value	
for	nicotine	receptor	binding	for	patient	marked	number	1	was	not	available	(marked	with	
a	circle),	due	to	technical	difficulties	with	the	PET	tracer	and	for	the	purpose	of	calculating	
change	from	baseline,	we	extrapolated	an	average	of	baseline	values	from	the	other	three	
patients.	Reprinted	with	modifications	from	Eyjolfsdottir	et	al	2016,	with	permission	from	
BioMed	Central	(210).	
	
	
	
	
	
	
We	observed	no	change	in	11C	nicotine	receptor	binding	by	PET	during	the	6-month	trial	
step.	 Longitudinal	 change	 in	whole	 brain	 11C	 nicotine	 binding	 did	 though	 correlate	with	
change	from	baseline	in	MMSE	(fig.	14	c).		
	
Results	 from	previous	NGF	delivery	 trials	have,	 in	a	 subset	of	patients,	 shown	 improved	
cognitive	 performance	 (172),	 brain	 glucose	 utilization	 and	 nicotine	 receptor	 binding	 on	
PET	as	well	as	improved	EEG	pattern	(164,	165).	In	this	dose	step,	we	found	no	evidence	of	
improved	cognition	during	the	6	months,	as	was	expected	considering	the	short	duration	
of	 the	 trial	 step,	 but	 neither	 were	 there	 signs	 of	 a	 greater	 cognitive	 decline	 than	 was	
expected	 during	 6	months	 according	 to	 previous	 studies	 (225).	 There	 was	 no	 evidence	
from	 our	 data	 for	 changes	 in	 levels	 of	 the	 CSF	 biomarkers.	 NFL	 levels	 were	 though	
increased	at	 the	3-month	observation	and	although	 they	had	decreased	 somewhat	at	6	
months,	the	levels	were	still	increased	compared	to	baseline	and	this	was	also	reported	in	
the	 previous	 clinical	 trial	 with	 NGF-ECB	 (176).	 This	 has	 been	 interpreted	 as	 a	 sign	 of	 a	
temporal	neuronal	damage	related	to	the	neurosurgery.	NFL	is	a	marker	of	acute	neuronal	
damage	 (263)	 and	 a	 similar	 observation	 was	 also	 reported	 from	 a	 study	 of	 deep	 brain	
stimulation	electrode	 implantation	 in	Parkinson’s	disease	patients,	declining	over	 	a	 few	
months	(264).	Levels	of	GFAP,	a	marker	of	glial	cell	activation	after	damage,	were	however	
unaffected.		
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In	 accordance	with	our	 previous	 findings,	we	 found	 correlations	 between	 changes	 from	
baseline	in	MMSE	and	changes	in	three	markers	of	cholinergic	activity,	the	activities	of	the	
ACh	synthesizer	ChAT	and	the	ACh	degrading	enzyme	AChE	and	nicotine	receptor	binding	
measured	by	PET.	There	were	no	changes	on	atrophy	parameters	measured	by	MRI	in	this	
dose	cohort,	but	this	was	not	to	be	expected	considering	the	short	trial	period.		
	
	
	
4.7 STRENGTHS	AND	LIMITATIONS	
Encapsulated	cell	biodelivery	has	advanced	as	a	therapeutic	option	for	neurodegenerative	
disorders.	 This	 technology	 has	 several	 advantages	 from	 a	 safety	 perspective.	 The	 cells	
being	encapsulated	provides	immunoisolation	reducing	risk	for	immunoreactions,	and	the	
technique	also	makes	removal	of	the	cells	possible	in	case	of	complication	or	replacement	
of	 the	 implant	with	new	or	modified	cells	without	 the	use	of	 stereotactic	 surgery	 (213).	
Moreover,	there	 is	no	genetic	modification	of	the	patients’	own	cells,	diminishing	risk	of	
mutations	or	carcinogenesis.		
The	NGF-ECB	study	has	several	limitations,	the	most	significant	being	the	invasiveness	of	
the	 surgical	 procedure,	 which	 induces	 a	 strategic	 brain	 lesion	 during	 implantation.	 The	
method	 is	 still	 at	 an	 early	 experimental	 stage,	 and	 poses	 heavy	 regulatory,	 ethical	 and	
economical	 demands	 on	 the	 investigators,	which	 explains	 the	 small	 number	 of	 patients	
included.	This	in	turn	limits	the	use	of	conventional	statistics	so	that	interpretation	of	the	
data	calls	for	due	caution.	As	a	partial	countermeasure	for	this	limitation,	control	groups	
were	 included	 for	 data	 comparisons	 in	 two	 studies	 from	 this	 group	 (papers	 II	 &	 IV).	
Another	 limitation	 in	 statistical	 analyses	 (in	 papers	 II	&	 III),	 is	 that	 no	 corrections	 for	
multiple	 comparisons	were	done	due	 to	 the	exploratory	nature	of	 the	 studies,	 but	 as	 a	
compensation	we	weighted	the	overall	patterns	of	observations	rather	than	emphasizing	
isolated	findings.	An	additional	limitation	is	that	there	was	no	possibility	to	determine	the	
NGF	release	 in	vivo	 in	 the	brain,	making	 it	 impossible	to	relate	changes	 in	cognition	and	
biomarkers	to	the	in	vivo	release	of	NGF,	until	the	NGF-ECB	implants	were	retrieved.		
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5 CONCLUDING	REMARKS	
The	main	aim	of	this	thesis	was	to	explore	the	potential	of	encapsulated	cell	biodelivery	
of	NGF	with	regard	to	safety,	tolerability	and	possible	disease-modifying	effects	in	a	total	
of	ten	AD	patients.	A	secondary	aim	was	to	explore	the	levels	of	neurotrophins	and	their	
respective	pro-peptides	in	CSF.		
	
In	papers	II-IV,	effects	of	NGF	delivery	using	a	NGF-ECB	implant,	in	a	first	in	man	study	in	
six	 AD	 patients,	 were	 explored	 on	 cholinergic	 markers	 in	 CSF,	 EEG	 spectral	 power	 and	
spatial	 distribution	 and	 atrophy	 on	MRI.	 In	 paper	 V,	 safety,	 tolerability	 and	 effects	 on	
biomarkers	 were	 explored	 for	 a	 second-generation	 NGF-ECB	 implant,	 targeted	 to	 the	
cholinergic	 basal	 forebrain	 in	 four	AD	patients.	 In	paper	 I,	we	 investigated	 levels	 of	 the	
neurotrophins	NGF	and	BDNF	and	their	respective	pro-forms	in	CSF	samples	from	subjects	
with	AD,	compared	to	subjects	with	MCI	and	SCI.		
In	our	studies	on	biological	effects	of	NGF	delivery,	the	results	point	towards	a	stimulation	
of	the	cholinergic	system,	as	measured	by	an	 increase	 in	the	activities	of	the	cholinergic	
markers	 ChAT	 and	 AChE	 in	 CSF,	 a	 favorable	 change	 in	 EEG	 power	 in	 the	 fast	 alpha	
spectrum,	and	a	slowing	rate	of	brain	atrophy	in	a	subset	of	patients.	Our	studies	on	CSF	
levels	of	neurotrophins	our	results	indicate	an	alteration	in	the	levels	of	neurotrophin	pro-
forms	in	MCI.		
	
The	key	findings	of	this	thesis	may	be	summarized	as	follows:	
	
• safety	 and	 tolerability	 was	 demonstrated	 for	 both	 NGF-ECB	 implants	 and	 no	
adverse	 events	 in	 all	 three	 dose	 cohorts	 were	 deemed	 to	 be	 related	 to	 NGF	
delivery	or	the	ECB-NGF	device,	
• the	second-generation	NGF-ECB	implant	NsG0202.1	showed	a	sustained	release	of	
NGF	in	a	majority	of	implants	and	released	five	times	higher	levels	of	NGF	than	the	
first-generation	NsG0202	implant,	
• the	cholinergic	marker	ChAT,	 recently	demonstrated	to	be	present	extracellularly	
in	 CSF,	 may	 be	 a	 useful	 biomarker	 for	 monitoring	 treatment	 effect	 on	 the	
cholinergic	system,	
• the	results	suggest,	for	the	first	time,	a	pattern	of	associations	between	cholinergic	
markers	in	CSF,	suggestive	of	beneficial	effects	of	NGF	delivery,	supporting	a	proof-
of-principle	effect,		
• increase	in	power	in	the	narrow	fast	alpha	frequency	band	in	EEG	was	associated	
with	 a	 less	 decline	 in	 MMSE	 and	 an	 increase	 in	 ChAT	 activity	 following	 NGF	
delivery,	in	particular	after	the	first	three	months	of	treatment,	further	supporting	
observed	modifications	of	the	cholinergic	system,	
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• less	cognitive	decline	was	associated	with	less	brain	atrophy	following	NGF	delivery	
in	 a	 subset	 of	 patients,	 and	 the	 observed	 slower	 rate	 of	 brain	 atrophy	was	 also	
associated	with	favorable	changes	in	clinical	outcome	measures,	
• changes	in	neurotrophin	pro-peptides	may	be	predictive	of	a	progress	in	cognitive	
decline	in	subjects	with	MCI.		
	
	
	
6 FUTURE	RESEARCH	DIRECTIONS	
There	is	convincing	evidence	supporting	the	role	of	cholinergic	dysfunction	as	one	of	the	
pathophysiological	events	 leading	to	the	development	of	AD.	The	importance	of	NGF	for	
the	growth	and	 survival	of	 cholinergic	basal	 forebrain	neurons	 is	 also	well	documented.		
There	 is	 thus	 great	 support	 for	 the	 implication	 of	 NGF	 delivery	 as	 a	 potential	 disease-
modifying	 therapeutic	 strategy	 in	 this	 neurodegenerative	 disease.	 There	 is,	 however,	 a	
huge	caveat	 in	 that	 the	NGF	molecule	does	not	pass	 the	blood-brain	barrier,	and	that	 it	
cannot	be	administered	systemically	to	the	central	nervous	system	due	to	side-effects.		
Extensive	testing	with	NGF	delivery	to	the	cholinergic	basal	 forebrain	 in	animals	prior	to	
human	 trials	 have	 demonstrated	 safety,	 tolerability	 and	 possible	 therapeutic	 effects.	 A	
handful	 of	 trials	 have	 now	 been	 conducted	 but	 they	 have	 all	 been	 limited	 by	 the	
invasiveness	of	the	stereotactic	neurosurgery	and	by	the	risks	of	general	anesthesia	in	this	
sensitive	patient	group.	The	patients	must	therefore	be	selected	carefully	with	regard	to	
age	and	comorbidities.		
With	this	said,	it	would	be	very	attractive	to	be	able	to	develop	a	non-invasive	way	of	NGF	
administration	 without	 the	 side-effects	 of	 systemic	 administration,	 and	 this	 is	 indeed	
under	current	investigation	in	animals	(265)	in	the	form	of	intranasal	delivery	of	NGF.	
	
As	for	future	development	of	the	NGF-ECB	technique,	the	implant	design	is	under	further	
refinement	 to	obtain	an	even	more	predictable	and	stable	delivery.	For	a	phase	 II	 study	
testing	 effects	 on	biomarkers	 and	 clinical	 outcome	measures,	 a	 trial	 on	 a	 larger	 cohort,	
with	 a	 longer	 duration,	 and	 preferably	 with	 a	 sham-operated	 control	 group	 for	
comparison,	 or	 at	 least	 a	 control	 group	 of	 ChEI-treated	 AD	 patients,	monitored	 closely	
with	 regard	 to	 the	 same	 outcome	 measures,	 would	 be	 desirable.	 Our	 overall	 results	
indicate	that	AD	patients	enrolled	in	such	a	trial	will	optimally	need	to	have	a	rather	stable	
cognitive	performance	prior	to	enrollment	and	furthermore,	have	a	mild	degree	of	brain	
atrophy,	to	reduce	safety	risks	of	the	surgical	procedure.	
	
	
	
	
 	46	
7 ACKNOWLEDGEMENTS	
	
I	wish	to	express	my	sincere	gratitude	to	all	the	people	who	supported	me	through	thick	
and	thin	during	my	six	years	as	a	doctoral	student.	Especially,	I	would	like	to	thank:	
	
First	and	foremost,	Maria	Eriksdotter,	my	main	supervisor.	It	was	you	who	inspired	me	to	
take	 this	 step	 and	 introduced	me	 to	 the	 captivating	world	 of	 research.	 You	 inspire	me	
through	your	competence	in	research	and	as	a	physician	as	well	as	through	your	passion	
for	 teaching	 and	 your	 thoughtful	 leadership.	 You	 have	 shown	 me	 that	 it	 is	 possible,	
although	not	always	easy,	to	build	a	carrier	in	academia	and	as	a	doctor,	alongside	having	
a	family.		
	
My	co-supervisors.	Åke	Seiger,	for	your	incredibly	sharp	mind,	kindness	and	believe	in	my	
potential.	Vesna	Jelic,	for	inspiring	me	as	a	physician	and	a	researcher,	for	being	a	mentor	
to	me	during	my	 time	as	a	 resident	at	 the	Memory	clinic,	and	 for	 sharing	with	me	your	
scientific	 knowledge.	 Marianne	 Schultzberg,	 for	 your	 vast	 scientific	 knowledge	 and	
experience,	your	attention	for	detail	and	your	kindness.	My	mentor	Pálmi	V.	Jónsson,	for	
your	kindness	and	support	through	the	years.	
	
The	participating	NGF-ECB	patients	and	their	families	and	all	the	individuals	who	donated	
cerebrospinal	fluid	to	the	biobank	at	the	Memory	Clinic,	Karolinska	University	Hospital	in	
Huddinge.		
	
My	sincere	thanks	to	all	my	collaborators	and	co-authors.	Special	thanks	to	Erik	Hjorth	for	
your	 knowledge	 and	 experience	 in	 basic	 research,	 inspiration	 and	 friendship.	 Azadeh	
Karami,	 for	 your	 inspiring	 work	 ethic,	 all	 your	 help,	 support	 and	 friendship.	 Your	
thoughtfulness	 towards	 others	 is	 very	 warming.	 Daniel	 Ferreira,	 for	 your	 knowledge,	
happy	 spirits	 and	 contagious	 laugh!	 Per	 Almqvist,	 for	 a	 friendly	 supervision	 and	
collaboration	in	the	writing	of	the	NGF-ECB	paper,	inspiring	meetings	and	talks	about	the	
future	of	the	NGF-ECB	technique.	Eric	Westman	for	your	competence	as	a	scientist	and	a	
head	of	the	clinical	geriatrics	division.	Taher	Darreh-Shori,	for	a	nice	collaboration	on	the	
ChAT	 paper	 and	 your	 passion	 for	 research.	 Collaborators	 at	 the	 department	 of	
Neurosurgery,	Göran	Lind	and	Bengt	Linderoth	for	a	very	nice	and	friendly	collaboration.	
Collaborators	 at	 NsGene	 in	 Denmark	 and	 USA,	 Lars	 Wahlund	 and	 Bengt	 Juliusson	 for	
enthusiasm	for	research	and	inspiration.	All	my	fantastic	former	and	current	colleagues	at	
NVS,	 Gabriela	 Spulber,	 Mingquin	 Zhu,	 Heela	 Sarlus,	 Daniela	 Enache,	 Dorota	 Religa,	
Farshad	 Falahati,	 Seyed	 Mohammad	 Fereshtehnejad,	 Soheil	 Damangir,	 Pavla	
Cermakova,	Dorota	Religa	and	Märta	Dahlström	–	Thanks!	
 47	 	
	
Bengt	 Winblad	 for	 your	 inspiring	 passion	 for	 research,	 for	 building	 up	 a	 fantastically	
impressive	 research	 unit	 in	 dementia	 disorders	 at	 NVS	 and	 the	 Swedish	 Brain	 Power	
research	 network	 and	 for	 your	 systematic	 efforts	 to	 engage	 geriatricians	 in	 training	 to	
become	involved	in	research.	Gunilla	Johansson	for	your	competent	administration,	your	
helpfulness	and	your	positive	spirits	that	spread	warmth	in	the	office.		
	
Former	 colleagues	 at	 the	 Geriatric	 clinic,	 Karolinska	 Huddinge,	 especially	 Frida	 Göthe,	
Katja	 Schubert	 Samuelsson,	 Daas	 Sater,	 Mirek	 Surowiak	 and	 Johan	 Lundberg,	 for	
friendships,	support	and	good	times	as	a	resident	at	Karolinska.	Also,	former	and	current	
chief	physicians	of	the	Geriatric	clinic,	Sinikka	Svensson	and	Johan	Lökk	 for	allowing	me	
time	to	do	research.		
	
Current	 colleagues,	 senior	 consultants	 at	 the	 Geriatric	 clinic	 at	 Danderyds	 hospital,	
especially	chief	physician	Rakel	Beckserius	 for	supporting	me	in	continuing	my	research,	
Helena	 Sjögren	 and	 Ingrid	 Dalenbring	 for	 your	 help	 and	 understanding.	 Anne	
Braunschweig,	for	our	morning	chats	on	feminism	and	life.		
	
My	parents	Eyjolfur	and	Gerdur	and	brother	Baldur,	for	always	being	there	for	me.		
	
My	 husband	 Thorgeir,	 my	 partner	 in	 crime.	 For	 your	 endless	 support,	 skillful	 coffee-
making,	for	giving	our	children	your	calm	and	last	but	not	least	handsome	DNA.	Also,	for	
your	sharp	mind	and	professional	input	on	this	thesis.	My	children	Eyvi,	Gestur	and	Hekla,	
for	 putting	 everything	 into	 perspective	 and	 for	making	me	 practice	 the	 art	 of	 patience,	
daily.		
	
My	friends	Steinunn,	for	being	my	Siamese	twin	during	our	residency,	for	all	the	laughter,	
lunches,	cappuchino,	skiing,	support	and	inspiration.	Eyrún,	for	the	enormous	support	and	
kindness	during	the	last	months,	for	making	me	laugh	and	for	our	crazy	evening	workouts	
in	 the	 forest.	Lóa,	 for	all	 the	 fun	 times	and	also	more	 stressful	 times	writing	our	 theses	
simultaneously.	Guðríður	(Gurrý)	for	your	fantastic	help	on	proof-reading	the	thesis,	you	
are	a	true	friend!	Margrét	Sturlu,	Helga	Margrét	and	Steinunn	Arnar	for	all	the	good	food	
and	 even	 better	 company.	Move	 back	 to	 Stockholm	please!	Gunna	Björk	and	Diddi	 for	
your	friendship,	good	humor	and	lovely	company	during	your	Stockholm	years.		
	
My	wonderful	 friends	 in	Reykjavik,	Copenhagen,	Los	Angeles	and	Århus:	Margrét,	Linda,	
Kristbjörg,	Hulda,	Drífa,	Helga	Jóhanna	and	Steinunn.	I	miss	you,	you	beautiful	songbirds.	
Also,	Saga	and	Nathalía	(also	a	beautiful	songbird),	miss	you	guys,	always.		
	
	
 	48	
8 REFERENCES	
1.	 Puzzo	D,	Gulisano	W,	Arancio	O,	Palmeri	A.	The	keystone	of	Alzheimer	pathogenesis	
might	be	sought	in	Abeta	physiology.	Neuroscience.	2015;307:26-36.	
2.	 Barnes	DE,	Yaffe	K.	The	projected	effect	of	risk	factor	reduction	on	Alzheimer's	
disease	prevalence.	Lancet	Neurol.	2011;10(9):819-28.	
3.	 De	Strooper	B,	Karran	E.	The	Cellular	Phase	of	Alzheimer's	Disease.	Cell.	
2016;164(4):603-15.	
4.	 Alzheimer	A,	Stelzmann	RA,	Schnitzlein	HN,	Murtagh	FR.	An	English	translation	of	
Alzheimer's	1907	paper,	"Uber	eine	eigenartige	Erkankung	der	Hirnrinde".	Clin	Anat.	
1995;8(6):429-31.	
5.	 World	Alzheimer	report	2015.	Available	from:	
https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.	Accessed	
October	21,	2016.	
6.	 Schrijvers	EM,	Verhaaren	BF,	Koudstaal	PJ,	Hofman	A,	Ikram	MA,	Breteler	MM.	Is	
dementia	incidence	declining?:	Trends	in	dementia	incidence	since	1990	in	the	
Rotterdam	Study.	Neurology.	2012;78(19):1456-63.	
7.	 National	Guidelines	for	Care	in	cases	of	Dementia.	Available	from:	
http://www.socialstyrelsen.se/nationalguidelines/nationalguidelinesforcareincases
ofdementia.	Accessed	October	20,	2016.	
8.	 Socialstyrelsen.	Demenssjukdomarnas	samhällskostnader	i	Sverige	2012.	Stockholm:	
Socialstyrelsen	(National	Board	of	Health	and	Welfare);	2014.	Available	from:	
http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19444/2014-6-
3.pdf.	Accessed	November	27,	2016.	
9.	 Esiri	MM,	Chance	SA.	Cognitive	reserve,	cortical	plasticity	and	resistance	to	
Alzheimer's	disease.	Alzheimers	Res	Ther.	2012;4(2):7.	
10.	 Corder	EH,	Saunders	AM,	Strittmatter	WJ,	Schmechel	DE,	Gaskell	PC,	Small	GW,	et	al.	
Gene	dose	of	apolipoprotein	E	type	4	allele	and	the	risk	of	Alzheimer's	disease	in	late	
onset	families.	Science.	1993;261(5123):921-3.	
11.	 Raber	J,	Huang	Y,	Ashford	JW.	ApoE	genotype	accounts	for	the	vast	majority	of	AD	
risk	and	AD	pathology.	Neurobiol	Aging.	2004;25(5):641-50.	
12.	 Blennow	K,	de	Leon	MJ,	Zetterberg	H.	Alzheimer's	disease.	Lancet.	
2006;368(9533):387-403.	
13.	 Guerreiro	R,	Wojtas	A,	Bras	J,	Carrasquillo	M,	Rogaeva	E,	Majounie	E,	et	al.	TREM2	
variants	in	Alzheimer's	disease.	N	Engl	J	Med.	2013;368(2):117-27.	
14.	 Guerreiro	R,	Hardy	J.	Genetics	of	Alzheimer's	disease.	Neurotherapeutics.	
2014;11(4):732-7.	
15.	 Scheltens	P,	Blennow	K,	Breteler	MM,	de	Strooper	B,	Frisoni	GB,	Salloway	S,	et	al.	
Alzheimer's	disease.	Lancet.	2016;388(10043):505-17.	
 49	 	
	
16.	 Winblad	B,	Amouyel	P,	Andrieu	S,	Ballard	C,	Brayne	C,	Brodaty	H,	et	al.	Defeating	
Alzheimer's	disease	and	other	dementias:	a	priority	for	European	science	and	
society.	Lancet	Neurol.	2016;15(5):455-532.	
17.	 de	Bruijn	RF,	Bos	MJ,	Portegies	ML,	Hofman	A,	Franco	OH,	Koudstaal	PJ,	et	al.	The	
potential	for	prevention	of	dementia	across	two	decades:	the	prospective,	
population-based	Rotterdam	Study.	BMC	Med.	2015;13:132.	
18.	 Kivipelto	M,	Rovio	S,	Ngandu	T,	Kareholt	I,	Eskelinen	M,	Winblad	B,	et	al.	
Apolipoprotein	E	epsilon4	magnifies	lifestyle	risks	for	dementia:	a	population-based	
study.	J	Cell	Mol	Med.	2008;12(6B):2762-71.	
19.	 Daviglus	ML,	Bell	CC,	Berrettini	W,	Bowen	PE,	Connolly	ES,	Jr.,	Cox	NJ,	et	al.	National	
Institutes	of	Health	State-of-the-Science	Conference	statement:	preventing	
alzheimer	disease	and	cognitive	decline.	Ann	Intern	Med.	2010;153(3):176-81.	
20.	 Shively	S,	Scher	AI,	Perl	DP,	Diaz-Arrastia	R.	Dementia	resulting	from	traumatic	brain	
injury:	what	is	the	pathology?	Arch	Neurol.	2012;69(10):1245-51.	
21.	 Fleminger	S,	Oliver	DL,	Lovestone	S,	Rabe-Hesketh	S,	Giora	A.	Head	injury	as	a	risk	
factor	for	Alzheimer's	disease:	the	evidence	10	years	on;	a	partial	replication.	J	
Neurol	Neurosurg	Psychiatry.	2003;74(7):857-62.	
22.	 Van	den	Heuvel	C,	Blumbergs	PC,	Finnie	JW,	Manavis	J,	Jones	NR,	Reilly	PL,	et	al.	
Upregulation	of	amyloid	precursor	protein	messenger	RNA	in	response	to	traumatic	
brain	injury:	an	ovine	head	impact	model.	Exp	Neurol.	1999;159(2):441-50.	
23.	 Johnson	VE,	Stewart	JE,	Begbie	FD,	Trojanowski	JQ,	Smith	DH,	Stewart	W.	
Inflammation	and	white	matter	degeneration	persist	for	years	after	a	single	
traumatic	brain	injury.	Brain.	2013;136(Pt	1):28-42.	
24.	 Karran	E,	Mercken	M,	De	Strooper	B.	The	amyloid	cascade	hypothesis	for	
Alzheimer's	disease:	an	appraisal	for	the	development	of	therapeutics.	Nat	Rev	Drug	
Discov.	2011;10(9):698-712.	
25.	 Karch	CM,	Goate	AM.	Alzheimer's	disease	risk	genes	and	mechanisms	of	disease	
pathogenesis.	Biol	Psychiatry.	2015;77(1):43-51.	
26.	 Chavez-Gutierrez	L,	Bammens	L,	Benilova	I,	Vandersteen	A,	Benurwar	M,	Borgers	M,	
et	al.	The	mechanism	of	gamma-Secretase	dysfunction	in	familial	Alzheimer	disease.	
EMBO	J.	2012;31(10):2261-74.	
27.	 Haass	C,	Neumann	M.	Frontotemporal	dementia:	from	molecular	mechanisms	to	
therapy.	J	Neurochem.	2016;138	Suppl	1:3-5.	
28.	 Small	SA,	Duff	K.	Linking	Abeta	and	tau	in	late-onset	Alzheimer's	disease:	a	dual	
pathway	hypothesis.	Neuron.	2008;60(4):534-42.	
29.	 Bilgel	M,	An	Y,	Lang	A,	Prince	J,	Ferrucci	L,	Jedynak	B,	et	al.	Trajectories	of	Alzheimer	
disease-related	cognitive	measures	in	a	longitudinal	sample.	Alzheimers	Dement.	
2014;10(6):735-42	e4.	
30.	 Caselli	RJ,	Locke	DE,	Dueck	AC,	Knopman	DS,	Woodruff	BK,	Hoffman-Snyder	C,	et	al.	
The	neuropsychology	of	normal	aging	and	preclinical	Alzheimer's	disease.	
Alzheimers	Dement.	2014;10(1):84-92.	
 	50	
31.	 Chen	P,	Ratcliff	G,	Belle	SH,	Cauley	JA,	DeKosky	ST,	Ganguli	M.	Cognitive	tests	that	
best	discriminate	between	presymptomatic	AD	and	those	who	remain	
nondemented.	Neurology.	2000;55(12):1847-53.	
32.	 Hedden	T,	Oh	H,	Younger	AP,	Patel	TA.	Meta-analysis	of	amyloid-cognition	relations	
in	cognitively	normal	older	adults.	Neurology.	2013;80(14):1341-8.	
33.	 Amieva	H,	Jacqmin-Gadda	H,	Orgogozo	JM,	Le	Carret	N,	Helmer	C,	Letenneur	L,	et	al.	
The	9	year	cognitive	decline	before	dementia	of	the	Alzheimer	type:	a	prospective	
population-based	study.	Brain.	2005;128(Pt	5):1093-101.	
34.	 Wilson	RS,	Segawa	E,	Boyle	PA,	Anagnos	SE,	Hizel	LP,	Bennett	DA.	The	natural	history	
of	cognitive	decline	in	Alzheimer's	disease.	Psychol	Aging.	2012;27(4):1008-17.	
35.	 Mortamais	M,	Ash	JA,	Harrison	J,	Kaye	J,	Kramer	J,	Randolph	C,	et	al.	Detecting	
cognitive	changes	in	preclinical	Alzheimer's	disease:	A	review	of	its	feasibility.	
Alzheimers	Dement.	2016.	Epub	ahead	of	print.	
36.	 Hirni	DI,	Kivisaari	SL,	Monsch	AU,	Taylor	KI.	Distinct	neuroanatomical	bases	of	
episodic	and	semantic	memory	performance	in	Alzheimer's	disease.	
Neuropsychologia.	2013;51(5):930-7.	
37.	 Flicker	C,	Ferris	SH,	Reisberg	B.	Mild	cognitive	impairment	in	the	elderly:	predictors	
of	dementia.	Neurology.	1991;41(7):1006-9.	
38.	 Kane	MJ,	Engle	RW.	The	role	of	prefrontal	cortex	in	working-memory	capacity,	
executive	attention,	and	general	fluid	intelligence:	an	individual-differences	
perspective.	Psychon	Bull	Rev.	2002;9(4):637-71.	
39.	 Monsell	SE,	Mock	C,	Hassenstab	J,	Roe	CM,	Cairns	NJ,	Morris	JC,	et	al.	
Neuropsychological	changes	in	asymptomatic	persons	with	Alzheimer	disease	
neuropathology.	Neurology.	2014;83(5):434-40.	
40.	 International	Classification	of	Disease	10th	Revision	(ICD-10).	World	Health	
Organization	1992.	Available	from:	http://www.who.int/classifications/icd/en/.	
Accessed	October	18,	2016.	
41.	 Amerian	Psychiatric	Association.	Diagnostic	and	Statistical	Manual	of	Mental	
Disorders	4,	Text	Revision.	Washington,	DC.:	American	Psychiatric	Association;	2000.	
42.	 McKhann	G,	Drachman	D,	Folstein	M,	Katzman	R,	Price	D,	Stadlan	EM.	Clinical	
diagnosis	of	Alzheimer's	disease:	report	of	the	NINCDS-ADRDA	Work	Group	under	
the	auspices	of	Department	of	Health	and	Human	Services	Task	Force	on	Alzheimer's	
Disease.	Neurology.	1984;34(7):939-44.	
43.	 Dubois	B,	Feldman	HH,	Jacova	C,	Cummings	JL,	Dekosky	ST,	Barberger-Gateau	P,	et	
al.	Revising	the	definition	of	Alzheimer's	disease:	a	new	lexicon.	Lancet	Neurol.	
2010;9(11):1118-27.	
44.	 Burns	A,	Zaudig	M.	Mild	cognitive	impairment	in	older	people.	Lancet.	
2002;360(9349):1963-5.	
45.	 McGuinness	B,	Barrett	SL,	McIlvenna	J,	Passmore	AP,	Shorter	GW.	Predicting	
conversion	to	dementia	in	a	memory	clinic:	A	standard	clinical	approach	compared	
with	an	empirically	defined	clustering	method	(latent	profile	analysis)	for	mild	
cognitive	impairment	subtyping.	Alzheimers	Dement	(Amst).	2015;1(4):447-54.	
 51	 	
	
46.	 Bondi	MW,	Edmonds	EC,	Jak	AJ,	Clark	LR,	Delano-Wood	L,	McDonald	CR,	et	al.	
Neuropsychological	criteria	for	mild	cognitive	impairment	improves	diagnostic	
precision,	biomarker	associations,	and	progression	rates.	J	Alzheimers	Dis.	
2014;42(1):275-89.	
47.	 Jak	AJ,	Preis	SR,	Beiser	AS,	Seshadri	S,	Wolf	PA,	Bondi	MW,	et	al.	Neuropsychological	
Criteria	for	Mild	Cognitive	Impairment	and	Dementia	Risk	in	the	Framingham	Heart	
Study.	J	Int	Neuropsychol	Soc.	2016;22(9):937-43.	
48.	 Petersen	RC.	Clinical	practice.	Mild	cognitive	impairment.	N	Engl	J	Med.	
2011;364(23):2227-34.	
49.	 Winblad	B,	Palmer	K,	Kivipelto	M,	Jelic	V,	Fratiglioni	L,	Wahlund	LO,	et	al.	Mild	
cognitive	impairment--beyond	controversies,	towards	a	consensus:	report	of	the	
International	Working	Group	on	Mild	Cognitive	Impairment.	J	Intern	Med.	
2004;256(3):240-6.	
50.	 Jessen	F.	Subjective	and	objective	cognitive	decline	at	the	pre-dementia	stage	of	
Alzheimer's	disease.	Eur	Arch	Psychiatry	Clin	Neurosci.	2014;264	Suppl	1:S3-7.	
51.	 Wang	Y,	Risacher	SL,	West	JD,	McDonald	BC,	Magee	TR,	Farlow	MR,	et	al.	Altered	
default	mode	network	connectivity	in	older	adults	with	cognitive	complaints	and	
amnestic	mild	cognitive	impairment.	J	Alzheimers	Dis.	2013;35(4):751-60.	
52.	 Risacher	SL,	Wudunn	D,	Pepin	SM,	MaGee	TR,	McDonald	BC,	Flashman	LA,	et	al.	
Visual	contrast	sensitivity	in	Alzheimer's	disease,	mild	cognitive	impairment,	and	
older	adults	with	cognitive	complaints.	Neurobiol	Aging.	2013;34(4):1133-44.	
53.	 Scheef	L,	Spottke	A,	Daerr	M,	Joe	A,	Striepens	N,	Kolsch	H,	et	al.	Glucose	metabolism,	
gray	matter	structure,	and	memory	decline	in	subjective	memory	impairment.	
Neurology.	2012;79(13):1332-9.	
54.	 Biomarkers	Definitions	Working	G.	Biomarkers	and	surrogate	endpoints:	preferred	
definitions	and	conceptual	framework.	Clin	Pharmacol	Ther.	2001;69(3):89-95.	
55.	 Counts	SE,	Ikonomovic	MD,	Mercado	N,	Vega	IE,	Mufson	EJ.	Biomarkers	for	the	Early	
Detection	and	Progression	of	Alzheimer's	Disease.	Neurotherapeutics.	2016.	
56.	 Weiner	MW,	Veitch	DP,	Aisen	PS,	Beckett	LA,	Cairns	NJ,	Cedarbaum	J,	et	al.	2014	
Update	of	the	Alzheimer's	Disease	Neuroimaging	Initiative:	A	review	of	papers	
published	since	its	inception.	Alzheimers	Dement.	2015;11(6):e1-120.	
57.	 Sperling	RA,	Aisen	PS,	Beckett	LA,	Bennett	DA,	Craft	S,	Fagan	AM,	et	al.	Toward	
defining	the	preclinical	stages	of	Alzheimer's	disease:	recommendations	from	the	
National	Institute	on	Aging-Alzheimer's	Association	workgroups	on	diagnostic	
guidelines	for	Alzheimer's	disease.	Alzheimers	Dement.	2011;7(3):280-92.	
58.	 Jack	CR,	Jr.,	Bennett	DA,	Blennow	K,	Carrillo	MC,	Feldman	HH,	Frisoni	GB,	et	al.	
A/T/N:	An	unbiased	descriptive	classification	scheme	for	Alzheimer	disease	
biomarkers.	Neurology.	2016;87(5):539-47.	
59.	 Mattsson	N,	Zetterberg	H,	Hansson	O,	Andreasen	N,	Parnetti	L,	Jonsson	M,	et	al.	CSF	
biomarkers	and	incipient	Alzheimer	disease	in	patients	with	mild	cognitive	
impairment.	JAMA.	2009;302(4):385-93.	
 	52	
60.	 Klunk	WE,	Engler	H,	Nordberg	A,	Wang	Y,	Blomqvist	G,	Holt	DP,	et	al.	Imaging	brain	
amyloid	in	Alzheimer's	disease	with	Pittsburgh	Compound-B.	Ann	Neurol.	
2004;55(3):306-19.	
61.	 Scholl	M,	Lockhart	SN,	Schonhaut	DR,	O'Neil	JP,	Janabi	M,	Ossenkoppele	R,	et	al.	PET	
Imaging	of	Tau	Deposition	in	the	Aging	Human	Brain.	Neuron.	2016;89(5):971-82.	
62.	 Jack	CR,	Jr.,	Knopman	DS,	Jagust	WJ,	Petersen	RC,	Weiner	MW,	Aisen	PS,	et	al.	
Tracking	pathophysiological	processes	in	Alzheimer's	disease:	an	updated	
hypothetical	model	of	dynamic	biomarkers.	Lancet	Neurol.	2013;12(2):207-16.	
63.	 Mattsson	N,	Carrillo	MC,	Dean	RA,	Devous	MD,	Sr.,	Nikolcheva	T,	Pesini	P,	et	al.	
Revolutionizing	Alzheimer's	disease	and	clinical	trials	through	biomarkers.	
Alzheimers	Dement	(Amst).	2015;1(4):412-9.	
64.	 Brier	MR,	Gordon	B,	Friedrichsen	K,	McCarthy	J,	Stern	A,	Christensen	J,	et	al.	Tau	and	
Abeta	imaging,	CSF	measures,	and	cognition	in	Alzheimer's	disease.	Sci	Transl	Med.	
2016;8(338):338ra66.	
65.	 Novak	P,	Schmidt	R,	Kontsekova	E,	Zilka	N,	Kovacech	B,	Skrabana	R,	et	al.	Safety	and	
immunogenicity	of	the	tau	vaccine	AADvac1	in	patients	with	Alzheimer's	disease:	a	
randomised,	double-blind,	placebo-controlled,	phase	1	trial.	Lancet	Neurol.	2016.	
Epub	ahead	of	print.	
66.	 Duits	FH,	Teunissen	CE,	Bouwman	FH,	Visser	PJ,	Mattsson	N,	Zetterberg	H,	et	al.	The	
cerebrospinal	fluid	"Alzheimer	profile":	easily	said,	but	what	does	it	mean?	
Alzheimers	Dement.	2014;10(6):713-23	e2.	
67.	 Mattsson	N,	Andreasson	U,	Persson	S,	Carrillo	MC,	Collins	S,	Chalbot	S,	et	al.	CSF	
biomarker	variability	in	the	Alzheimer's	Association	quality	control	program.	
Alzheimers	Dement.	2013;9(3):251-61.	
68.	 Bartus	RT,	Dean	RL,	3rd,	Beer	B,	Lippa	AS.	The	cholinergic	hypothesis	of	geriatric	
memory	dysfunction.	Science.	1982;217(4558):408-14.	
69.	 Wilkinson	DG,	Francis	PT,	Schwam	E,	Payne-Parrish	J.	Cholinesterase	inhibitors	used	
in	the	treatment	of	Alzheimer's	disease:	the	relationship	between	pharmacological	
effects	and	clinical	efficacy.	Drugs	Aging.	2004;21(7):453-78.	
70.	 Deardorff	WJ,	Feen	E,	Grossberg	GT.	The	Use	of	Cholinesterase	Inhibitors	Across	All	
Stages	of	Alzheimer's	Disease.	Drugs	Aging.	2015;32(7):537-47.	
71.	 Mohamed	LA,	Qosa	H,	Kaddoumi	A.	Age-Related	Decline	in	Brain	and	Hepatic	
Clearance	of	Amyloid-Beta	is	Rectified	by	the	Cholinesterase	Inhibitors	Donepezil	
and	Rivastigmine	in	Rats.	ACS	Chem	Neurosci.	2015;6(5):725-36.	
72.	 Winblad	B,	Wimo	A,	Engedal	K,	Soininen	H,	Verhey	F,	Waldemar	G,	et	al.	3-year	
study	of	donepezil	therapy	in	Alzheimer's	disease:	effects	of	early	and	continuous	
therapy.	Dement	Geriatr	Cogn	Disord.	2006;21(5-6):353-63.	
73.	 Xu	H,	Sweeney	D,	Wang	R,	Thinakaran	G,	Lo	AC,	Sisodia	SS,	et	al.	Generation	of	
Alzheimer	beta-amyloid	protein	in	the	trans-Golgi	network	in	the	apparent	absence	
of	vesicle	formation.	Proc	Natl	Acad	Sci	U	S	A.	1997;94(8):3748-52.	
 53	 	
	
74.	 Zou	K,	Gong	JS,	Yanagisawa	K,	Michikawa	M.	A	novel	function	of	monomeric	amyloid	
beta-protein	serving	as	an	antioxidant	molecule	against	metal-induced	oxidative	
damage.	J	Neurosci.	2002;22(12):4833-41.	
75.	 Gu	L,	Guo	Z.	Alzheimer's	Abeta42	and	Abeta40	peptides	form	interlaced	amyloid	
fibrils.	J	Neurochem.	2013;126(3):305-11.	
76.	 Jarrett	JT,	Berger	EP,	Lansbury	PT,	Jr.	The	carboxy	terminus	of	the	beta	amyloid	
protein	is	critical	for	the	seeding	of	amyloid	formation:	implications	for	the	
pathogenesis	of	Alzheimer's	disease.	Biochemistry.	1993;32(18):4693-7.	
77.	 Selkoe	DJ.	Alzheimer's	disease	is	a	synaptic	failure.	Science.	2002;298(5594):789-91.	
78.	 Shankar	GM,	Li	S,	Mehta	TH,	Garcia-Munoz	A,	Shepardson	NE,	Smith	I,	et	al.	
Amyloid-beta	protein	dimers	isolated	directly	from	Alzheimer's	brains	impair	
synaptic	plasticity	and	memory.	Nat	Med.	2008;14(8):837-42.	
79.	 Del	Prete	D,	Checler	F,	Chami	M.	Ryanodine	receptors:	physiological	function	and	
deregulation	in	Alzheimer	disease.	Mol	Neurodegener.	2014;9:21.	
80.	 Mesulam	MM.	Neuroplasticity	failure	in	Alzheimer's	disease:	bridging	the	gap	
between	plaques	and	tangles.	Neuron.	1999;24(3):521-9.	
81.	 Amanatkar	HR,	Papagiannopoulos	B,	Grossberg	GT.	Analysis	of	recent	failures	of	
disease	modifying	therapies	in	Alzheimer's	disease	suggesting	a	new	methodology	
for	future	studies.	Expert	Rev	Neurother.	2016:1-10.	
82.	 Santacruz	K,	Lewis	J,	Spires	T,	Paulson	J,	Kotilinek	L,	Ingelsson	M,	et	al.	Tau	
suppression	in	a	neurodegenerative	mouse	model	improves	memory	function.	
Science.	2005;309(5733):476-81.	
83.	 Gotz	J,	Ittner	LM,	Kins	S.	Do	axonal	defects	in	tau	and	amyloid	precursor	protein	
transgenic	animals	model	axonopathy	in	Alzheimer's	disease?	J	Neurochem.	
2006;98(4):993-1006.	
84.	 Ittner	LM,	Ke	YD,	Gotz	J.	Phosphorylated	Tau	interacts	with	c-Jun	N-terminal	kinase-
interacting	protein	1	(JIP1)	in	Alzheimer	disease.	J	Biol	Chem.	2009;284(31):20909-
16.	
85.	 Ittner	LM,	Gotz	J.	Amyloid-beta	and	tau--a	toxic	pas	de	deux	in	Alzheimer's	disease.	
Nat	Rev	Neurosci.	2011;12(2):65-72.	
86.	 Mesulam	MM,	Mufson	EJ,	Levey	AI,	Wainer	BH.	Cholinergic	innervation	of	cortex	by	
the	basal	forebrain:	cytochemistry	and	cortical	connections	of	the	septal	area,	
diagonal	band	nuclei,	nucleus	basalis	(substantia	innominata),	and	hypothalamus	in	
the	rhesus	monkey.	J	Comp	Neurol.	1983;214(2):170-97.	
87.	 Mesulam	MM,	Geula	C.	Nucleus	basalis	(Ch4)	and	cortical	cholinergic	innervation	in	
the	human	brain:	observations	based	on	the	distribution	of	acetylcholinesterase	and	
choline	acetyltransferase.	J	Comp	Neurol.	1988;275(2):216-40.	
88.	 Zaborszky	L.	The	modular	organization	of	brain	systems.	Basal	forebrain:	the	last	
frontier.	Prog	Brain	Res.	2002;136:359-72.	
 	54	
89.	 Zaborszky	L,	Hoemke	L,	Mohlberg	H,	Schleicher	A,	Amunts	K,	Zilles	K.	Stereotaxic	
probabilistic	maps	of	the	magnocellular	cell	groups	in	human	basal	forebrain.	
Neuroimage.	2008;42(3):1127-41.	
90.	 Zaborszky	L,	Csordas	A,	Mosca	K,	Kim	J,	Gielow	MR,	Vadasz	C,	et	al.	Neurons	in	the	
basal	forebrain	project	to	the	cortex	in	a	complex	topographic	organization	that	
reflects	corticocortical	connectivity	patterns:	an	experimental	study	based	on	
retrograde	tracing	and	3D	reconstruction.	Cereb	Cortex.	2015;25(1):118-37.	
91.	 Fine	A,	Hoyle	C,	Maclean	CJ,	Levatte	TL,	Baker	HF,	Ridley	RM.	Learning	impairments	
following	injection	of	a	selective	cholinergic	immunotoxin,	ME20.4	IgG-saporin,	into	
the	basal	nucleus	of	Meynert	in	monkeys.	Neuroscience.	1997;81(2):331-43.	
92.	 Crow	TJ,	Grove-White	IG.	An	analysis	of	the	learning	deficit	following	hyoscine	
administration	to	man.	Br	J	Pharmacol.	1973;49(2):322-7.	
93.	 Hasselmo	ME,	Anderson	BP,	Bower	JM.	Cholinergic	modulation	of	cortical	
associative	memory	function.	J	Neurophysiol.	1992;67(5):1230-46.	
94.	 Kozak	R,	Bruno	JP,	Sarter	M.	Augmented	prefrontal	acetylcholine	release	during	
challenged	attentional	performance.	Cereb	Cortex.	2006;16(1):9-17.	
95.	 Whitehouse	PJ,	Price	DL,	Clark	AW,	Coyle	JT,	DeLong	MR.	Alzheimer	disease:	
evidence	for	selective	loss	of	cholinergic	neurons	in	the	nucleus	basalis.	Ann	Neurol.	
1981;10(2):122-6.	
96.	 Terry	RD,	Masliah	E,	Salmon	DP,	Butters	N,	DeTeresa	R,	Hill	R,	et	al.	Physical	basis	of	
cognitive	alterations	in	Alzheimer's	disease:	synapse	loss	is	the	major	correlate	of	
cognitive	impairment.	Ann	Neurol.	1991;30(4):572-80.	
97.	 Mufson	EJ,	Kroin	JS,	Sendera	TJ,	Sobreviela	T.	Distribution	and	retrograde	transport	
of	trophic	factors	in	the	central	nervous	system:	functional	implications	for	the	
treatment	of	neurodegenerative	diseases.	Prog	Neurobiol.	1999;57(4):451-84.	
98.	 Schmitz	TW,	Nathan	Spreng	R,	Alzheimer's	Disease	Neuroimaging	I.	Basal	forebrain	
degeneration	precedes	and	predicts	the	cortical	spread	of	Alzheimer's	pathology.	
Nat	Commun.	2016;7:13249.	
99.	 Allen	SJ,	Watson	JJ,	Dawbarn	D.	The	neurotrophins	and	their	role	in	Alzheimer's	
disease.	Curr	Neuropharmacol.	2011;9(4):559-73.	
100.	 Schliebs	R,	Arendt	T.	The	significance	of	the	cholinergic	system	in	the	brain	during	
aging	and	in	Alzheimer's	disease.	J	Neural	Transm	(Vienna).	2006;113(11):1625-44.	
101.	 Ferreira-Vieira	TH,	Guimaraes	IM,	Silva	FR,	Ribeiro	FM.	Alzheimer's	disease:	
Targeting	the	Cholinergic	System.	Curr	Neuropharmacol.	2016;14(1):101-15.	
102.	 Wilcock	GK,	Esiri	MM,	Bowen	DM,	Smith	CC.	Alzheimer's	disease.	Correlation	of	
cortical	choline	acetyltransferase	activity	with	the	severity	of	dementia	and	
histological	abnormalities.	J	Neurol	Sci.	1982;57(2-3):407-17.	
103.	 Strada	O,	Vyas	S,	Hirsch	EC,	Ruberg	M,	Brice	A,	Agid	Y,	et	al.	Decreased	choline	
acetyltransferase	mRNA	expression	in	the	nucleus	basalis	of	Meynert	in	Alzheimer	
disease:	an	in	situ	hybridization	study.	Proc	Natl	Acad	Sci	U	S	A.	1992;89(20):9549-
53.	
 55	 	
	
104.	 Sims	NR,	Bowen	DM,	Allen	SJ,	Smith	CC,	Neary	D,	Thomas	DJ,	et	al.	Presynaptic	
cholinergic	dysfunction	in	patients	with	dementia.	J	Neurochem.	1983;40(2):503-9.	
105.	 Oda	Y.	Choline	acetyltransferase:	the	structure,	distribution	and	pathologic	changes	
in	the	central	nervous	system.	Pathol	Int.	1999;49(11):921-37.	
106.	 Brisson	A,	Unwin	PN.	Quaternary	structure	of	the	acetylcholine	receptor.	Nature.	
1985;315(6019):474-7.	
107.	 Fenster	CP,	Rains	MF,	Noerager	B,	Quick	MW,	Lester	RA.	Influence	of	subunit	
composition	on	desensitization	of	neuronal	acetylcholine	receptors	at	low	
concentrations	of	nicotine.	J	Neurosci.	1997;17(15):5747-59.	
108.	 Nai	Q,	McIntosh	JM,	Margiotta	JF.	Relating	neuronal	nicotinic	acetylcholine	receptor	
subtypes	defined	by	subunit	composition	and	channel	function.	Mol	Pharmacol.	
2003;63(2):311-24.	
109.	 Seguela	P,	Wadiche	J,	Dineley-Miller	K,	Dani	JA,	Patrick	JW.	Molecular	cloning,	
functional	properties,	and	distribution	of	rat	brain	alpha	7:	a	nicotinic	cation	channel	
highly	permeable	to	calcium.	J	Neurosci.	1993;13(2):596-604.	
110.	 Bonner	TI,	Buckley	NJ,	Young	AC,	Brann	MR.	Identification	of	a	family	of	muscarinic	
acetylcholine	receptor	genes.	Science.	1987;237(4814):527-32.	
111.	 Seiler	M,	Schwab	ME.	Specific	retrograde	transport	of	nerve	growth	factor	(NGF)	
from	neocortex	to	nucleus	basalis	in	the	rat.	Brain	Res.	1984;300(1):33-9.	
112.	 Williams	BJ,	Eriksdotter-Jonhagen	M,	Granholm	AC.	Nerve	growth	factor	in	
treatment	and	pathogenesis	of	Alzheimer's	disease.	Prog	Neurobiol.	2006;80(3):114-
28.	
113.	 Olson	L,	Bäckman	L,	Ebendal	T,	Eriksdotter-Jönhagen	M,	Hoffer	B,	Humpel	C,	et	al.	
Role	of	growth	factors	in	degeneration	and	regeneration	in	the	central	nervous	
system;	clinical	experiences	with	NGF	in	Parkinson's	and	Alzheimer's	diseases.	
Journal	of	neurology.	1994;242:12-5.	
114.	 Reichardt	LF.	Neurotrophin-regulated	signalling	pathways.	Philos	Trans	R	Soc	Lond	B	
Biol	Sci.	2006;361(1473):1545-64.	
115.	 Skaper	SD.	The	biology	of	neurotrophins,	signalling	pathways,	and	functional	peptide	
mimetics	of	neurotrophins	and	their	receptors.	CNS	Neurol	Disord	Drug	Targets.	
2008;7(1):46-62.	
116.	 Tuszynski	MH.	Nerve	growth	factor	gene	delivery:	animal	models	to	clinical	trials.	
Dev	Neurobiol.	2007;67(9):1204-15.	
117.	 Teng	KK,	Hempstead	BL.	Neurotrophins	and	their	receptors:	signaling	trios	in	
complex	biological	systems.	Cell	Mol	Life	Sci.	2004;61(1):35-48.	
118.	 Huang	EJ,	Reichardt	LF.	Trk	receptors:	roles	in	neuronal	signal	transduction.	Annu	
Rev	Biochem.	2003;72:609-42.	
119.	 Lee	R,	Kermani	P,	Teng	KK,	Hempstead	BL.	Regulation	of	cell	survival	by	secreted	
proneurotrophins.	Science.	2001;294(5548):1945-8.	
 	56	
120.	 Josephy-Hernandez	S,	Jmaeff	S,	Pirvulescu	I,	Aboulkassim	T,	Saragovi	HU.	
Neurotrophin	receptor	agonists	and	antagonists	as	therapeutic	agents:	An	evolving	
paradigm.	Neurobiol	Dis.	2016.	
121.	 Vaegter	CB,	Jansen	P,	Fjorback	AW,	Glerup	S,	Skeldal	S,	Kjolby	M,	et	al.	Sortilin	
associates	with	Trk	receptors	to	enhance	anterograde	transport	and	neurotrophin	
signaling.	Nat	Neurosci.	2011;14(1):54-61.	
122.	 Skeldal	S,	Sykes	AM,	Glerup	S,	Matusica	D,	Palstra	N,	Autio	H,	et	al.	Mapping	of	the	
interaction	site	between	sortilin	and	the	p75	neurotrophin	receptor	reveals	a	
regulatory	role	for	the	sortilin	intracellular	domain	in	p75	neurotrophin	receptor	
shedding	and	apoptosis.	J	Biol	Chem.	2012;287(52):43798-809.	
123.	 Mufson	EJ,	Ma	SY,	Cochran	EJ,	Bennett	DA,	Beckett	LA,	Jaffar	S,	et	al.	Loss	of	nucleus	
basalis	neurons	containing	trkA	immunoreactivity	in	individuals	with	mild	cognitive	
impairment	and	early	Alzheimer's	disease.	J	Comp	Neurol.	2000;427(1):19-30.	
124.	 Mufson	EJ,	Ma	SY,	Dills	J,	Cochran	EJ,	Leurgans	S,	Wuu	J,	et	al.	Loss	of	basal	forebrain	
P75(NTR)	immunoreactivity	in	subjects	with	mild	cognitive	impairment	and	
Alzheimer's	disease.	J	Comp	Neurol.	2002;443(2):136-53.	
125.	 Chao	MV,	Bothwell	MA,	Ross	AH,	Koprowski	H,	Lanahan	AA,	Buck	CR,	et	al.	Gene	
transfer	and	molecular	cloning	of	the	human	NGF	receptor.	Science.	
1986;232(4749):518-21.	
126.	 Mamidipudi	V,	Wooten	MW.	Dual	role	for	p75(NTR)	signaling	in	survival	and	cell	
death:	can	intracellular	mediators	provide	an	explanation?	J	Neurosci	Res.	
2002;68(4):373-84.	
127.	 Klein	R,	Jing	SQ,	Nanduri	V,	O'Rourke	E,	Barbacid	M.	The	trk	proto-oncogene	encodes	
a	receptor	for	nerve	growth	factor.	Cell.	1991;65(1):189-97.	
128.	 Klesse	LJ,	Parada	LF.	Trks:	signal	transduction	and	intracellular	pathways.	Microsc	
Res	Tech.	1999;45(4-5):210-6.	
129.	 Longo	FM,	Massa	SM.	Small-molecule	modulation	of	neurotrophin	receptors:	a	
strategy	for	the	treatment	of	neurological	disease.	Nat	Rev	Drug	Discov.	
2013;12(7):507-25.	
130.	 Sofroniew	MV,	Howe	CL,	Mobley	WC.	Nerve	growth	factor	signaling,	
neuroprotection,	and	neural	repair.	Annu	Rev	Neurosci.	2001;24:1217-81.	
131.	 Hefti	F,	Mash	DC.	Localization	of	nerve	growth	factor	receptors	in	the	normal	human	
brain	and	in	Alzheimer's	disease.	Neurobiol	Aging.	1989;10(1):75-87.	
132.	 Eriksdotter-Nilsson	M,	Skirboll	S,	Ebendal	T,	Hersh	L,	Grassi	J,	Massoulie	J,	et	al.	NGF	
treatment	promotes	development	of	basal	forebrain	tissue	grafts	in	the	anterior	
chamber	of	the	eye.	Exp	Brain	Res.	1989;74(1):89-98.	
133.	 Hartikka	J,	Hefti	F.	Comparison	of	nerve	growth	factor's	effects	on	development	of	
septum,	striatum,	and	nucleus	basalis	cholinergic	neurons	in	vitro.	J	Neurosci	Res.	
1988;21(2-4):352-64.	
134.	 Ruberti	F,	Capsoni	S,	Comparini	A,	Di	Daniel	E,	Franzot	J,	Gonfloni	S,	et	al.	Phenotypic	
knockout	of	nerve	growth	factor	in	adult	transgenic	mice	reveals	severe	deficits	in	
 57	 	
	
basal	forebrain	cholinergic	neurons,	cell	death	in	the	spleen,	and	skeletal	muscle	
dystrophy.	J	Neurosci.	2000;20(7):2589-601.	
135.	 Capsoni	S,	Ugolini	G,	Comparini	A,	Ruberti	F,	Berardi	N,	Cattaneo	A.	Alzheimer-like	
neurodegeneration	in	aged	antinerve	growth	factor	transgenic	mice.	Proc	Natl	Acad	
Sci	U	S	A.	2000;97(12):6826-31.	
136.	 Thoenen	H.	Neurotrophins	and	neuronal	plasticity.	Science.	1995;270(5236):593-8.	
137.	 Cuello	AC.	Effects	of	trophic	factors	on	the	CNS	cholinergic	phenotype.	Prog	Brain	
Res.	1996;109:347-58.	
138.	 Korsching	S,	Auburger	G,	Heumann	R,	Scott	J,	Thoenen	H.	Levels	of	nerve	growth	
factor	and	its	mRNA	in	the	central	nervous	system	of	the	rat	correlate	with	
cholinergic	innervation.	EMBO	J.	1985;4(6):1389-93.	
139.	 Kaplan	DR,	Miller	FD.	Neurobiology:	a	move	to	sort	life	from	death.	Nature.	
2004;427(6977):798-9.	
140.	 Harrington	AW,	Ginty	DD.	Long-distance	retrograde	neurotrophic	factor	signalling	in	
neurons.	Nat	Rev	Neurosci.	2013;14(3):177-87.	
141.	 Kanaan	NM,	Pigino	GF,	Brady	ST,	Lazarov	O,	Binder	LI,	Morfini	GA.	Axonal	
degeneration	in	Alzheimer's	disease:	when	signaling	abnormalities	meet	the	axonal	
transport	system.	Exp	Neurol.	2013;246:44-53.	
142.	 Chu	Y,	Cochran	EJ,	Bennett	DA,	Mufson	EJ,	Kordower	JH.	Down-regulation	of	trkA	
mRNA	within	nucleus	basalis	neurons	in	individuals	with	mild	cognitive	impairment	
and	Alzheimer's	disease.	J	Comp	Neurol.	2001;437(3):296-307.	
143.	 Counts	SE,	Mufson	EJ.	The	role	of	nerve	growth	factor	receptors	in	cholinergic	basal	
forebrain	degeneration	in	prodromal	Alzheimer	disease.	J	Neuropathol	Exp	Neurol.	
2005;64(4):263-72.	
144.	 Fahnestock	M,	Michalski	B,	Xu	B,	Coughlin	MD.	The	precursor	pro-nerve	growth	
factor	is	the	predominant	form	of	nerve	growth	factor	in	brain	and	is	increased	in	
Alzheimer's	disease.	Mol	Cell	Neurosci.	2001;18(2):210-20.	
145.	 Peng	S,	Wuu	J,	Mufson	EJ,	Fahnestock	M.	Increased	proNGF	levels	in	subjects	with	
mild	cognitive	impairment	and	mild	Alzheimer	disease.	J	Neuropathol	Exp	Neurol.	
2004;63(6):641-9.	
146.	 Goedert	M,	Fine	A,	Hunt	SP,	Ullrich	A.	Nerve	growth	factor	mRNA	in	peripheral	and	
central	rat	tissues	and	in	the	human	central	nervous	system:	lesion	effects	in	the	rat	
brain	and	levels	in	Alzheimer's	disease.	Brain	Res.	1986;387(1):85-92.	
147.	 Masoudi	R,	Ioannou	MS,	Coughlin	MD,	Pagadala	P,	Neet	KE,	Clewes	O,	et	al.	
Biological	activity	of	nerve	growth	factor	precursor	is	dependent	upon	relative	levels	
of	its	receptors.	J	Biol	Chem.	2009;284(27):18424-33.	
148.	 Mufson	EJ,	Counts	SE,	Fahnestock	M,	Ginsberg	SD.	Cholinotrophic	molecular	
substrates	of	mild	cognitive	impairment	in	the	elderly.	Curr	Alzheimer	Res.	
2007;4(4):340-50.	
 	58	
149.	 Cuello	AC,	Bruno	MA,	Allard	S,	Leon	W,	Iulita	MF.	Cholinergic	involvement	in	
Alzheimer's	disease.	A	link	with	NGF	maturation	and	degradation.	J	Mol	Neurosci.	
2010;40(1-2):230-5.	
150.	 Bruno	MA,	Cuello	AC.	Activity-dependent	release	of	precursor	nerve	growth	factor,	
conversion	to	mature	nerve	growth	factor,	and	its	degradation	by	a	protease	
cascade.	Proc	Natl	Acad	Sci	U	S	A.	2006;103(17):6735-40.	
151.	 Bruno	MA,	Leon	WC,	Fragoso	G,	Mushynski	WE,	Almazan	G,	Cuello	AC.	Amyloid	
beta-induced	nerve	growth	factor	dysmetabolism	in	Alzheimer	disease.	J	
Neuropathol	Exp	Neurol.	2009;68(8):857-69.	
152.	 Allard	S,	Leon	WC,	Pakavathkumar	P,	Bruno	MA,	Ribeiro-da-Silva	A,	Cuello	AC.	
Impact	of	the	NGF	maturation	and	degradation	pathway	on	the	cortical	cholinergic	
system	phenotype.	J	Neurosci.	2012;32(6):2002-12.	
153.	 Asahina	M,	Yoshiyama	Y,	Hattori	T.	Expression	of	matrix	metalloproteinase-9	and	
urinary-type	plasminogen	activator	in	Alzheimer's	disease	brain.	Clin	Neuropathol.	
2001;20(2):60-3.	
154.	 Deb	S,	Wenjun	Zhang	J,	Gottschall	PE.	Beta-amyloid	induces	the	production	of	active,	
matrix-degrading	proteases	in	cultured	rat	astrocytes.	Brain	Res.	2003;970(1-2):205-
13.	
155.	 Costantini	C,	Weindruch	R,	Della	Valle	G,	Puglielli	L.	A	TrkA-to-p75NTR	molecular	
switch	activates	amyloid	beta-peptide	generation	during	aging.	Biochem	J.	
2005;391(Pt	1):59-67.	
156.	 Cooper	JD,	Salehi	A,	Delcroix	JD,	Howe	CL,	Belichenko	PV,	Chua-Couzens	J,	et	al.	
Failed	retrograde	transport	of	NGF	in	a	mouse	model	of	Down's	syndrome:	reversal	
of	cholinergic	neurodegenerative	phenotypes	following	NGF	infusion.	Proc	Natl	Acad	
Sci	U	S	A.	2001;98(18):10439-44.	
157.	 Cattaneo	A,	Capsoni	S,	Paoletti	F.	Towards	non	invasive	nerve	growth	factor	
therapies	for	Alzheimer's	disease.	J	Alzheimers	Dis.	2008;15(2):255-83.	
158.	 Burgos	I,	Cuello	AC,	Liberini	P,	Pioro	E,	Masliah	E.	NGF-mediated	synaptic	sprouting	
in	the	cerebral	cortex	of	lesioned	primate	brain.	Brain	Res.	1995;692(1-2):154-60.	
159.	 Charles	V,	Mufson	EJ,	Friden	PM,	Bartus	RT,	Kordower	JH.	Atrophy	of	cholinergic	
basal	forebrain	neurons	following	excitotoxic	cortical	lesions	is	reversed	by	
intravenous	administration	of	an	NGF	conjugate.	Brain	Res.	1996;728(2):193-203.	
160.	 Hefti	F.	Nerve	growth	factor	promotes	survival	of	septal	cholinergic	neurons	after	
fimbrial	transections.	J	Neurosci.	1986;6(8):2155-62.	
161.	 Mufson	EJ,	Counts	SE,	Perez	SE,	Ginsberg	SD.	Cholinergic	system	during	the	
progression	of	Alzheimer's	disease:	therapeutic	implications.	Expert	Rev	Neurother.	
2008;8(11):1703-18.	
162.	 Covaceuszach	S,	Capsoni	S,	Ugolini	G,	Spirito	F,	Vignone	D,	Cattaneo	A.	Development	
of	a	non	invasive	NGF-based	therapy	for	Alzheimer's	disease.	Curr	Alzheimer	Res.	
2009;6(2):158-70.	
163.	 Lee	HJ,	Lim	IJ,	Park	SW,	Kim	YB,	Ko	Y,	Kim	SU.	Human	neural	stem	cells	genetically	
modified	to	express	human	nerve	growth	factor	(NGF)	gene	restore	cognition	in	the	
 59	 	
	
mouse	with	ibotenic	acid-induced	cognitive	dysfunction.	Cell	Transplant.	
2012;21(11):2487-96.	
164.	 Olson	L,	Nordberg	A,	von	Holst	H,	Backman	L,	Ebendal	T,	Alafuzoff	I,	et	al.	Nerve	
growth	factor	affects	11C-nicotine	binding,	blood	flow,	EEG,	and	verbal	episodic	
memory	in	an	Alzheimer	patient	(case	report).	J	Neural	Transm	Park	Dis	Dement	
Sect.	1992;4(1):79-95.	
165.	 Eriksdotter	Jonhagen	M,	Nordberg	A,	Amberla	K,	Backman	L,	Ebendal	T,	Meyerson	B,	
et	al.	Intracerebroventricular	infusion	of	nerve	growth	factor	in	three	patients	with	
Alzheimer's	disease.	Dement	Geriatr	Cogn	Disord.	1998;9(5):246-57.	
166.	 Apfel	SC,	Kessler	JA,	Adornato	BT,	Litchy	WJ,	Sanders	C,	Rask	CA.	Recombinant	
human	nerve	growth	factor	in	the	treatment	of	diabetic	polyneuropathy.	NGF	Study	
Group.	Neurology.	1998;51(3):695-702.	
167.	 McArthur	JC,	Yiannoutsos	C,	Simpson	DM,	Adornato	BT,	Singer	EJ,	Hollander	H,	et	al.	
A	phase	II	trial	of	nerve	growth	factor	for	sensory	neuropathy	associated	with	HIV	
infection.	AIDS	Clinical	Trials	Group	Team	291.	Neurology.	2000;54(5):1080-8.	
168.	 McKelvey	L,	Shorten	GD,	O'Keeffe	GW.	Nerve	growth	factor-mediated	regulation	of	
pain	signalling	and	proposed	new	intervention	strategies	in	clinical	pain	
management.	J	Neurochem.	2013;124(3):276-89.	
169.	 Hao	J,	Ebendal	T,	Xu	X,	Wiesenfeld-Hallin	Z,	Eriksdotter	Jonhagen	M.	
Intracerebroventricular	infusion	of	nerve	growth	factor	induces	pain-like	response	in	
rats.	Neurosci	Lett.	2000;286(3):208-12.	
170.	 Tuszynski	MH,	U	HS,	Amaral	DG,	Gage	FH.	Nerve	growth	factor	infusion	in	the	
primate	brain	reduces	lesion-induced	cholinergic	neuronal	degeneration.	J	Neurosci.	
1990;10(11):3604-14.	
171.	 Sydow	O,	Hansson	P,	Young	D,	Meyerson	B,	Backlund	EO,	Ebendal	T,	et	al.	Long-term	
beneficial	effects	of	adrenal	medullary	autografts	supported	by	nerve	growth	factor	
in	Parkinson's	disease.	Eur	J	Neurol.	1995;2(5):445-54.	
172.	 Tuszynski	MH,	Thal	L,	Pay	M,	Salmon	DP,	U	HS,	Bakay	R,	et	al.	A	phase	1	clinical	trial	
of	nerve	growth	factor	gene	therapy	for	Alzheimer	disease.	Nat	Med.	
2005;11(5):551-5.	
173.	 Rafii	MS,	Baumann	TL,	Bakay	RA,	Ostrove	JM,	Siffert	J,	Fleisher	AS,	et	al.	A	phase1	
study	of	stereotactic	gene	delivery	of	AAV2-NGF	for	Alzheimer's	disease.	Alzheimers	
Dement.	2014;10(5):571-81.	
174.	 Bartus	RT,	Johnson	EM,	Jr.	Clinical	tests	of	neurotrophic	factors	for	human	
neurodegenerative	diseases,	part	1:	Where	have	we	been	and	what	have	we	
learned?	Neurobiol	Dis.	2016.	
175.	 Tuszynski	MH,	Yang	JH,	Barba	D,	U	HS,	Bakay	RA,	Pay	MM,	et	al.	Nerve	Growth	
Factor	Gene	Therapy:	Activation	of	Neuronal	Responses	in	Alzheimer	Disease.	JAMA	
Neurol.	2015;72(10):1139-47.	
176.	 Eriksdotter-Jonhagen	M,	Linderoth	B,	Lind	G,	Aladellie	L,	Almkvist	O,	Andreasen	N,	et	
al.	Encapsulated	cell	biodelivery	of	nerve	growth	factor	to	the	Basal	forebrain	in	
patients	with	Alzheimer's	disease.	Dement	Geriatr	Cogn	Disord.	2012;33(1):18-28.	
 	60	
177.	 Wahlberg	LU,	Lind	G,	Almqvist	PM,	Kusk	P,	Tornoe	J,	Juliusson	B,	et	al.	Targeted	
delivery	of	nerve	growth	factor	via	encapsulated	cell	biodelivery	in	Alzheimer	
disease:	a	technology	platform	for	restorative	neurosurgery.	J	Neurosurg.	
2012;117(2):340-7.	
178.	 Phillips	HS,	Hains	JM,	Laramee	GR,	Rosenthal	A,	Winslow	JW.	Widespread	expression	
of	BDNF	but	not	NT3	by	target	areas	of	basal	forebrain	cholinergic	neurons.	Science.	
1990;250(4978):290-4.	
179.	 Wetmore	C,	Ernfors	P,	Persson	H,	Olson	L.	Localization	of	brain-derived	neurotrophic	
factor	mRNA	to	neurons	in	the	brain	by	in	situ	hybridization.	Exp	Neurol.	
1990;109(2):141-52.	
180.	 Ghosh	A,	Carnahan	J,	Greenberg	ME.	Requirement	for	BDNF	in	activity-dependent	
survival	of	cortical	neurons.	Science.	1994;263(5153):1618-23.	
181.	 Hyman	C,	Hofer	M,	Barde	YA,	Juhasz	M,	Yancopoulos	GD,	Squinto	SP,	et	al.	BDNF	is	a	
neurotrophic	factor	for	dopaminergic	neurons	of	the	substantia	nigra.	Nature.	
1991;350(6315):230-2.	
182.	 Huang	EJ,	Reichardt	LF.	Neurotrophins:	roles	in	neuronal	development	and	function.	
Annu	Rev	Neurosci.	2001;24:677-736.	
183.	 Minichiello	L.	TrkB	signalling	pathways	in	LTP	and	learning.	Nat	Rev	Neurosci.	
2009;10(12):850-60.	
184.	 Koponen	E,	Voikar	V,	Riekki	R,	Saarelainen	T,	Rauramaa	T,	Rauvala	H,	et	al.	
Transgenic	mice	overexpressing	the	full-length	neurotrophin	receptor	trkB	exhibit	
increased	activation	of	the	trkB-PLCgamma	pathway,	reduced	anxiety,	and	facilitated	
learning.	Mol	Cell	Neurosci.	2004;26(1):166-81.	
185.	 Ginsberg	SD,	Che	S,	Wuu	J,	Counts	SE,	Mufson	EJ.	Down	regulation	of	trk	but	not	
p75NTR	gene	expression	in	single	cholinergic	basal	forebrain	neurons	mark	the	
progression	of	Alzheimer's	disease.	J	Neurochem.	2006;97(2):475-87.	
186.	 Tanila	H.	The	role	of	BDNF	in	Alzheimer's	disease.	Neurobiol	Dis.	2016.	
187.	 Belrose	JC,	Masoudi	R,	Michalski	B,	Fahnestock	M.	Increased	pro-nerve	growth	
factor	and	decreased	brain-derived	neurotrophic	factor	in	non-Alzheimer's	disease	
tauopathies.	Neurobiol	Aging.	2014;35(4):926-33.	
188.	 Eide	FF,	Vining	ER,	Eide	BL,	Zang	K,	Wang	XY,	Reichardt	LF.	Naturally	occurring	
truncated	trkB	receptors	have	dominant	inhibitory	effects	on	brain-derived	
neurotrophic	factor	signaling.	J	Neurosci.	1996;16(10):3123-9.	
189.	 Michaelsen	K,	Zagrebelsky	M,	Berndt-Huch	J,	Polack	M,	Buschler	A,	Sendtner	M,	et	
al.	Neurotrophin	receptors	TrkB.T1	and	p75NTR	cooperate	in	modulating	both	
functional	and	structural	plasticity	in	mature	hippocampal	neurons.	Eur	J	Neurosci.	
2010;32(11):1854-65.	
190.	 Wong	J,	Higgins	M,	Halliday	G,	Garner	B.	Amyloid	beta	selectively	modulates	
neuronal	TrkB	alternative	transcript	expression	with	implications	for	Alzheimer's	
disease.	Neuroscience.	2012;210:363-74.	
 61	 	
	
191.	 Sakuragi	S,	Tominaga-Yoshino	K,	Ogura	A.	Involvement	of	TrkB-	and	p75(NTR)-
signaling	pathways	in	two	contrasting	forms	of	long-lasting	synaptic	plasticity.	
Scientific	reports.	2013;3:3185.	
192.	 Kitiyanant	N,	Kitiyanant	Y,	Svendsen	CN,	Thangnipon	W.	BDNF-,	IGF-1-	and	GDNF-
secreting	human	neural	progenitor	cells	rescue	amyloid	beta-induced	toxicity	in	
cultured	rat	septal	neurons.	Neurochem	Res.	2012;37(1):143-52.	
193.	 Arancibia	S,	Silhol	M,	Mouliere	F,	Meffre	J,	Hollinger	I,	Maurice	T,	et	al.	Protective	
effect	of	BDNF	against	beta-amyloid	induced	neurotoxicity	in	vitro	and	in	vivo	in	rats.	
Neurobiol	Dis.	2008;31(3):316-26.	
194.	 Zeng	Y,	Zhao	D,	Xie	CW.	Neurotrophins	enhance	CaMKII	activity	and	rescue	amyloid-
beta-induced	deficits	in	hippocampal	synaptic	plasticity.	J	Alzheimers	Dis.	
2010;21(3):823-31.	
195.	 Criscuolo	C,	Fabiani	C,	Bonadonna	C,	Origlia	N,	Domenici	L.	BDNF	prevents	amyloid-
dependent	impairment	of	LTP	in	the	entorhinal	cortex	by	attenuating	p38	MAPK	
phosphorylation.	Neurobiol	Aging.	2015;36(3):1303-9.	
196.	 Mufson	EJ,	He	B,	Nadeem	M,	Perez	SE,	Counts	SE,	Leurgans	S,	et	al.	Hippocampal	
proNGF	signaling	pathways	and	beta-amyloid	levels	in	mild	cognitive	impairment	
and	Alzheimer	disease.	J	Neuropathol	Exp	Neurol.	2012;71(11):1018-29.	
197.	 Peng	S,	Wuu	J,	Mufson	EJ,	Fahnestock	M.	Precursor	form	of	brain-derived	
neurotrophic	factor	and	mature	brain-derived	neurotrophic	factor	are	decreased	in	
the	pre-clinical	stages	of	Alzheimer's	disease.	J	Neurochem.	2005;93(6):1412-21.	
198.	 Michalski	B,	Fahnestock	M.	Pro-brain-derived	neurotrophic	factor	is	decreased	in	
parietal	cortex	in	Alzheimer's	disease.	Brain	Res	Mol	Brain	Res.	2003;111(1-2):148-
54.	
199.	 Mashayekhi	F,	Salehin	Z.	Cerebrospinal	fluid	nerve	growth	factor	levels	in	patients	
with	Alzheimer's	disease.	Ann	Saudi	Med.	2006;26(4):278-82.	
200.	 Marksteiner	J,	Pirchl	M,	Ullrich	C,	Oberbauer	H,	Blasko	I,	Lederer	W,	et	al.	Analysis	of	
cerebrospinal	fluid	of	Alzheimer	patients.	Biomarkers	and	toxic	properties.	
Pharmacology.	2008;82(3):214-20.	
201.	 Hock	C,	Heese	K,	Muller-Spahn	F,	Huber	P,	Riesen	W,	Nitsch	RM,	et	al.	Increased	CSF	
levels	of	nerve	growth	factor	in	patients	with	Alzheimer's	disease.	Neurology.	
2000;54(10):2009-11.	
202.	 Li	G,	Peskind	ER,	Millard	SP,	Chi	P,	Sokal	I,	Yu	CE,	et	al.	Cerebrospinal	fluid	
concentration	of	brain-derived	neurotrophic	factor	and	cognitive	function	in	non-
demented	subjects.	PLoS	One.	2009;4(5):e5424.	
203.	 Laske	C,	Stransky	E,	Leyhe	T,	Eschweiler	GW,	Maetzler	W,	Wittorf	A,	et	al.	BDNF	
serum	and	CSF	concentrations	in	Alzheimer's	disease,	normal	pressure	
hydrocephalus	and	healthy	controls.	J	Psychiatr	Res.	2007;41(5):387-94.	
204.	 Blasko	I,	Lederer	W,	Oberbauer	H,	Walch	T,	Kemmler	G,	Hinterhuber	H,	et	al.	
Measurement	of	thirteen	biological	markers	in	CSF	of	patients	with	Alzheimer's	
disease	and	other	dementias.	Dement	Geriatr	Cogn	Disord.	2006;21(1):9-15.	
 	62	
205.	 Weinstein	G,	Beiser	AS,	Choi	SH,	Preis	SR,	Chen	TC,	Vorgas	D,	et	al.	Serum	brain-
derived	neurotrophic	factor	and	the	risk	for	dementia:	the	Framingham	Heart	Study.	
JAMA	Neurol.	2014;71(1):55-61.	
206.	 Angelucci	F,	Spalletta	G,	di	Iulio	F,	Ciaramella	A,	Salani	F,	Colantoni	L,	et	al.	
Alzheimer's	disease	(AD)	and	Mild	Cognitive	Impairment	(MCI)	patients	are	
characterized	by	increased	BDNF	serum	levels.	Curr	Alzheimer	Res.	2010;7(1):15-20.	
207.	 Faria	MC,	Goncalves	GS,	Rocha	NP,	Moraes	EN,	Bicalho	MA,	Gualberto	Cintra	MT,	et	
al.	Increased	plasma	levels	of	BDNF	and	inflammatory	markers	in	Alzheimer's	
disease.	J	Psychiatr	Res.	2014;53:166-72.	
208.	 Forlenza	OV,	Diniz	BS,	Teixeira	AL,	Radanovic	M,	Talib	LL,	Rocha	NP,	et	al.	Lower	
Cerebrospinal	Fluid	Concentration	of	Brain-Derived	Neurotrophic	Factor	Predicts	
Progression	from	Mild	Cognitive	Impairment	to	Alzheimer's	Disease.	Neuromolecular	
Med.	2015;17(3):326-32.	
209.	 Folstein	MF,	Folstein	SE,	McHugh	PR.	"Mini-mental	state".	A	practical	method	for	
grading	the	cognitive	state	of	patients	for	the	clinician.	J	Psychiatr	Res.	
1975;12(3):189-98.	
210.	 Eyjolfsdottir	H,	Eriksdotter	M,	Linderoth	B,	Lind	G,	Juliusson	B,	Kusk	P,	et	al.	Targeted	
delivery	of	nerve	growth	factor	to	the	cholinergic	basal	forebrain	of	Alzheimer's	
disease	patients:	application	of	a	second-generation	encapsulated	cell	biodelivery	
device.	Alzheimers	Res	Ther.	2016;8(1):30.	
211.	 Reisberg	B,	Gauthier	S.	Current	evidence	for	subjective	cognitive	impairment	(SCI)	as	
the	pre-mild	cognitive	impairment	(MCI)	stage	of	subsequently	manifest	Alzheimer's	
disease.	International	psychogeriatrics	/	IPA.	2008;20(1):1-16.	
212.	 Reisberg	B,	Prichep	L,	Mosconi	L,	John	ER,	Glodzik-Sobanska	L,	Boksay	I,	et	al.	The	
pre-mild	cognitive	impairment,	subjective	cognitive	impairment	stage	of	Alzheimer's	
disease.	Alzheimer's	&	dementia	:	the	journal	of	the	Alzheimer's	Association.	
2008;4(1	Suppl	1):S98-S108.	
213.	 Fjord-Larsen	L,	Kusk	P,	Tornoe	J,	Juliusson	B,	Torp	M,	Bjarkam	CR,	et	al.	Long-term	
delivery	of	nerve	growth	factor	by	encapsulated	cell	biodelivery	in	the	Gottingen	
minipig	basal	forebrain.	Mol	Ther.	2010;18(12):2164-72.	
214.	 Fjord-Larsen	L,	Kusk	P,	Emerich	DF,	Thanos	C,	Torp	M,	Bintz	B,	et	al.	Increased	
encapsulated	cell	biodelivery	of	nerve	growth	factor	in	the	brain	by	transposon-
mediated	gene	transfer.	Gene	Ther.	2012;19(10):1010-7.	
215.	 Mates	L,	Chuah	MK,	Belay	E,	Jerchow	B,	Manoj	N,	Acosta-Sanchez	A,	et	al.	Molecular	
evolution	of	a	novel	hyperactive	Sleeping	Beauty	transposase	enables	robust	stable	
gene	transfer	in	vertebrates.	Nat	Genet.	2009;41(6):753-61.	
216.	 Mohs	RC,	Knopman	D,	Petersen	RC,	Ferris	SH,	Ernesto	C,	Grundman	M,	et	al.	
Development	of	cognitive	instruments	for	use	in	clinical	trials	of	antidementia	drugs:	
additions	to	the	Alzheimer's	Disease	Assessment	Scale	that	broaden	its	scope.	The	
Alzheimer's	Disease	Cooperative	Study.	Alzheimer	Dis	Assoc	Disord.	1997;11	Suppl	
2:S13-21.	
217.	 Olsson	A,	Vanderstichele	H,	Andreasen	N,	De	Meyer	G,	Wallin	A,	Holmberg	B,	et	al.	
Simultaneous	measurement	of	beta-amyloid(1-42),	total	tau,	and	phosphorylated	
 63	 	
	
tau	(Thr181)	in	cerebrospinal	fluid	by	the	xMAP	technology.	Clin	Chem.	
2005;51(2):336-45.	
218.	 Rosengren	LE,	Karlsson	JE,	Karlsson	JO,	Persson	LI,	Wikkelso	C.	Patients	with	
amyotrophic	lateral	sclerosis	and	other	neurodegenerative	diseases	have	increased	
levels	of	neurofilament	protein	in	CSF.	J	Neurochem.	1996;67(5):2013-8.	
219.	 Rosengren	LE,	Wikkelso	C,	Hagberg	L.	A	sensitive	ELISA	for	glial	fibrillary	acidic	
protein:	application	in	CSF	of	adults.	J	Neurosci	Methods.	1994;51(2):197-204.	
220.	 Lundqvist	H,	Nordberg	A,	Hartvig	P,	Långström	B.	(S)-(-)-[11C]	Nicotine	Binding	
Assessed	by	PET:	A	Dual	Tracer	Model	Evaluated	in	the	Rhesus	Monkey	Brain.	
Alzheimer	Disease	&	Associated	Disorders.	1998;12(3):238.	
221.	 Nordberg	A,	Lundqvist	H,	Hartvig	P,	Lilja	A,	Långström	B.	Kinetic	Analysis	of	Regional	
(S)(-)	11C-Nicotine	Binding	in	Normal	and	Alzheimer	Brains	In	Vivo	Assessment	Using	
Positron	Emission	Tomography.	Alzheimer	Disease	&	Associated	Disorders.	
1995;9(1):21.	
222.	 Patlak	CS,	Blasberg	RG,	Fenstermacher	JD.	Graphical	evaluation	of	blood-to-brain	
transfer	constants	from	multiple-time	uptake	data.	J	Cereb	Blood	Flow	Metab.	
1983;3(1):1-7.	
223.	 Vijayaraghavan	S,	Karami	A,	Aeinehband	S,	Behbahani	H,	Grandien	A,	Nilsson	B,	et	al.	
Regulated	Extracellular	Choline	Acetyltransferase	Activity-	The	Plausible	Missing	Link	
of	the	Distant	Action	of	Acetylcholine	in	the	Cholinergic	Anti-Inflammatory	Pathway.	
PLoS	One.	2013;8(6):e65936.	
224.	 Darreh-Shori	T,	Kadir	A,	Almkvist	O,	Grut	M,	Wall	A,	Blomquist	G,	et	al.	Inhibition	of	
acetylcholinesterase	in	CSF	versus	brain	assessed	by	11C-PMP	PET	in	AD	patients	
treated	with	galantamine.	Neurobiol	Aging.	2008;29(2):168-84.	
225.	 Lopez	OL,	Becker	JT,	Wisniewski	S,	Saxton	J,	Kaufer	DI,	DeKosky	ST.	Cholinesterase	
inhibitor	treatment	alters	the	natural	history	of	Alzheimer's	disease.	J	Neurol	
Neurosurg	Psychiatry.	2002;72(3):310-4.	
226.	 Han	L.	Top	cited	papers	in	International	Psychogeriatrics:	6c.	Tracking	cognitive	
decline	in	Alzheimer's	disease	using	the	Mini-mental	State	Examination:	a	meta-
analysis	("mini"	is	not	necessarily	trivial!).	Int	Psychogeriatr.	2009;21(6):1037-40.	
227.	 Karami	A,	Eyjolfsdottir	H,	Vijayaraghavan	S,	Lind	G,	Almqvist	P,	Kadir	A,	et	al.	
Changes	in	CSF	cholinergic	biomarkers	in	response	to	cell	therapy	with	NGF	in	
patients	with	Alzheimer's	disease.	Alzheimers	Dement.	2015;11(11):1316-28.	
228.	 Koenig	T,	Kottlow	M,	Stein	M,	Melie-Garcia	L.	Ragu:	a	free	tool	for	the	analysis	of	
EEG	and	MEG	event-related	scalp	field	data	using	global	randomization	statistics.	
Comput	Intell	Neurosci.	2011;2011:938925.	
229.	 Koenig	T,	Melie-Garcia	L,	Stein	M,	Strik	W,	Lehmann	C.	Establishing	correlations	of	
scalp	field	maps	with	other	experimental	variables	using	covariance	analysis	and	
resampling	methods.	Clin	Neurophysiol.	2008;119(6):1262-70.	
230.	 Westman	E,	Aguilar	C,	Muehlboeck	JS,	Simmons	A.	Regional	magnetic	resonance	
imaging	measures	for	multivariate	analysis	in	Alzheimer's	disease	and	mild	cognitive	
impairment.	Brain	Topogr.	2013;26(1):9-23.	
 	64	
231.	 Mueller	SG,	Weiner	MW,	Thal	LJ,	Petersen	RC,	Jack	CR,	Jagust	W,	et	al.	Ways	toward	
an	early	diagnosis	in	Alzheimer's	disease:	the	Alzheimer's	Disease	Neuroimaging	
Initiative	(ADNI).	Alzheimers	Dement.	2005;1(1):55-66.	
232.	 Wyman	BT,	Harvey	DJ,	Crawford	K,	Bernstein	MA,	Carmichael	O,	Cole	PE,	et	al.	
Standardization	of	analysis	sets	for	reporting	results	from	ADNI	MRI	data.	Alzheimers	
Dement.	2013;9(3):332-7.	
233.	 Hughes	CP,	Berg	L,	Danziger	WL,	Coben	LA,	Martin	RL.	A	new	clinical	scale	for	the	
staging	of	dementia.	Br	J	Psychiatry.	1982;140:566-72.	
234.	 Delsite	R,	Djakiew	D.	Characterization	of	nerve	growth	factor	precursor	protein	
expression	by	human	prostate	stromal	cells:	a	role	in	selective	neurotrophin	
stimulation	of	prostate	epithelial	cell	growth.	Prostate.	1999;41(1):39-48.	
235.	 Mowla	SJ,	Farhadi	HF,	Pareek	S,	Atwal	JK,	Morris	SJ,	Seidah	NG,	et	al.	Biosynthesis	
and	post-translational	processing	of	the	precursor	to	brain-derived	neurotrophic	
factor.	J	Biol	Chem.	2001;276(16):12660-6.	
236.	 Mashayekhi	F,	Salehi	Z,	Jamalzadeh	HR.	Quantitative	analysis	of	cerebrospinal	fluid	
brain	derived	neurotrophic	factor	in	the	patients	with	multiple	sclerosis.	Acta	Medica	
(Hradec	Kralove).	2012;55(2):83-6.	
237.	 Mandel	AL,	Ozdener	H,	Utermohlen	V.	Identification	of	pro-	and	mature	brain-
derived	neurotrophic	factor	in	human	saliva.	Arch	Oral	Biol.	2009;54(7):689-95.	
238.	 Lim	KC,	Tyler	CM,	Lim	ST,	Giuliano	R,	Federoff	HJ.	Proteolytic	processing	of	proNGF	is	
necessary	for	mature	NGF	regulated	secretion	from	neurons.	Biochem	Biophys	Res	
Commun.	2007;361(3):599-604.	
239.	 Counts	SE,	He	B,	Prout	JG,	Michalski	B,	Farotti	L,	Fahnestock	M,	et	al.	Cerebrospinal	
Fluid	proNGF:	A	Putative	Biomarker	for	Early	Alzheimer's	Disease.	Curr	Alzheimer	
Res.	2016;13(7):800-8.	
240.	 Garcia-Ptacek	S,	Cavallin	L,	Kareholt	I,	Kramberger	MG,	Winblad	B,	Jelic	V,	et	al.	
Subjective	cognitive	impairment	subjects	in	our	clinical	practice.	Dement	Geriatr	
Cogn	Dis	Extra.	2014;4(3):419-30.	
241.	 Pang	PT,	Teng	HK,	Zaitsev	E,	Woo	NT,	Sakata	K,	Zhen	S,	et	al.	Cleavage	of	proBDNF	by	
tPA/plasmin	is	essential	for	long-term	hippocampal	plasticity.	Science.	
2004;306(5695):487-91.	
242.	 Keifer	J,	Sabirzhanov	BE,	Zheng	Z,	Li	W,	Clark	TG.	Cleavage	of	proBDNF	to	BDNF	by	a	
tolloid-like	metalloproteinase	is	required	for	acquisition	of	in	vitro	eyeblink	classical	
conditioning.	J	Neurosci.	2009;29(47):14956-64.	
243.	 Hanzel	CE,	Iulita	MF,	Eyjolfsdottir	H,	Hjorth	E,	M.	S,	Eriksdotter	M,	et	al.	Analysis	of	
matrix	metallo-proteases	and	the	plasminogen	system	in	Mild	Cognitive	Impairment	
and	Alzheimer’s	disease	cerebro-spinal	fluid.	Journal	of	Alzheimer's	disease.	
2014;40(3):667-78.	
244.	 Gnahn	H,	Hefti	F,	Heumann	R,	Schwab	ME,	Thoenen	H.	NGF-mediated	increase	of	
choline	acetyltransferase	(ChAT)	in	the	neonatal	rat	forebrain:	evidence	for	a	
physiological	role	of	NGF	in	the	brain?	Brain	Res.	1983;285(1):45-52.	
 65	 	
	
245.	 Honegger	P,	Lenoir	D.	Nerve	growth	factor	(NGF)	stimulation	of	cholinergic	
telencephalic	neurons	in	aggregating	cell	cultures.	Brain	Res.	1982;255(2):229-38.	
246.	 Nordberg	A,	Darreh-Shori	T,	Peskind	E,	Soininen	H,	Mousavi	M,	Eagle	G,	et	al.	
Different	cholinesterase	inhibitor	effects	on	CSF	cholinesterases	in	Alzheimer	
patients.	Curr	Alzheimer	Res.	2009;6(1):4-14.	
247.	 Darreh-Shori	T,	Meurling	L,	Pettersson	T,	Hugosson	K,	Hellstrom-Lindahl	E,	
Andreasen	N,	et	al.	Changes	in	the	activity	and	protein	levels	of	CSF	
acetylcholinesterases	in	relation	to	cognitive	function	of	patients	with	mild	
Alzheimer's	disease	following	chronic	donepezil	treatment.	J	Neural	Transm	
(Vienna).	2006;113(11):1791-801.	
248.	 Giacobini	E.	Cholinergic	function	and	Alzheimer's	disease.	Int	J	Geriatr	Psychiatry.	
2003;18(Suppl	1):S1-5.	
249.	 Rossner	S,	Schliebs	R,	Hartig	W,	Bigl	V.	192IGG-saporin-induced	selective	lesion	of	
cholinergic	basal	forebrain	system:	neurochemical	effects	on	cholinergic	
neurotransmission	in	rat	cerebral	cortex	and	hippocampus.	Brain	Res	Bull.	
1995;38(4):371-81.	
250.	 Wenk	GL,	Stoehr	JD,	Quintana	G,	Mobley	S,	Wiley	RG.	Behavioral,	biochemical,	
histological,	and	electrophysiological	effects	of	192	IgG-saporin	injections	into	the	
basal	forebrain	of	rats.	J	Neurosci.	1994;14(10):5986-95.	
251.	 Sanchez-Alavez	M,	Robledo	P,	Wills	DN,	Havstad	J,	Ehlers	CL.	Cholinergic	modulation	
of	event-related	oscillations	(ERO).	Brain	Res.	2014;1559:11-25.	
252.	 Jelic	V,	Dierks	T,	Amberla	K,	Almkvist	O,	Winblad	B,	Nordberg	A.	Longitudinal	
changes	in	quantitative	EEG	during	long-term	tacrine	treatment	of	patients	with	
Alzheimer's	disease.	Neurosci	Lett.	1998;254(2):85-8.	
253.	 Moretti	DV.	Alpha	rhythm	oscillations	and	MMSE	scores	are	differently	modified	by	
transdermal	or	oral	rivastigmine	in	patients	with	Alzheimer's	disease.	Am	J	
Neurodegener	Dis.	2014;3(2):72-83.	
254.	 Eckart	C,	Wozniak-Kwasniewska	A,	Herweg	NA,	Fuentemilla	L,	Bunzeck	N.	
Acetylcholine	modulates	human	working	memory	and	subsequent	familiarity	based	
recognition	via	alpha	oscillations.	Neuroimage.	2016;137:61-9.	
255.	 Jelic	V,	Johansson	SE,	Almkvist	O,	Shigeta	M,	Julin	P,	Nordberg	A,	et	al.	Quantitative	
electroencephalography	in	mild	cognitive	impairment:	longitudinal	changes	and	
possible	prediction	of	Alzheimer's	disease.	Neurobiol	Aging.	2000;21(4):533-40.	
256.	 Jelic	V,	Shigeta	M,	Julin	P,	Almkvist	O,	Winblad	B,	Wahlund	LO.	Quantitative	
electroencephalography	power	and	coherence	in	Alzheimer's	disease	and	mild	
cognitive	impairment.	Dementia.	1996;7(6):314-23.	
257.	 Ferreira	D,	Westman	E,	Eyjolfsdottir	H,	Almqvist	P,	Lind	G,	Linderoth	B,	et	al.	Brain	
changes	in	Alzheimer's	disease	patients	with	implanted	encapsulated	cells	releasing	
nerve	growth	factor.	J	Alzheimers	Dis.	2015;43(3):1059-72.	
258.	 Lawton	MP,	Brody	EM.	Assessment	of	older	people:	self-maintaining	and	
instrumental	activities	of	daily	living.	Gerontologist.	1969;9(3):179-86.	
259.	 Stern	Y.	Cognitive	reserve.	Neuropsychologia.	2009;47(10):2015-28.	
 	66	
260.	 Hampel	H,	Lista	S,	Teipel	SJ,	Garaci	F,	Nistico	R,	Blennow	K,	et	al.	Perspective	on	
future	role	of	biological	markers	in	clinical	therapy	trials	of	Alzheimer's	disease:	a	
long-range	point	of	view	beyond	2020.	Biochem	Pharmacol.	2014;88(4):426-49.	
261.	 Ivics	Z,	Hackett	PB,	Plasterk	RH,	Izsvak	Z.	Molecular	reconstruction	of	Sleeping	
Beauty,	a	Tc1-like	transposon	from	fish,	and	its	transposition	in	human	cells.	Cell.	
1997;91(4):501-10.	
262.	 Ivics	Z,	Izsvak	Z.	The	expanding	universe	of	transposon	technologies	for	gene	and	cell	
engineering.	Mob	DNA.	2010;1(1):25.	
263.	 Shahim	P.	Blood	biomarkers	for	traumatic	brain	injury:	University	of	Gothenburg;	
2015.	(Thesis).	
264.	 Constantinescu	R,	Holmberg	B,	Rosengren	L,	Corneliusson	O,	Johnels	B,	Zetterberg	H.	
Light	subunit	of	neurofilament	triplet	protein	in	the	cerebrospinal	fluid	after	
subthalamic	nucleus	stimulation	for	Parkinson's	disease.	Acta	Neurol	Scand.	
2011;124(3):206-10.	
265.	 Capsoni	S,	Marinelli	S,	Ceci	M,	Vignone	D,	Amato	G,	Malerba	F,	et	al.	Intranasal	
"painless"	human	Nerve	Growth	Factor	[corrected]	slows	amyloid	
neurodegeneration	and	prevents	memory	deficits	in	App	X	PS1	mice.	PLoS	One.	
2012;7(5):e37555.	
	
